

1 *Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy*

2 *Abstract*

3 Lipodystrophy syndromes are rare diseases that are often characterized by a
4 general or partial absence of body fat. Fat tissues are also known as adipose tissues,
5 and the lack of adipose tissues would lead to serious consequences and the
6 development of a series of metabolic issues. These syndromes are genetically and
7 clinically heterogeneous, with different phenotypes influenced by underlying molecular
8 defects. They are all factors that determine the type of lipodystrophy a patient has. Due
9 to the rarity of this disorder, not many studies have been done on it, which leads to
10 people's lack of knowledge about this disease and increases the difficulty of treating it.
11 In this article, we first consider the classification and clinical aspects of lipodystrophy
12 syndromes, covering the onset and the differences in phenotypes of patients. Then, we
13 discuss the molecular and cellular mechanisms of several types of lipodystrophies and
14 the role they play in the development of adipose tissues. Next, we focus on other
15 metabolic dysfunctions caused by lipodystrophy, such as insulin resistance, fatty liver,
16 and hypertriglyceridemia. Lastly, we evaluate therapeutic strategies aimed at improving
17 metabolic control and quality of life in affected patients. Future direction of study and
18 potential therapies may be improved with a deeper and thorough understanding of the
19 genetic and mechanistic basis of lipodystrophy.

20

21 **Keywords:** Lipodystrophy syndromes, adipose tissue, adipogenesis, gene mutations,
22 metabolic dysfunctions

23

24 *Introduction*

25 Lipodystrophy syndromes (LD) are a heterogeneous group of rare disorders that
26 often present as the lack of mature adipose tissue in specific or generalized areas. It
27 leads to the inability to store body fat and excess nutrients (Fourman and Grinspoon
28 2022). Two main classes of lipodystrophy are Congenital Generalized Lipodystrophy
29 (CGL) and Familial Partial Lipodystrophy (FPLD). Adipose tissues are formed through a
30 process called adipogenesis, and it is crucial for the adipose tissue to function normally.

31 Adipogenesis is the process by which mesenchymal stem cells develop and
32 differentiate into mature adipose tissues and ends with cell apoptosis. This also includes
33 the triacylglycerol (TAG) fatty acid cycle. It is the process where the lipid droplets
34 undergo lipolysis (the breakdown of lipid droplets) and lipogenesis (the synthesis of new
35 lipid droplets)(Poulos et al. 2016). However, if a gene mutation or other factors affect the
36 components that play a role in regulating this process, it would lead to serious,
37 life-threatening consequences.

38 LD can be either congenital or acquired, and it is classified based on the location
39 of lost adipose tissue, and further divided into subtypes according to the gene segment
40 that is mutated (Akinci, Gular, and Oral 2024) (Table 1). CGL (also called

41 Berardinelli-Seip syndrome) is characterized by the total absence of adipocytes, both
42 mechanical and metabolic fat tissues (Oswiecimska n.d.). CGLs are autosomal
43 recessive, and the symptoms often start showing shortly after birth. It is further divided
44 into CGL1, CGL2, CGL3, and CGL4, which link to four different gene mutations. FPLD
45 presents as an abnormal distribution of adipose tissue, with fat loss around the limbs,
46 torso, and hips. It can be autosomal recessive or dominant depending on the gene that
47 is involved. Since the body is not able to store excess energy in those areas, other body
48 parts, such as the face, neck, and internal organs like the liver, gain extra adipose tissue
49 (Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
50 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic n.d.).
51 Same as CGL, it is also divided into several subtypes, including FPLD1
52 (Kobberling-type lipodystrophy), FPLD2 (Dunnigan Variety lipodystrophy), FPLD3,
53 FPLD4, FPLD5, and FPLD6. The product of all the genes associated with any kind of
54 lipodystrophy plays an important role in phospholipid and triglyceride synthesis.
55 Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and Acquired Partial
56 Lipodystrophy (APL, Barraquer-Simons syndrome) have similar symptoms, respectively;
57 however, they can be caused by autoimmune diseases, the side effects of antiretroviral
58 therapy (ART) for HIV patients, and sometimes idiopathic (Misra and Garg 2003).

59 Not only will the lack of excess energy affect the body's normal functions, but
60 other complications that arise with lipodystrophy also have a big effect on patients' lives.
61 Some common metabolic abnormalities include leptin deficiency, insulin resistance,
62 diabetes, hypertriglyceridemia, and fatty liver disease (figure 1). Currently, there are a
63 lot of clinical trials in progress, trying to discover a new way to treat or cure
64 lipodystrophy, especially targeting leptin deficiency. Metrelepin, for example, is a
65 treatment created specifically for LD patients. It is a targeted treatment for leptin
66 deficiency, which is a common metabolic issue associated with LD. (Araújo-Vilar e
67 Santini 2019). However, patients still need to have a healthy diet and other medications
68 for other metabolic issues. Currently, there is only one treatment that is directly for LD
69 patients due to the rarity of this disease. According to studies, only about 3/million
70 people around the world are affected by some type of lipodystrophy syndrome. While
71 the prevalence of CGL is estimated to be 0.23/ million people, the prevalence of FPDL
72 is around 2.84/million people (Chiquette et al. 2017). It is also estimated to shorten a
73 patient's lifespan by 30 or more years. The main cause of death is shown to be liver
74 diseases and infections caused by adipose tissue dysfunction, but also varies from type
75 to type of lipodystrophy (Lima et al. 2018).

76


Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/adolescence.	Palpable "ledge" between normal and lipodystrophic
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Lost of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not effected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

77

78 ▲ (Table 1) Classification, clinical features, and molecular basis of
79 lipodystrophies

80

Comparison of adipocyte functions between healthy person and lipodystrophy patient



81

82 ▲ (Figure 1) Comparison of adipocytes functions between a healthy person and a
83 lipodystrophy patient. The storage of an adipocytes is limited in lipodystrophy patients.
84 Common metabolic abnormalities include leptin deficiency, insulin resistance and
85 increase glucose level in blood streams. (Made by Biorender)

86

87 *Clinical aspects of lipodystrophy syndromes*

88 Since lipodystrophy is such a rare disease and not well known to the public, it is
89 often misdiagnosed or undiagnosed by clinicians. It heavily relies on clinical history and
90 physical examinations that reveal the composition of adipose tissues. Metabolic
91 dysfunctions are also important markers when diagnosing lipodystrophy. Although
92 patients with CGL show symptoms such as a lack of body fat shortly after birth, it is
93 often left undiagnosed until their childhood or adulthood, when they start showing
94 metabolic abnormalities. As for FPDL, it is even more commonly unrecognized due to
95 patients only losing adipose tissue partially. It could be easily mixed up with other types
96 of common metabolic diseases like obesity or severe diabetes mellitus. Presentations of
97 AGL and APL are generally similar to CGL and FPDL, also including the metabolic
98 issues that come with it(Lima et al. 2025).

99 Some phenotypes that are associated with lipodystrophy are muscular
100 appearance, prominent veins, and the lack of body fat. For CGL patients, the absence
101 of metabolic adipose tissues is more common than mechanical tissues. Although
102 patients still in some degrees lack functional mechanical fat tissues. Except for CGL2, in
103 which patients generally do not acquire both kinds of fat tissues(Garg 2011). In contrast,
104 FPDL is characterized by the abnormal distribution with a slight loss of adipose tissue,
105 meaning that patients still acquire most of their functional fat tissues. In addition, as
106 mentioned before, the onset of CGL is often shortly after birth, but for FPDLS, its onset
107 is usually around puberty or adolescence. Next, we will be discussing some specific
108 types of lipodystrophies in detail based on the step of adipogenesis affected and the
109 mechanisms behind them.


110

111 *Genetics behind lipodystrophy*

112 *Type 1 Congenital Generalized Lipodystrophy (CGL1)*

113 Type 1 Congenital Generalized Lipodystrophy (CGL1) is caused by a mutation in
114 the gene AGPAT2. AGPAT2 is the gene coding for a specific enzyme,
115 1-acylglycerol-3-phosphate O-acyltransferase 2, which catalyzes the acylation of
116 lysophosphatidic acid (1-acylglycerol-3-phosphate) to phosphatidic acid (1,2
117 diacylglycerol-3-phosphate)(Gale et al. 2006) (figure 2). It is an important precursor of
118 the biosynthesis of triacylglycerol (TAG) and phospholipid synthesis from
119 glycerol-3-phosphate. This step esterifies a second fatty acyl group at the sn-2 position
120 of the glycerol backbone. Phosphatidic acid is further acylated by other enzymes,
121 creating triacylglycerol and phospholipids. The AGPAT family consists of 11 isomers;

122 however, AGPAT2 is expressed at higher levels in adipose tissue than the other
123 isomers. The presence of mechanical adipose tissue can be explained by the increased
124 expression of the other isomers. However, studies have shown that the expression of
125 AGPAT2 is required for the accumulation of triacylglycerol, especially in metabolic
126 adipose tissues. Defects in AGPAT2 genes also impact insulin signaling, meaning that
127 gluconeogenesis will be unrestricted, which leads to the development of hyperglycemia
128 and diabetes(de Melo et al. 2025).
129



130
131 ▲ (Figure 2) The process of Triacylglycerol synthesis. In the second step, where LPA
132 is acylated to PA, AGPAT is the enzyme that catalyzes this reaction. Without it, the
133 reactions after it will not occur properly, meaning that adipocytes can't develop properly.
134 (Made by Biorender)

135


136 *Type 4 Congenital Generalized Lipodystrophy (CGL4)*

137 Type four Congenital Generalized Lipodystrophy (CGL4) is associated with the
138 gene mutation in the PTRF gene (Polymerase I and Transcript Release
139 Factor)(Salle-Teyssières et al. 2016). The PTRF gene encodes cavin-1, which is one of
140 the essential proteins that is required for the biogenesis of caveolae. Caveolae are one
141 of the most abundant invaginations in the cell membrane of lots of mammalian cells
142 (Figure 3). Cavin-1 starts the whole process of the synthesis of caveolae by recruiting
143 other proteins necessary, such as caveolins. Without it, cells won't be able to produce
144 caveolae. Although it is abundant, its functions have only been understood in the past

145 few decades. It plays a role in signal transduction, endocytosis, and
146 mechanotransduction (Stea and D'Alessio 2025). Cavin-1 binds with the caveolins to
147 form Caveolae. There are three members in the caveolin family, caveolin 1,2 is
148 expressed in a lot of cells, like smooth muscle cells, fibroblasts, and adipocytes.
149 Caveolin 3 is expressed exclusively in cardiac and skeletal muscle. It is shown that the
150 lack of PTRF-CAVIN doesn't affect the level of caveolin expressed (Rajab et al. 2010).
151 However, it affects caveolin's ability to localize to the cell's surface, which makes the
152 formation of caveolae impossible. Absence of caveolae causes the cell to not be able to
153 develop properly, causing abnormalities and dysfunctions.

154 Some symptoms that are uniquely associated with this type of lipodystrophy are
155 myopathy, which affects skeletal muscle structure, and distal metaphyseal deformation,
156 causing bone stiffness and limited range of motion (Ardissone et al. 2013). Cardiac
157 arrhythmias are also one of the symptoms caused by the lack of PTRF-CAVIN, and it
158 could be life-threatening (Rajab et al. 2010). These symptoms can be explained by the
159 location where caveolins 1,2 and 3 are expressed.

160



161

162 ▲ (Figure 3) The structure of caveolae. Caveolae are clusters in the cell membrane.
163 Cavin-1 and caveolin 1 bind together and form caveolae. (Made by Biorender)

164

165 *Type 2 Familial Partial Lipodystrophy (FPDL2)*

166 The gene LMNA, which encodes the protein called Lamins, is the gene that
167 causes Type 2 Familial Partial Lipodystrophy (FPDL2). It is also the most common type
168 of lipodystrophy syndrome (Corsa et al. 2021). In cells, Lamin A and Lamin C are
169 expressed predominantly. The main functions of Lamin A/C are the regulation of
170 nucleus shape, providing structural stability to the nuclear envelope and cytoskeleton

171 and also controlling gene regulation (Maung et al. 2026)(Bagias et al. 2020).
172 Specifically nuclear lamina and chromatin, and the interaction between them. One way
173 that Lamin A can affect cell development is the interference with the cleavage step of
174 post translational regulation of Lamin A. ZMPSTE24 plays an important role in this, and
175 it is also considered to be one of the factors that causes lipodystrophy. This modification
176 is crucial and ensures that Prelamin A (the precursor of Lamin A before the post
177 translational regulation) will function normally. Not only will the lack of Lamin A affect cell
178 functions, but the accumulation of Prelamin A could also be toxic to cells (Varlet, Helfer,
179 and Badens 2020).

180 A high risk of cardiovascular diseases is also associated with FPD2. Epicardial
181 adipose tissue (EAT), which is fat tissue surrounding the myocardium and major
182 coronary arteries(Talman et al. 2014), is a recently found biomarker that is related to
183 FPD2. It is found that FPD2 patients have higher EAT volume than type two diabetes
184 patients (Godoy-Matos et al. 2015). However, it is not related to other metabolic issues
185 that are also presented in lipodystrophy (Lamothe et al. 2025). Other studies will also
186 need to be done to have a clearer insight into this condition and the correlation between
187 them.

188

189 *Type 3 Familial Partial Lipodystrophy (FPDL3)*

190 Type 3 Familial Partial Lipodystrophy (FPDL3) is caused by pathogenic variants
191 of the PPARG gene. PPARG encodes for PPAR γ (Peroxisome proliferator-activated
192 receptor γ), known as the master regulator of adipocyte differentiation, maintenance,
193 and functions(Broekema et al. 2019). PPAR γ has three isomers, PPAR γ 1, PPAR γ 2, and
194 PPAR γ 3. Among them, PPAR γ 2 is predominantly expressed in adipocytes. PPAR γ acts
195 as a ligand-activated transcription factor. It binds to its target gene as a heterodimer with
196 PPAR-response elements (PPREs)(Madsen et al. 2022). After binding, PPAR γ induces
197 many targeted genes that are involved in the development of adipose tissues. The TAG
198 cycle is also upregulated. Mutations in PPARG might cause excess differentiation and
199 growth of adipocytes. Therefore, it leads to increased cellular stress and dysfunctions in
200 adipocytes(Soares et al. 2024).

201 Compared to FPD2, FPD3 patients show less severe fat loss. One way to
202 explain this is that more large adipocytes are preserved since mutations in PPARG
203 could lead to excess cell growth. Fat accumulation in areas such as the face and neck
204 are also not observed(Bagias et al. 2020). However, FPD3 patients also show more
205 severe metabolic symptoms, specifically hypertriglyceridemia, diabetes, and insulin
206 resistance(Soares et al. 2024).

207

208 *Acquired Generalized Lipodystrophy (AGL)*

209 As we can see, a wide variety of gene mutations that affect different cellular
210 functions could all lead to LD. However, gene mutations are not the only cause of

211 lipodystrophy. Other environmental factors can also trigger the onset of lipodystrophy.
212 Acquired Generalized Lipodystrophy (AGL, also called Lawrence Syndrome) is another
213 form of lipodystrophy, which has similar symptoms to CGL but is not caused by genetic
214 mutations(Al-Jawad et al. 2025).

215 Adverse effects of highly active antiretroviral therapy (HAART) in patients with
216 HIV are one of the factors that lead to AGL. The mechanism by which antiretroviral
217 drugs play a role in the development of lipodystrophy is not understood completely.
218 Proteins such as thymidine analog nucleoside reverse transcriptase inhibitors (NRTI),
219 which are used in HAART, are shown to disrupt adipose tissue functions(Guzman and
220 Vijayan 2025). It decreases the expression of adiponectin, which regulates the oxidation
221 of glucose and fatty acids. NRTI also induces mitochondrial toxicity, which also plays a
222 role in the development of AGL.

223 Another possible cause of AGL is autoimmune disease. Specifically, perilipin 1
224 (PLIN1) autoantibodies are found in AGL patients (Corvillo et al. 2022). Anti-perilipin is
225 also found in patients with panniculitis associated AGL. Perilipin is found only in adipose
226 tissue and forms a layer that coats lipid droplets. It leads to an increase in lipolysis
227 activities, which decreases the fat storage in the body(Corvillo et al. 2018).






228

229 *Treatments*

230 *Metreleptin*

231 Currently, there isn't a definite treatment for lipodystrophy, but some treatments
232 for specific metabolic abnormalities are being invented (Araújo-Vilar and Santini 2019).
233 For example, Metreleptin (Recombinant methionyl human leptin) is a drug invented
234 specifically for lipodystrophy. It targets leptin deficiency in patients. Leptin is a hormone
235 that regulates energy metabolism. It is secreted by adipose tissue, and it regulates a
236 person's appetite and food intake (Tsoukas, Farr, and Mantzoros 2015). Since
237 lipodystrophy patients lack functional adipose tissue, leptin secretion also decreases.
238 This causes patients to show extreme hyperphagia, which means the excessive intake
239 of food. This worsens insulin resistance and creates excess fat that must be stored in
240 internal organs or muscles. Metreleptin's main purpose is to mimic the naturally
241 occurring leptin hormone, and it must be administered at least once daily (Rodriguez,
242 Mastronardi, and Paz-Filho 2015). Metreleptin is found to be more efficient in
243 Generalized lipodystrophy patients due to the low levels of leptin that are
244 produced(Gilio, Foss-Freitas, and Oral 2025). However, the risk of using Metreleptin for
245 special groups of people, such as pregnant women are not certain. Other common
246 drugs, such as insulin or metformin, can also help patients control their symptoms;
247 however, they are not a cure for LD. Cosmetic surgery is also an option for patients to
248 minimize the psychological discomfort and to have a better quality of life (Table 2).

249

	 Diet and exercise	 Glucose-lowering medications	 Lipid-lowering and CV medications	 LD-specific therapy	 Other
Treatment type	<ul style="list-style-type: none"> Well-balanced, low-fat, low-calorie diet Exercise is encouraged in the absence of specific contraindications 	<ul style="list-style-type: none"> Metformin Insulin Thiazolidinediones GLP-1 receptor agonists SGLT2i 	<ul style="list-style-type: none"> Statins Fibrates Omega-3 fatty acids ACE inhibitors ARBs Beta-blockers 	<ul style="list-style-type: none"> Metreleptin 	<ul style="list-style-type: none"> Cosmetic surgery Counselling
Objectives	<ul style="list-style-type: none"> Cornerstone of LD treatment To help manage weight gain and control calorie and fat intake 	<ul style="list-style-type: none"> Glycemic control 	<ul style="list-style-type: none"> Long-term cardiovascular risk reduction 	<ul style="list-style-type: none"> Only currently approved specific treatment for LD (to treat complications of leptin deficiency adjunct to diet) In PL, often used only once SOC therapies are considered no longer effective 	<ul style="list-style-type: none"> May help patients feel better about their physical appearance and may offer an improved QoL
Challenges and considerations	<ul style="list-style-type: none"> Considered burdensome for patients. Restrictive long-term diets are not easy to maintain Dietary restriction challenging in hyperphagic patients 	<ul style="list-style-type: none"> Patient adherence to therapy High need for careful monitoring especially patients requiring high-doses of insulin Challenges with administering in patients with GL due to lack of subcutaneous fat 	<ul style="list-style-type: none"> Patient adherence to therapy 	<ul style="list-style-type: none"> Often used only once SOC therapies are considered no longer effective Challenges with administering in patients with GL due to lack of subcutaneous fat Restricted access in some regions (e.g., REMS program) 	<ul style="list-style-type: none"> Cosmetic surgery rarely mentioned by participants as a treatment option.

250

251 ▲ (Table 2) Possible medications to control metabolic issues that arises with
 252 lipodystrophy. Including the objectives, possible challenges and other considerations
 253 Reproduced from (Patni et al. 2024) under the terms of the CC BY license


254

255 *Change in Daily Routine*

256 Although Metreleptin can generally help with metabolic dysfunctions, lifestyle
 257 modification also plays a significant role in managing lipodystrophy. A low-fat diet is
 258 recommended for patients. Carbohydrate intake is also restricted to control diabetes.
 259 Physical exercises are also encouraged. However, patients with cardiovascular issues
 260 should avoid doing too much exercise to prevent the development of other serious
 261 complications (Akinici et al. 2024).

262

263 *Conclusion and the Future*



264

265 ▲ (Figure 4) Steps of adipogenesis. Starting from mesenchymal stem cells, after
 266 proliferation and differentiation, it develops into preadipocytes. Then, through
 267 lipogenesis, preadipocytes grow into mature adipocytes. When a person is fasting,
 268 adipocytes go through lipolysis to produce energy by breaking down triglycerides into
 269 glycerol and free fatty acid. The last step is apoptosis, which ultimately leads to cell
 270 death. (Made by Biorender)

271

272 Among the four types of lipodystrophies discussed above, they demonstrate how
 273 any stage of adipogenesis can cause LD. In this review, we discussed CGL1, CGL4,
 274 FPDL2, and FPDL3 just as examples of how different gene mutations that regulate
 275 different steps of adipogenesis all lead to similar consequences (Figure 4). In addition,
 276 we showed that acquired causes can also lead to adipocyte dysfunctions, which lead to
 277 AGL. Genes that are associated with lipodystrophy have a large variety, which play
 278 roles in various processes. They all lead to the lack or abnormal distribution of mature
 279 adipocytes, which is the most common phenotype of lipodystrophy. The amount of lost
 280 adipocytes differs, as well as the location for CGL and FPDL patients. Metabolic
 281 abnormalities also play an important role in the characterization of lipodystrophy. Insulin
 282 resistance, leptin deficiency, and fatty liver disease are all common metabolic issues
 283 that result from a lack of mature adipocytes. Currently, treatments can only target
 284 certain symptoms and are not able to cure them. Although treatments that are approved
 285 for lipodystrophy still only have limited effects, a change in the patient's daily routine
 286 would also help in controlling this disease.

287

In the future, gene editing could be applied to the treatment of this disease.
 288 Preclinical trials have been conducted on mouse models with CGL2, which has a gene
 289 mutation at the BSCL2 gene. Seipin knockout (SKO) mice, which generally show similar
 290 metabolic symptoms to CGL2 patients, were generated, and were injected with
 291 adeno-associated virus (AAV) vectors (Sommer et al. 2022). AAV targets adipocytes,

292 which act as a target in gene therapy for lipodystrophy. The results of the trials show
293 that gene therapy effectively restores adipose tissue development and function (Tiwari
294 et al. 2024). However, there is still a lot that needs to be done to start using gene
295 therapy for lipodystrophy in humans.

296

297

298

299

300

301

302

303

304 References

305

306 Akinci, Baris, Merve Celik Gular, and Elif A. Oral. 2024. "Lipodystrophy Syndromes:
307 Presentation and Treatment." in *Endotext [Internet]*. MDText.com, Inc.

308 Al-Jawad, Mohammad, Lina Mawaldi, Nada Mawaldi, Mariam Krimsty, and Silva
309 Ishkanian. 2025. "Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome)
310 with Both-Side Axillary Breasts: A Case Report." *International Journal of Surgery*
311 *Case Reports* 129:111202. doi:10.1016/j.ijscr.2025.111202.

312 Araújo-Vilar, D., and F. Santini. 2019. "Diagnosis and Treatment of Lipodystrophy: A
313 Step-by-Step Approach." *Journal of Endocrinological Investigation* 42(1):61–73.
314 doi:10.1007/s40618-018-0887-z.

315 Ardissonne, Anna, Cinzia Bragato, Lorella Caffi, Flavia Blasevich, Sabrina Maestrini,
316 Maria Luisa Bianchi, Lucia Morandi, Isabella Moroni, and Marina Mora. 2013.
317 "Novel PTRF Mutation in a Child with Mild Myopathy and Very Mild Congenital
318 Lipodystrophy." *BMC Medical Genetics* 14(1):89. doi:10.1186/1471-2350-14-89.

319 Bagias, Christos, Angeliki Xiarchou, Alexandra Bargiota, and Stelios Tigas. 2020.
320 "Familial Partial Lipodystrophy (FPLD): Recent Insights." *Diabetes, Metabolic*
321 *Syndrome and Obesity: Targets and Therapy* 13:1531–44.
322 doi:10.2147/DMSO.S206053.

323 Broekema, Marjoleine F., Maarten P. G. Massink, Cinzia Donato, Joep De Ligt, Joerg
324 Schaarschmidt, Anouska Borgman, Marieke G. Schooneman, Diana Melchers,
325 Martin N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia,
326 Houshang Monajemi, Gijs W. Van Haaften, Maarten R. Soeters, and Eric
327 Kalkhoven. 2019. "Natural Helix 9 Mutants of PPAR γ Differently Affect Its

- 328 Transcriptional Activity.” *Molecular Metabolism* 20:115–27.
329 doi:10.1016/j.molmet.2018.12.005.
- 330 Chiquette, Elaine, Elif A. Oral, Abhimanyu Garg, David Araújo-Vilar, and Praveen
331 Dhankhar. 2017. “Estimating the Prevalence of Generalized and Partial
332 Lipodystrophy: Findings and Challenges.” *Diabetes, Metabolic Syndrome and
333 Obesity* 10:375–83. doi:10.2147/DMSO.S130810.
- 334 Corsa, Callie A. S., Carolyn M. Walsh, Devika P. Bagchi, Maria C. Foss Freitas, Ziru Li,
335 Julie Hardij, Katrina Granger, Hiroyuki Mori, Rebecca L. Schill, Kenneth T. Lewis,
336 Jessica N. Maung, Ruth D. Azaria, Amy E. Rothberg, Elif A. Oral, and Ormond A.
337 MacDougald. 2021. “Adipocyte-Specific Deletion of Lamin A/C Largely Models
338 Human Familial Partial Lipodystrophy Type 2.” *Diabetes* 70(9):1970–84.
339 doi:10.2337/db20-1001.
- 340 Corvillo, Fernando, Brent S. Abel, Alberto López-Lera, Giovanni Ceccarini, Silvia
341 Magno, Ferruccio Santini, David Araújo-Vilar, Rebecca J. Brown, Pilar Nozal, and
342 Margarita López-Trascasa. 2022. “Characterization and Clinical Association of
343 Autoantibodies Against Perilipin 1 in Patients With Acquired Generalized
344 Lipodystrophy.” *Diabetes* 72(1):71–84. doi:10.2337/db21-1086.
- 345 Corvillo, Fernando, Verónica Aparicio, Alberto López-Lera, Sofía Garrido, David
346 Araújo-Vilar, María P. de Miguel, and Margarita López-Trascasa. 2018.
347 “Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized
348 Lipodystrophy.” *Frontiers in Immunology* 9. doi:10.3389/fimmu.2018.02142.
- 349 Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
350 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford
351 Academic. n.d. Retrieved January 19, 2026.
352 <https://academic.oup.com/jcem/article/101/12/4500/2764979>.
- 353 Fourman, Lindsay T., and Steven K. Grinspoon. 2022. “Approach to the Patient With
354 Lipodystrophy.” *The Journal of Clinical Endocrinology & Metabolism*
355 107(6):1714–26. doi:10.1210/clinem/dgac079.
- 356 Gale, Sarah E., Andrey Frolov, Xianlin Han, Perry E. Bickel, Li Cao, Anne Bowcock,
357 Jean E. Schaffer, and Daniel S. Ory. 2006. “A Regulatory Role for
358 1-Acylglycerol-3-Phosphate-O-Acyltransferase 2 in Adipocyte Differentiation *.”
359 *Journal of Biological Chemistry* 281(16):11082–89. doi:10.1074/jbc.M509612200.

- 360 Garg, Abhimanyu. 2011. "Lipodystrophies: Genetic and Acquired Body Fat Disorders."
361 *The Journal of Clinical Endocrinology & Metabolism* 96(11):3313–25.
362 doi:10.1210/jc.2011-1159.
- 363 Gilio, Donatella, Maria Foss-Freitas, and Elif A. Oral. 2025. "Clinical Guidance for
364 Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment." *Current*
365 *Diabetes Reports* 25(1):47. doi:10.1007/s11892-025-01603-4.
- 366 Godoy-Matos, Amélio Fernando, Cynthia M. Valério, Juliana Bonadiman e. Bragança,
367 Ricardo de Andrade Oliveira, Roberto Luis Zagury, Rodolfo de Paula Lustosa,
368 Gabriel Cordeiro Camargo, César Augusto da Silva Nascimento, and Rodrigo O.
369 Moreira. 2015. "Evaluation of Epicardial Adipose Tissue in Familial Partial
370 Lipodystrophy." *Diabetology & Metabolic Syndrome* 7(1):29.
371 doi:10.1186/s13098-015-0024-5.
- 372 Guzman, Nilmarie, and Vini Vijayan. 2025. "HIV-Associated Lipodystrophy." in
373 *StatPearls*. Treasure Island (FL): StatPearls Publishing.
- 374 Lamothe, Sophie, Patricia Ancel, Inès Belalem, Leïla Lecaque, Joris Fournel, Alexis
375 Jacquier, Zouhair Houhou, Jean-Baptiste Julla, Jean-François Gautier, Corinne
376 Vigouroux, Bénédicte Gaborit, and Camille Vatie. 2025. "Increased Epicardial
377 Adipose Tissue Is Part of the Phenotype of LMNA-Associated Partial
378 Lipodystrophy and Could Contribute to Increased Cardiovascular Risk." *Diabetes*
379 *& Metabolism* 51(6):101710. doi:10.1016/j.diabet.2025.101710.
- 380 Lima, Josivan Gomes, Lucas Nobrega Lima, Vitor Yan Bezerra Araujo, Lucia Helena
381 Coelho Nobrega, and Julliane Tamara Araújo de Melo Campos. 2025. "Diagnosis
382 of Congenital and Acquired Generalized Lipodystrophies—Similarities and
383 Differences." *Endocrines* 6(4):55. doi:10.3390/endocrines6040055.
- 384 Lima, Josivan Gomes, Lucia Helena C. Nobrega, Natalia Nobrega Lima, Marcel Catão
385 Ferreira dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P. Baracho,
386 Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo
387 Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O. Mendes-Aguiar,
388 and Selma Maria B. Jeronimo. 2018. "Causes of Death in Patients with
389 Berardinelli-Seip Congenital Generalized Lipodystrophy." *PLOS ONE*
390 13(6):e0199052. doi:10.1371/journal.pone.0199052.
- 391 Madsen, Maria Stahl, Marjoleine F. Broekema, Martin Rønn Madsen, Arjen Koppen,
392 Anouska Borgman, Cathrin Gräwe, Elisabeth G. K. Thomsen, Denise Westland,
393 Mariette E. G. Kranendonk, Marian Groot Koerkamp, Nicole Hamers, Alexandre
394 M. J. J. Bonvin, José M. Ramos Pittol, Kedar Nath Natarajan, Sander Kersten,

- 395 Frank C. P. Holstege, Houshang Monajemi, Saskia W. C. van Mil, Michiel
396 Vermeulen, Birthe B. Kragelund, David Cassiman, Susanne Mandrup, and Eric
397 Kalkhoven. 2022. "PPAR γ Lipodystrophy Mutants Reveal Intermolecular
398 Interactions Required for Enhancer Activation." *Nature Communications*
399 13(1):7090. doi:10.1038/s41467-022-34766-9.
- 400 Maung, Jessica N., Rebecca L. Schill, Akira Nishii, Maria Foss de Freitas, Bonje N.
401 Obua, Marcus Nygård, Maria D. Mendez-Casillas, Isabel D. K. Hermsmeyer,
402 Donatella Gilio, Ozge Besci, Yang Chen, Brian Desrosiers, Rose E. Adler,
403 Anabela D. Gomes, Merve Celik Guler, Hiroyuki Mori, Romina M. Uranga, Ziru Li,
404 Hadla Hariri, Liping Zhang, Anderson de Paula Souza, Keegan S. Hoose,
405 Kenneth T. Lewis, Taryn A. Hetrick, Paul Cederna, Carey N. Lumeng, Susanne
406 Mandrup, Elif A. Oral, and Ormond A. MacDougald. 2026. "Altered Lipid
407 Metabolism and Inflammatory Programs Associate with Adipocyte Loss in
408 Familial Partial Lipodystrophy 2." *The Journal of Clinical Investigation* 136(1).
409 doi:10.1172/JCI198387.
- 410 de Melo, Maria Eduarda Cardoso, Letícia Marques Gomes da Silva, Ana Carolina Costa
411 Cavalcante, Josivan Gomes Lima, and Julliane Tamara Araújo de Melo Campos.
412 2025. "The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital
413 Generalized Lipodystrophy Pathophysiology." *International Journal of Molecular
414 Sciences* 26(11):5416. doi:10.3390/ijms26115416.
- 415 Misra, Anoop, and Abhimanyu Garg. 2003. "Clinical Features and Metabolic
416 Derangements in Acquired Generalized Lipodystrophy: Case Reports and
417 Review of the Literature." *Medicine* 82(2):129–46.
418 doi:10.1097/00005792-200303000-00007.
- 419 Oswiecimska, Joanna. n.d. "A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2
420 Splicesite Mutation and Concomitant Development of Non-Diabetic
421 Polyneuropathy - Journal of Clinical Research in Pediatric Endocrinology."
422 Retrieved January 19, 2026.
423 <https://jcrpe.org/articles/doi/jcrpe.galenos.2018.2018.0227>.
- 424 Poulos, Sylvia P., Michael V. Dodson, Melinda F. Culver, and Gary J. Hausman. 2016.
425 "The Increasingly Complex Regulation of Adipocyte Differentiation." *Experimental
426 Biology and Medicine* 241(5):449–56. doi:10.1177/1535370215619041.
- 427 Rajab, Anna, Volker Straub, Liza J. McCann, Dominik Seelow, Raymonda Varon, Rita
428 Barresi, Anne Schulze, Barbara Lucke, Susanne Lützkendorf, Mohsen
429 Karbasiyan, Sebastian Bachmann, Simone Spuler, and Markus Schuelke. 2010.
430 "Fatal Cardiac Arrhythmia and Long-QT Syndrome in a New Form of Congenital

- 431 Generalized Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN
432 Mutations." *PLOS Genetics* 6(3):e1000874. doi:10.1371/journal.pgen.1000874.
- 433 Rodriguez, Alexander J., Claudio A. Mastronardi, and Gilberto J. Paz-Filho. 2015. "New
434 Advances in the Treatment of Generalized Lipodystrophy: Role of Metreleptin."
435 *Therapeutics and Clinical Risk Management* 11:1391–1400.
436 doi:10.2147/TCRM.S66521.
- 437 Salle-Teyssières, Laurence, Martine Auclair, Faraj Terro, Mona Nemani, Solaf M.
438 Elsayed, Ezzat Elsobky, Mark Lathrop, Marc Délépine, Olivier Lascols,
439 Jacqueline Capeau, Jocelyne Magré, and Corinne Vigouroux. 2016.
440 "Maladaptative Autophagy Impairs Adipose Function in Congenital Generalized
441 Lipodystrophy Due to Cavin-1 Deficiency." *The Journal of Clinical Endocrinology
442 & Metabolism* 101(7):2892–2904. doi:10.1210/jc.2016-1086.
- 443 Soares, Reivla Marques Vasconcelos, Monique Alvares da Silva, Julliane Tamara
444 Araújo de Melo Campos, and Josivan Gomes Lima. 2024. "Familial Partial
445 Lipodystrophy Resulting from Loss-of-Function PPAR γ Pathogenic Variants:
446 Phenotypic, Clinical, and Genetic Features." *Frontiers in Endocrinology* 15.
447 doi:10.3389/fendo.2024.1394102.
- 448 Sommer, Nadine, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J.
449 Rochford, and George D. Mcilroy. 2022. "Gene Therapy Restores Adipose Tissue
450 and Metabolic Health in a Pre-Clinical Mouse Model of Lipodystrophy." *Molecular
451 Therapy Methods & Clinical Development* 27:206–16.
452 doi:10.1016/j.omtm.2022.09.014.
- 453 Stea, Dante Maria, and Alessio D'Alessio. 2025. "Caveolae: Metabolic Platforms at the
454 Crossroads of Health and Disease." *International Journal of Molecular Sciences*
455 26(7):2918. doi:10.3390/ijms26072918.
- 456 Talman, Andrew H., Peter J. Psaltis, James D. Cameron, Ian T. Meredith, Sujith K.
457 Seneviratne, and Dennis T. L. Wong. 2014. "Epicardial Adipose Tissue: Far More
458 than a Fat Depot." *Cardiovascular Diagnosis and Therapy* 4(6):416–29.
459 doi:10.3978/j.issn.2223-3652.2014.11.05.
- 460 Tiwari, Mansi, Ahlima Roumane, Nadine Sommer, Weiping Han, Mirela Delibegović,
461 Justin J. Rochford, and George D. Mcilroy. 2024. "Preclinical Evaluation of
462 Tissue-Selective Gene Therapies for Congenital Generalised Lipodystrophy."
463 *Gene Therapy* 31(9):445–54. doi:10.1038/s41434-024-00471-z.

464 Tsoukas, Michael A., Olivia M. Farr, and Christos S. Mantzoros. 2015. "Leptin in
465 Congenital and HIV-Associated Lipodystrophy." *Metabolism* 64(1):47–59.
466 doi:10.1016/j.metabol.2014.07.017.

467 Varlet, Alice-Anaïs, Emmanuèle Helfer, and Catherine Badens. 2020. "Molecular and
468 Mechanobiological Pathways Related to the Physiopathology of FPLD2." *Cells*
469 9(9):1947. doi:10.3390/cells9091947.

470

Thank you for submitting your manuscript, entitled “*Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy.*” The topic is timely and clinically relevant, and your review covers important genetic and mechanistic aspects of lipodystrophy syndromes.

Before the manuscript can proceed to peer review, **we ask that you revise the paper to include a dedicated Methods section appropriate for a review article.** Specifically, please describe:

- The databases searched (e.g., PubMed, Scopus, Web of Science, etc.)
- The time frame covered by the search
- Keywords and Boolean search criteria used
- Inclusion and exclusion criteria
- Whether any language or study-category restrictions were applied
- The general approach to study selection and synthesis

Providing this information will necessarily strengthen transparency and methodological rigor.

In addition, we encourage you to address the editorial comments below to improve clarity, structure, and scholarly precision before external review:

- Again, the manuscript currently lacks a methods/search strategy section. As this is a narrative review, it should at the bare minimum state the search strategy, selection criteria, and how evidence was prioritized.
- Several references could be dated in the future or are otherwise very recent (e.g., 2025 and 2026). Please confirm that these are all published or in press, that DOIs are accurate, and that no placeholder or non-verifiable sources are included.
- The organization and flow are a bit unclear and repetitive. I would introduce a clearer structural outline (e.g., genetics -> pathophysiology -> clinical features -> treatment -> future directions), shorten some of your paragraphs on genetics to not distract as much from the main points, and reduce repetition in your introduction vs. conclusion. You should not have to repeat yourself over and over again to make the point clear. Integration > repetition.
- If the figures were made by the author in BioRender, please make this clear, and if not made by the author, they should be properly sourced.
- Some language could be made more precise.
 - Avoid statements such as “only one treatment” without qualification (what do you mean? what is this treatment?)
 - Replace informal or awkward phrasing with precise language (e.g., “a lot of clinical trials.” How many? Do you mean trials or treatments? Do you really need to use this phrasing when you introduce the treatments later on?)
 - Some minor grammatical issues (e.g., adipogenesis “ends with apoptosis.” What do you mean? This does not sound correct as-is)

Moreover, **the review remains largely descriptive.** I would, for instance, highlight more unresolved issues in the field, compare mechanistic differences across CGL vs. FPLD, and provide some more critical commentary on translational barriers for gene therapy.

We look forward to receiving your revised manuscript, and again, we believe that the core of your manuscript shows promise.

1 *Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy*

2 *Abstract*

3 Lipodystrophy syndromes are rare diseases that are often characterized by a
4 general or partial absence of body fat. Fat tissues are also known as adipose tissues, and
5 the lack of adipose tissues would lead to serious consequences and the development of a
6 series of metabolic issues. These syndromes are genetically and clinically heterogeneous,
7 with different phenotypes influenced by underlying molecular defects. They are all factors
8 that determine the type of lipodystrophy a patient has. Due to the rarity of this disorder,
9 not many studies have been done on it, which leads to people's lack of knowledge about
10 this disease and increases the difficulty of treating it. In this article, we first consider the
11 classification and clinical aspects of lipodystrophy syndromes, covering the onset and the
12 differences in phenotypes of patients. Then, we discuss the molecular and cellular
13 mechanisms of several types of lipodystrophies and the role they play in the development
14 of adipose tissues. Next, we focus on other metabolic dysfunctions caused by
15 lipodystrophy, such as insulin resistance, fatty liver, and hypertriglyceridemia. Lastly, we
16 evaluate therapeutic strategies aimed at improving metabolic control and quality of life in
17 affected patients. Future direction of study and potential therapies may be improved with
18 a deeper and thorough understanding of the genetic and mechanistic basis of
19 lipodystrophy.

20

21 *Keywords:* Lipodystrophy syndromes, adipose tissue, adipogenesis, gene mutations,
22 metabolic dysfunctions

23

24 1. *Introduction*

25 Lipodystrophy syndromes (LD) are a heterogeneous group of rare disorders
26 characterized by the partial or complete loss of mature adipose tissue in localized or
27 generalized areas. This results in the inability to store body fat and excess nutrients
28 (Fourman and Grinspoon 2022). Two main classes of lipodystrophy are Congenital
29 Generalized Lipodystrophy (CGL) and Familial Partial Lipodystrophy (FPLD). Adipose
30 tissues are formed through a process called adipogenesis, and it is crucial for the adipose
31 tissue to function normally.

32 Adipogenesis is the process by which mesenchymal stem cells differentiate into
33 mature adipose tissue. This process also includes the triacylglycerol (TAG) fatty acid cycle,
34 which regulates lipid storage and mobilization in adipocytes. It is the process where the
35 lipid droplets undergo lipolysis (the breakdown of lipid droplets) and lipogenesis (the
36 synthesis of new lipid droplets) (Poulos et al. 2016). However, if a gene mutation or other
37 factors affect the components that play a role in regulating adipogenesis, it would lead to
38 serious, life-threatening consequences.

39 LD can be either congenital or acquired, and it is classified based on the location of
40 lost adipose tissue, and further divided into subtypes according to the gene segment that

41 is mutated (Akinçi, Gular, and Oral 2024) (Table 1). CGL (also called Berardinelli-Seip
 42 syndrome) is characterized by the near-complete absence of adipocytes, both mechanical
 43 and metabolic fat tissues (Oswiecimska n.d.). CGLs are autosomal recessive, and the
 44 symptoms often start showing shortly after birth. It is further divided into CGL1, CGL2,
 45 CGL3, and CGL4, which link to four different gene mutations. FPLD presents as an
 46 abnormal distribution of adipose tissue, with fat loss around the limbs, torso, and hips. It
 47 can be autosomal recessive or dominant depending on the gene that is involved. Since the
 48 body is not able to store excess energy in those areas, other body parts, such as the face,
 49 neck, and internal organs like the liver, gain extra adipose tissue (Diagnosis and
 50 Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline | The
 51 Journal of Clinical Endocrinology & Metabolism | Oxford Academic n.d.). Same as CGL, it is
 52 also divided into several subtypes, including FPLD1 (Kobberling-type lipodystrophy),
 53 FPLD2 (Dunnigan Variety lipodystrophy), FPLD3, FPLD4, FPLD5, and FPLD6. Proteins or
 54 enzymes that are encoded by the genes associated with any kind of lipodystrophy all play
 55 important roles in the development of adipocyte. Acquired Generalized Lipodystrophy
 56 (AGL, Lawrence Syndrome) and Acquired Partial Lipodystrophy (APL, Barraquer-Simons
 57 syndrome) have similar symptoms, respectively; however, they can be caused by
 58 autoimmune diseases, the side effects of antiretroviral therapy (ART) for HIV patients, and
 59 sometimes idiopathic (Misra and Garg 2003).

60

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobberling)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/adolescence.	Palpable "ledge" between normal and lipodystrophic
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not affected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

61

62 ▲ Table 1: Classification, clinical features, and molecular basis of lipodystrophies (Made
 63 with Google Sheet)


64

65 Not only will the lack of excess energy affect the body's normal functions, but other
66 complications that arise with lipodystrophy also have a big effect on patients' lives. Some
67 common metabolic abnormalities include leptin deficiency, insulin resistance, diabetes,
68 hypertriglyceridemia, and fatty liver disease (figure 1). **Currently, around 200 clinical trials**
69 **are in progress**, trying to discover a new way to treat or cure lipodystrophy, especially
70 targeting leptin deficiency. Metreleptin, for example, is a treatment created specifically for
71 LD patients. It is a targeted treatment for leptin deficiency, which is a common metabolic
72 issue associated with LD. (Araújo-Vilar e Santini 2019). **It currently the only FDA-**
73 **approved treatment for LD patients. Due to the rarity of this disease, limited research has**
74 **been done, making Metreleptin the primary choice for LD patients (Ajluni et al. 2016).**
75 Patients will still need to have a healthy diet and other medications for other metabolic
76 issues. According to studies, only about 3/million people around the world are affected by
77 some type of lipodystrophy syndrome. While the prevalence of CGL is estimated to be
78 0.23/ million people, the prevalence of FPLD is around 2.84/million people (Chiquette et
79 al. 2017). It is also estimated to shorten a patient's lifespan by 30 or more years. The main
80 cause of death is shown to be liver diseases and infections caused by adipose tissue
81 dysfunction, but also varies from type to type of lipodystrophy (Lima et al. 2018).

82 This literature review aims to highlight the molecular mechanisms of lipodystrophy,
83 focusing on the genetic causes, differences between types of lipodystrophies, and other
84 metabolic conditions caused by adipose tissue abnormalities. In addition, the treatment
85 developed and other possibilities for a cure.

86

Comparison of adipocyte functions between healthy person and lipodystrophy patient



87

88 ▲ Figure 1: Comparison of adipocytes functions between a healthy person and a
89 lipodystrophy patient. The storage of an adipocytes is limited in lipodystrophy patients.
90 Common metabolic abnormalities include leptin deficiency, insulin resistance and increase
91 glucose level in blood streams. (Made with BioRender)

92

93 2. Method

94 A literature search was conducted using PubMed and Google Scholar databases.
95 The search included following keywords: "lipodystrophy genetics", "adipocyte
96 differentiation", "AGPAT2", "PTRF Cavin-1", "LMNA mutation", "PPAR γ mutation",
97 "lipodystrophy metabolic abnormalities". Articles published between 2000 and 2026 were
98 included. Only publications in English language were considered. Studies were included if
99 they were peer-reviewed primary research articles or comprehensive reviews focusing on
100 genetic, molecular, or metabolic mechanisms of lipodystrophy syndromes. Case studies
101 with relevant insights and information were also included. Non peer reviewed sources,
102 articles published before 2000, case reports with only quantitative data and without
103 further analysis were excluded. Titles and abstracts were first screened for relevance. Full
104 article was reviewed if they met the inclusion criteria.


105

106 Discussion

107 3. Genetics and Pathophysiology

108 3.1 Type 1 Congenital Generalized Lipodystrophy (CGL1)

109 Type 1 Congenital Generalized Lipodystrophy (CGL1) is caused by a mutation in
 110 the gene AGPAT2. AGPAT2 is the gene coding for a specific enzyme,
 111 1-acylglycerol-3-phosphate O-acyltransferase 2, which catalyzes the acylation of
 112 lysophosphatidic acid (1-acylglycerol-3-phosphate) to phosphatidic acid (1,2
 113 diacylglycerol-3-phosphate)(Gale et al. 2006) (figure 2). It is an important precursor of
 114 the biosynthesis of triacylglycerol (TAG) and phospholipid synthesis from
 115 glycerol-3-phosphate. This step esterifies a second fatty acyl group at the sn-2 position of
 116 the glycerol backbone. Phosphatidic acid is further acylated by other enzymes, creating
 117 triacylglycerol and phospholipids. The AGPAT family consists of 11 isomers; however,
 118 AGPAT2 is expressed at higher levels in adipose tissue than the other isomers. The
 119 presence of mechanical adipose tissue can be explained by the increased expression of
 120 the other isomers. However, studies have shown that the expression of AGPAT2 is
 121 required for the accumulation of triacylglycerol, especially in metabolic adipose tissues.
 122 Defects in AGPAT2 genes also impact insulin signaling, meaning that gluconeogenesis will
 123 be unrestricted, which leads to the development of hyperglycemia and diabetes(de Melo et
 124 al. 2025).
 125



126
 127 ▲ Figure 2: The process of Triacylglycerol synthesis. In the second step, where LPA is
 128 acylated to PA, AGPAT is the enzyme that catalyzes this reaction. Without it, the reactions
 129 after it will not occur properly, meaning that adipocytes can't develop properly. (Made
 130 with BioRender)


131

132 3.2 Type 4 Congenital Generalized Lipodystrophy (CGL4)

133 Type four Congenital Generalized Lipodystrophy (CGL4) is associated with the
134 gene mutation in the PTRF gene (Polymerase I and Transcript Release
135 Factor) (Salle-Teyssières et al. 2016). The PTRF gene encodes cavin-1, which is one of the
136 essential proteins that is required for the biogenesis of caveolae. Caveolae are one of the
137 most abundant invaginations in the cell membrane of lots of mammalian cells (Figure 3).
138 Cavin-1 starts the whole process of the synthesis of caveolae by recruiting other proteins
139 necessary, such as caveolins. Without it, cells won't be able to produce caveolae. Although
140 it is abundant, its functions have only been understood in the past few decades. It plays a
141 role in signal transduction, endocytosis, and mechanotransduction (Stea and D'Alessio
142 2025). Cavin-1 binds with the caveolins to form Caveolae. There are three members in the
143 caveolin family, caveolin 1,2 is expressed in a lot of cells, like smooth muscle cells,
144 fibroblasts, and adipocytes. Caveolin 3 is expressed exclusively in cardiac and skeletal
145 muscle. It is shown that the lack of PTRF-CAVIN doesn't affect the level of caveolin
146 expressed (Rajab et al. 2010). However, it affects caveolin's ability to localize to the cell's
147 surface, which makes the formation of caveolae impossible. Absence of caveolae causes
148 the cell to not be able to develop properly, causing abnormalities and dysfunctions.

149 Some symptoms that are uniquely associated with this type of lipodystrophy are
150 myopathy, which affects skeletal muscle structure, and distal metaphyseal deformation,
151 causing bone stiffness and limited range of motion (Ardissonne et al. 2013). Cardiac
152 arrhythmias are also one of the symptoms caused by the lack of PTRF-CAVIN, and it could
153 be life-threatening (Rajab et al. 2010). These symptoms can be explained by the location
154 where caveolins 1,2 and 3 are expressed.

155



156

157 ▲ Figure 3: The structure of caveolae. Caveolae are clusters in the cell membrane.
158 Cavin-1 and caveolin 1 bind together and form caveolae. (Made with Biorender)
159

160 3.3 Type 2 Familial Partial Lipodystrophy (FPLD2)

161 The gene LMNA, which encodes the protein called Lamins, is the gene that causes
162 Type 2 Familial Partial Lipodystrophy (FPLD2). It is also the most common type of
163 lipodystrophy syndrome (Corsa et al. 2021). In cells, Lamin A and Lamin C are expressed
164 predominantly. The main functions of Lamin A/C are the regulation of nucleus shape,
165 providing structural stability to the nuclear envelope and cytoskeleton and also controlling
166 gene regulation (Maung et al. 2026)(Bagias et al. 2020). Specifically nuclear lamina and
167 chromatin, and the interaction between them. One way that Lamin A can affect cell
168 development is the interference with the cleavage step of post translational regulation of
169 Lamin A. ZMPSTE24 plays an important role in this, and it is also considered to be one of
170 the factors that causes lipodystrophy. This modification is crucial and ensures that
171 Prelamin A (the precursor of Lamin A before the post translational regulation) will
172 function normally. Not only will the lack of Lamin A affect cell functions, but the
173 accumulation of Prelamin A could also be toxic to cells (Varlet, Helfer, and Badens 2020),
174 which could affect the cell's ability to develop properly.

175 A high risk of cardiovascular diseases is also associated with FPLD2. It is found that
176 FPLD2 patients have higher Epicardial adipose tissue (EAT) volume than type two
177 diabetes patients (Talman et al. 2014) (Godoy-Matos et al. 2015). However, it is not
178 related to other metabolic issues that are also presented in lipodystrophy (Lamothe et al.
179 2025). Other studies will also need to be done to have a clearer insight into this condition
180 and the correlation between them.

181

182 3.4 Type 3 Familial Partial Lipodystrophy (FPLD3)

183 Type 3 Familial Partial Lipodystrophy (FPLD3) is caused by pathogenic variants of
184 the PPARG gene. PPARG encodes for PPAR γ (Peroxisome proliferator-activated receptor
185 γ), known as the master regulator of adipocyte differentiation, maintenance, and
186 functions(Broekema et al. 2019). PPAR γ has three isoforms, PPAR γ 1, PPAR γ 2, and
187 PPAR γ 3. Among them, PPAR γ 2 is predominantly expressed in adipocytes. PPAR γ acts as a
188 ligand-activated transcription factor. It binds to its target gene as a heterodimer with
189 PPAR-response elements (PPREs)(Madsen et al. 2022). After binding, PPAR γ induces
190 many targeted genes that are involved in the development of adipose tissues. The TAG
191 cycle is also upregulated. Mutations in PPARG might cause excess differentiation and
192 growth of adipocytes. Therefore, it leads to increased cellular stress and dysfunctions in
193 adipocytes(Soares et al. 2024).

194 Compared to FPLD2, FPLD3 patients show less severe fat loss. One way to explain
195 this is that more large adipocytes are preserved since mutations in PPARG could lead to
196 excess cell growth. Fat accumulation in areas such as the face and neck are also not

197 observed (Bagias et al. 2020). However, FPLD3 patients also show more severe metabolic
198 symptoms, specifically hypertriglyceridemia, diabetes, and insulin resistance(Soares et al.
199 2024).

200

201 3.5 Acquired Generalized Lipodystrophy (AGL)

202 As we can see, a wide variety of gene mutations that affect different cellular
203 functions could all lead to LD. However, gene mutations are not the only cause of
204 lipodystrophy. Other environmental factors can also trigger the onset of lipodystrophy.
205 Acquired Generalized Lipodystrophy (AGL, also called Lawrence Syndrome) is another
206 form of lipodystrophy, which has similar symptoms to CGL but is not caused by genetic
207 mutations(Al-Jawad et al. 2025).

208 Adverse effects of highly active antiretroviral therapy (HAART) in patients with HIV
209 are one of the factors that lead to AGL. The mechanism by which antiretroviral drugs play
210 a role in the development of lipodystrophy is not understood completely. Proteins such as
211 thymidine analog nucleoside reverse transcriptase inhibitors (NRTI), which are used in
212 HAART, are shown to disrupt adipose tissue functions(Guzman and Vijayan 2025). It
213 decreases the expression of adiponectin, which regulates the oxidation of glucose and
214 fatty acids. NRTI also induces mitochondrial toxicity, which also plays a role in the
215 development of AGL.

216 Another possible cause of AGL is autoimmune disease. Specifically, perilipin 1
217 (PLIN1) autoantibodies are found in AGL patients (Corvillo et al. 2022). Anti-perilipin is
218 also found in patients with panniculitis associated AGL. Perilipin is found only in adipose
219 tissue and forms a layer that coats lipid droplets. It leads to an increase in lipolysis
220 activities, which decreases the fat storage in the body(Corvillo et al. 2018).

221

222 4. Diagnosis and Clinical Features

223 Since lipodystrophy is such a rare disease and not well known to the public, it is
224 often misdiagnosed or undiagnosed by clinicians. It heavily relies on clinical history and
225 physical examinations that reveal the composition of adipose tissues. Metabolic
226 dysfunctions are also important markers when diagnosing lipodystrophy. Although
227 patients with CGL show symptoms such as a lack of body fat shortly after birth, it is often
228 left undiagnosed until their childhood or adulthood, when they start showing metabolic
229 abnormalities. As for FPLD, it is even more commonly unrecognized due to patients only
230 losing adipose tissue partially. It could be easily mixed up with other types of common
231 metabolic diseases like obesity or severe diabetes mellitus. Presentations of AGL and APL
232 are generally similar to CGL and FPLD, also including the metabolic issues that come with
233 it (Lima et al. 2025).

234 Some phenotypes that are associated with lipodystrophy are muscular appearance,
235 prominent veins, and the lack of body fat. For CGL patients, the absence of metabolic
236 adipose tissues is more common than mechanical tissues. Metabolic adipose tissues are in

237 charge or energy storage and hormone secretion, while the mechanical tissues, also
238 known as subcutaneous fat tissue, are found under the skin and internal organs to
239 provide protection and support. Although patients still in some degrees lack functional
240 mechanical fat tissues. Except for CGL2, in which patients generally do not acquire both
241 kinds of fat tissues (Garg 2011). In contrast, FPLD is characterized by the abnormal
242 distribution with a slight loss of adipose tissue, meaning that patients still acquire most of
243 their functional fat tissues. In addition, as mentioned before, the onset of CGL is often
244 shortly after birth, but for FPLDs, its onset is usually around puberty or adolescence. In
245 general, CGL patients lack the ability to build up mature adipose tissues, while FPLD
246 patients can't store or regulate adipose tissue properly. Next, we will be discussing some
247 potential treatments for lipodystrophy and the mechanisms behind them.






248

249 5. Treatments

250 5.1 Metreleptin

251 Currently, there isn't a definite treatment for lipodystrophy, but some treatments
252 for specific metabolic abnormalities are being invented (Araújo-Vilar and Santini 2019).
253 For example, Metreleptin (Recombinant methionyl human leptin) is a drug invented
254 specifically for lipodystrophy. It targets leptin deficiency in patients. Leptin is a hormone
255 that regulates energy metabolism. It is secreted by adipose tissue, and it regulates a
256 person's appetite and food intake (Tsoukas, Farr, and Mantzoros 2015). Since
257 lipodystrophy patients lack functional adipose tissue, leptin secretion also decreases. This
258 causes patients to show extreme hyperphagia, which means the excessive intake of food.
259 This worsens insulin resistance and creates excess fat that must be stored in internal
260 organs or muscles. Metreleptin's main purpose is to mimic the naturally occurring leptin
261 hormone, and it must be administered at least once daily (Rodriguez, Mastronardi, and
262 Paz-Filho 2015). Metreleptin is found to be more efficient in Generalized lipodystrophy
263 patients due to the low levels of leptin that are produced (Gilio, Foss-Freitas, and Oral
264 2025). However, the risk of using Metreleptin for special groups of people, such as
265 pregnant women are not certain. Other common drugs, such as insulin or metformin, can
266 also help patients control their symptoms; however, they are not a cure for LD. Cosmetic
267 surgery is also an option for patients to minimize the psychological discomfort and to
268 have a better quality of life (Table 2).

269

	 Diet and exercise	 Glucose-lowering medications	 Lipid-lowering and CV medications	 LD-specific therapy	 Other
Treatment type	<ul style="list-style-type: none"> Well-balanced, low-fat, low-calorie diet Exercise is encouraged in the absence of specific contraindications 	<ul style="list-style-type: none"> Metformin Insulin Thiazolidinediones GLP-1 receptor agonists SGLT2i 	<ul style="list-style-type: none"> Statins Fibrates Omega-3 fatty acids ACE inhibitors ARBs Beta-blockers 	<ul style="list-style-type: none"> Metreleptin 	<ul style="list-style-type: none"> Cosmetic surgery Counselling
Objectives	<ul style="list-style-type: none"> Cornerstone of LD treatment To help manage weight gain and control calorie and fat intake 	<ul style="list-style-type: none"> Glycemic control 	<ul style="list-style-type: none"> Long-term cardiovascular risk reduction 	<ul style="list-style-type: none"> Only currently approved specific treatment for LD (to treat complications of leptin deficiency adjunct to diet) In PL, often used only once SOC therapies are considered no longer effective 	<ul style="list-style-type: none"> May help patients feel better about their physical appearance and may offer an improved QoL
Challenges and considerations	<ul style="list-style-type: none"> Considered burdensome for patients. Restrictive long-term diets are not easy to maintain Dietary restriction challenging in hyperphagic patients 	<ul style="list-style-type: none"> Patient adherence to therapy High need for careful monitoring especially patients requiring high-doses of insulin Challenges with administering in patients with GL due to lack of subcutaneous fat 	<ul style="list-style-type: none"> Patient adherence to therapy 	<ul style="list-style-type: none"> Often used only once SOC therapies are considered no longer effective Challenges with administering in patients with GL due to lack of subcutaneous fat Restricted access in some regions (e.g., REMS program) 	<ul style="list-style-type: none"> Cosmetic surgery rarely mentioned by participants as a treatment option.

270

271 ▲ Table 2: Possible medications to control metabolic issues that arises with
 272 lipodystrophy. Including the objectives, possible challenges and other considerations
 273 (Reproduced from (Patni et al. 2024) under the terms of the CC BY license)

274

275 5.2 Change in Daily Routine

276 Although Metreleptin can generally help with metabolic dysfunctions, lifestyle
 277 modification also plays a significant role in managing lipodystrophy. A low-fat diet is
 278 recommended for patients. Carbohydrate intake is also restricted to control diabetes.
 279 Physical exercises are also encouraged. However, patients with cardiovascular issues
 280 should avoid doing too much exercise to prevent the development of other serious
 281 complications (Akinci et al. 2024).

282

283 5.3 Limitations and Possibility of Gene Editing


284 Although Metreleptin is an effective way for LD patients to manage metabolic
 285 complications, it is not able to cure it. In the future, gene editing could be applied to the
 286 treatment of this disease. Preclinical trials have been conducted on mouse models with
 287 CGL2, which has a gene mutation at the BSCL2 gene. Seipin knockout (SKO) mice, which
 288 generally show similar metabolic symptoms to CGL2 patients, were generated, and were
 289 injected with adeno-associated virus (AAV) vectors (Sommer et al. 2022). AAV targets
 290 adipocytes, which act as a target in gene therapy for lipodystrophy. The results of the trials
 291 show that gene therapy effectively restores adipose tissue development and function
 292 (Tiwari et al. 2024). However, even though AAV is commonly used in clinical trials, it hasn't
 293 been used to directly target adipose tissue. Novel AAV serotypes that targets adipose
 294 tissue or alternative promoter are critical for the development of an improved gene
 295 therapy strategy for LD patients. Therefore, there isn't enough evidence currently to

296 suggest that the results from mouse models can be translated to humans. Continued
297 research on LD and advances in gene therapy are necessary to develop a more effective
298 therapeutic strategy for this rare disorder.

299

300 6. Conclusion and the Future

301



302

303 ▲ Figure 4: Steps of adipogenesis. Starting from mesenchymal stem cells, after
304 proliferation and differentiation, it develops into preadipocytes. Then, through lipogenesis,
305 preadipocytes grow into mature adipocytes. When a person is fasting, adipocytes go
306 through lipolysis to produce energy by breaking down triglycerides into glycerol and free
307 fatty acid. The last step is apoptosis, which ultimately leads to cell death. (Made with
308 BioRender)

309

310 Although genes involved in lipodystrophy syndromes affect various cellular
311 processes, such as lipid synthesis, signal transduction, and nuclear structure, they all lead
312 to a common outcome -impaired adipocyte development and function. The examples
313 discussed in this review, including CGL1, CGL4, FPLD2, and FPLD3, demonstrate how
314 different stages of adipogenesis and gene mutations that are involved in adipogenesis all
315 lead to similar consequences (Figure 4). In addition to genetic causes, acquired factors
316 can also contribute to adipocyte dysfunctions, as seen in AGL.

317 LD highlights the essential role of adipose tissue as an endocrine and metabolic
318 organ. It not only stores energy but also maintains metabolic homeostasis and regulates
319 hormones. The absence of adipocytes, as shown in this review, could cause
320 life-threatening disorders. Understanding this condition not only helps people recognize
321 the role of adipose tissue in metabolism but also helps raise awareness of rare diseases.
322 For conditions like lipodystrophy, many patients remain undiagnosed throughout their
323 lives. Not only is conducting research with so few samples challenging, but scientists may

324 be less willing to dedicate time to studying rare diseases compared to diseases that affect
325 a larger population. Increased awareness and improved diagnostic tools not only help
326 identify individuals affected by this disease earlier but also give them a chance to manage
327 their condition in a more effective way.

328 Since the discovery of lipodystrophy syndromes around the mid-20th century, lots
329 of progress has been made to get a better understanding of lipodystrophy. From the
330 phenotypes to the metabolic abnormalities and the underlying genetic causes, research
331 have been done to seek for ways to reduce patient's pain and suffering. Having a deep
332 understanding of lipodystrophy will be crucial to the development of a more effective and
333 targeted therapeutic strategy.

334

335 7. References

336

337 Akinci, Baris, Merve Celik Gular, and Elif A. Oral. 2024. "Lipodystrophy Syndromes:
338 Presentation and Treatment." in *Endotext [Internet]*. MDText.com, Inc.

339 Al-Jawad, Mohammad, Lina Mawaldi, Nada Mawaldi, Mariam Krimsty, and Silva Ishkanian.
340 2025. "Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome) with
341 Both-Side Axillary Breasts: A Case Report." *International Journal of Surgery Case
342 Reports* 129:111202. doi:10.1016/j.ijscr.2025.111202.

343 Araújo-Vilar, D., and F. Santini. 2019. "Diagnosis and Treatment of Lipodystrophy: A
344 Step-by-Step Approach." *Journal of Endocrinological Investigation* 42(1):61–73.
345 doi:10.1007/s40618-018-0887-z.

346 Ardissonne, Anna, Cinzia Bragato, Lorella Caffi, Flavia Blasevich, Sabrina Maestrini, Maria
347 Luisa Bianchi, Lucia Morandi, Isabella Moroni, and Marina Mora. 2013. "Novel
348 PTRF Mutation in a Child with Mild Myopathy and Very Mild Congenital
349 Lipodystrophy." *BMC Medical Genetics* 14(1):89. doi:10.1186/1471-2350-14-89.

350 Bagias, Christos, Angeliki Xiarchou, Alexandra Bargiota, and Stelios Tigas. 2020. "Familial
351 Partial Lipodystrophy (FPLD): Recent Insights." *Diabetes, Metabolic Syndrome and
352 Obesity: Targets and Therapy* 13:1531–44. doi:10.2147/DMSO.S206053.

353 Broekema, Marjoleine F., Maarten P. G. Massink, Cinzia Donato, Joep De Ligt, Joerg
354 Schaarschmidt, Anouska Borgman, Marieke G. Schooneman, Diana Melchers, Martin
355 N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia, Houshang
356 Monajemi, Gijs W. Van Haaften, Maarten R. Soeters, and Eric Kalkhoven. 2019.
357 "Natural Helix 9 Mutants of PPAR γ Differently Affect Its Transcriptional Activity."
358 *Molecular Metabolism* 20:115–27. doi:10.1016/j.molmet.2018.12.005.

- 359 Chiquette, Elaine, Elif A. Oral, Abhimanyu Garg, David Araújo-Vilar, and Praveen Dhankhar.
360 2017. "Estimating the Prevalence of Generalized and Partial Lipodystrophy:
361 Findings and Challenges." *Diabetes, Metabolic Syndrome and Obesity* 10:375–83.
362 doi:10.2147/DMSO.S130810.
- 363 Corsa, Callie A. S., Carolyn M. Walsh, Devika P. Bagchi, Maria C. Foss Freitas, Ziru Li, Julie
364 Hardij, Katrina Granger, Hiroyuki Mori, Rebecca L. Schill, Kenneth T. Lewis, Jessica
365 N. Maung, Ruth D. Azaria, Amy E. Rothberg, Elif A. Oral, and Ormond A. MacDougald.
366 2021. "Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial
367 Partial Lipodystrophy Type 2." *Diabetes* 70(9):1970–84. doi:10.2337/db20-1001.
- 368 Corvillo, Fernando, Brent S. Abel, Alberto López-Lera, Giovanni Ceccarini, Silvia Magno,
369 Ferruccio Santini, David Araújo-Vilar, Rebecca J. Brown, Pilar Nozal, and Margarita
370 López-Trascasa. 2022. "Characterization and Clinical Association of Autoantibodies
371 Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy." *Diabetes*
372 72(1):71–84. doi:10.2337/db21-1086.
- 373 Corvillo, Fernando, Verónica Aparicio, Alberto López-Lera, Sofía Garrido, David
374 Araújo-Vilar, María P. de Miguel, and Margarita López-Trascasa. 2018.
375 "Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized
376 Lipodystrophy." *Frontiers in Immunology* 9. doi:10.3389/fimmu.2018.02142.
- 377 Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
378 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic.
379 n.d. Retrieved January 19, 2026.
380 <https://academic.oup.com/jcem/article/101/12/4500/2764979>.
- 381 Fourman, Lindsay T., and Steven K. Grinspoon. 2022. "Approach to the Patient With
382 Lipodystrophy." *The Journal of Clinical Endocrinology & Metabolism*
383 107(6):1714–26. doi:10.1210/clinem/dgac079.
- 384 Gale, Sarah E., Andrey Frolov, Xianlin Han, Perry E. Bickel, Li Cao, Anne Bowcock, Jean E.
385 Schaffer, and Daniel S. Ory. 2006. "A Regulatory Role for
386 1-Acylglycerol-3-Phosphate-O-Acyltransferase 2 in Adipocyte Differentiation *."
387 *Journal of Biological Chemistry* 281(16):11082–89. doi:10.1074/jbc.M509612200.
- 388 Garg, Abhimanyu. 2011. "Lipodystrophies: Genetic and Acquired Body Fat Disorders." *The*
389 *Journal of Clinical Endocrinology & Metabolism* 96(11):3313–25.
390 doi:10.1210/jc.2011-1159.

- 391 Gilio, Donatella, Maria Foss-Freitas, and Elif A. Oral. 2025. "Clinical Guidance for
392 Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment." *Current*
393 *Diabetes Reports* 25(1):47. doi:10.1007/s11892-025-01603-4.
- 394 Godoy-Matos, Amélio Fernando, Cynthia M. Valério, Juliana Bonadiman e. Bragança,
395 Ricardo de Andrade Oliveira, Roberto Luis Zagury, Rodolfo de Paula Lustosa,
396 Gabriel Cordeiro Camargo, César Augusto da Silva Nascimento, and Rodrigo O.
397 Moreira. 2015. "Evaluation of Epicardial Adipose Tissue in Familial Partial
398 Lipodystrophy." *Diabetology & Metabolic Syndrome* 7(1):29.
399 doi:10.1186/s13098-015-0024-5.
- 400 Guzman, Nilmarie, and Vini Vijayan. 2025. "HIV-Associated Lipodystrophy." in *StatPearls*.
401 Treasure Island (FL): StatPearls Publishing.
- 402 Lamothe, Sophie, Patricia Ancel, Inès Belalem, Leïla Lecaque, Joris Fournel, Alexis Jacquier,
403 Zouhair Houhou, Jean-Baptiste Julla, Jean-François Gautier, Corinne Vigouroux,
404 Bénédicte Gaborit, and Camille Vatie. 2025. "Increased Epicardial Adipose Tissue Is
405 Part of the Phenotype of *LMNA*-Associated Partial Lipodystrophy and Could
406 Contribute to Increased Cardiovascular Risk." *Diabetes & Metabolism*
407 51(6):101710. doi:10.1016/j.diabet.2025.101710.
- 408 Lima, Josivan Gomes, Lucas Nobrega Lima, Vitor Yan Bezerra Araujo, Lucia Helena Coelho
409 Nobrega, and Julliane Tamara Araújo de Melo Campos. 2025. "Diagnosis of
410 Congenital and Acquired Generalized Lipodystrophies—Similarities and
411 Differences." *Endocrines* 6(4):55. doi:10.3390/endocrines6040055.
- 412 Lima, Josivan Gomes, Lucia Helena C. Nobrega, Natalia Nobrega Lima, Marcel Catão
413 Ferreira dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P. Baracho,
414 Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo
415 Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O. Mendes-Aguiar,
416 and Selma Maria B. Jeronimo. 2018. "Causes of Death in Patients with
417 Berardinelli-Seip Congenital Generalized Lipodystrophy." *PLOS ONE*
418 13(6):e0199052. doi:10.1371/journal.pone.0199052.
- 419 Madsen, Maria Stahl, Marjoleine F. Broekema, Martin Rønn Madsen, Arjen Koppen,
420 Anouska Borgman, Cathrin Gräwe, Elisabeth G. K. Thomsen, Denise Westland,
421 Mariette E. G. Kranendonk, Marian Groot Koerkamp, Nicole Hamers, Alexandre M. J.
422 J. Bonvin, José M. Ramos Pittol, Kedar Nath Natarajan, Sander Kersten, Frank C. P.
423 Holstege, Houshang Monajemi, Saskia W. C. van Mil, Michiel Vermeulen, Birthe B.
424 Kragelund, David Cassiman, Susanne Mandrup, and Eric Kalkhoven. 2022. "PPAR γ
425 Lipodystrophy Mutants Reveal Intermolecular Interactions Required for Enhancer

426 Activation." *Nature Communications* 13(1):7090.
427 doi:10.1038/s41467-022-34766-9.

428 Maung, Jessica N., Rebecca L. Schill, Akira Nishii, Maria Foss de Freitas, Bonje N. Obua,
429 Marcus Nygård, Maria D. Mendez-Casillas, Isabel D. K. Hermsmeyer, Donatella Gilio,
430 Ozge Besci, Yang Chen, Brian Desrosiers, Rose E. Adler, Anabela D. Gomes, Merve
431 Celik Guler, Hiroyuki Mori, Romina M. Uranga, Zirui Li, Hadla Hariri, Liping Zhang,
432 Anderson de Paula Souza, Keegan S. Hoose, Kenneth T. Lewis, Taryn A. Hetrick, Paul
433 Cederna, Carey N. Lumeng, Susanne Mandrup, Elif A. Oral, and Ormond A.
434 MacDougald. 2026. "Altered Lipid Metabolism and Inflammatory Programs
435 Associate with Adipocyte Loss in Familial Partial Lipodystrophy 2." *The Journal of*
436 *Clinical Investigation* 136(1). doi:10.1172/JCI198387.

437 de Melo, Maria Eduarda Cardoso, Letícia Marques Gomes da Silva, Ana Carolina Costa
438 Cavalcante, Josivan Gomes Lima, and Julliane Tamara Araújo de Melo Campos.
439 2025. "The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital
440 Generalized Lipodystrophy Pathophysiology." *International Journal of Molecular*
441 *Sciences* 26(11):5416. doi:10.3390/ijms26115416.

442 Misra, Anoop, and Abhimanyu Garg. 2003. "Clinical Features and Metabolic Derangements
443 in Acquired Generalized Lipodystrophy: Case Reports and Review of the
444 Literature." *Medicine* 82(2):129–46. doi:10.1097/00005792-200303000-00007.

445 Oswiecimska, Joanna. n.d. "A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2
446 Splicesite Mutation and Concomitant Development of Non-Diabetic Polyneuropathy
447 - Journal of Clinical Research in Pediatric Endocrinology." Retrieved January 19,
448 2026. <https://jcrpe.org/articles/doi/jcrpe.galenos.2018.2018.0227>. doi:
449 10.4274/jcrpe.galenos.2018.2018.0227

450 Poulos, Sylvia P., Michael V. Dodson, Melinda F. Culver, and Gary J. Hausman. 2016. "The
451 Increasingly Complex Regulation of Adipocyte Differentiation." *Experimental*
452 *Biology and Medicine* 241(5):449–56. doi:10.1177/1535370215619041.

453 Rajab, Anna, Volker Straub, Liza J. McCann, Dominik Seelow, Raymonda Varon, Rita
454 Barresi, Anne Schulze, Barbara Lucke, Susanne Lützkendorf, Mohsen Karbasiyan,
455 Sebastian Bachmann, Simone Spuler, and Markus Schuelke. 2010. "Fatal Cardiac
456 Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized
457 Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations." *PLOS*
458 *Genetics* 6(3):e1000874. doi:10.1371/journal.pgen.1000874.

- 459 Rodriguez, Alexander J., Claudio A. Mastronardi, and Gilberto J. Paz-Filho. 2015. "New
460 Advances in the Treatment of Generalized Lipodystrophy: Role of Metreleptin."
461 *Therapeutics and Clinical Risk Management* 11:1391–1400.
462 doi:10.2147/TCRM.S66521.
- 463 Salle-Teyssières, Laurence, Martine Auclair, Faraj Terro, Mona Nemani, Solaf M. Elsayed,
464 Ezzat Elsobky, Mark Lathrop, Marc Délépine, Olivier Lascols, Jacqueline Capeau,
465 Jocelyne Magré, and Corinne Vigouroux. 2016. "Maladaptative Autophagy Impairs
466 Adipose Function in Congenital Generalized Lipodystrophy Due to Cavin-1
467 Deficiency." *The Journal of Clinical Endocrinology & Metabolism*
468 101(7):2892–2904. doi:10.1210/jc.2016-1086.
- 469 Soares, Reivla Marques Vasconcelos, Monique Alvares da Silva, Julliane Tamara Araújo de
470 Melo Campos, and Josivan Gomes Lima. 2024. "Familial Partial Lipodystrophy
471 Resulting from Loss-of-Function PPAR γ Pathogenic Variants: Phenotypic, Clinical,
472 and Genetic Features." *Frontiers in Endocrinology* 15.
473 doi:10.3389/fendo.2024.1394102.
- 474 Sommer, Nadine, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J. Rochford,
475 and George D. Mcilroy. 2022. "Gene Therapy Restores Adipose Tissue and
476 Metabolic Health in a Pre-Clinical Mouse Model of Lipodystrophy." *Molecular*
477 *Therapy Methods & Clinical Development* 27:206–16.
478 doi:10.1016/j.omtm.2022.09.014.
- 479 Stea, Dante Maria, and Alessio D'Alessio. 2025. "Caveolae: Metabolic Platforms at the
480 Crossroads of Health and Disease." *International Journal of Molecular Sciences*
481 26(7):2918. doi:10.3390/ijms26072918.
- 482 Talman, Andrew H., Peter J. Psaltis, James D. Cameron, Ian T. Meredith, Sujith K.
483 Seneviratne, and Dennis T. L. Wong. 2014. "Epicardial Adipose Tissue: Far More
484 than a Fat Depot." *Cardiovascular Diagnosis and Therapy* 4(6):416–29.
485 doi:10.3978/j.issn.2223-3652.2014.11.05.
- 486 Tiwari, Mansi, Ahlima Roumane, Nadine Sommer, Weiping Han, Mirela Delibegović, Justin J.
487 Rochford, and George D. Mcilroy. 2024. "Preclinical Evaluation of Tissue-Selective
488 Gene Therapies for Congenital Generalised Lipodystrophy." *Gene Therapy*
489 31(9):445–54. doi:10.1038/s41434-024-00471-z.
- 490 Tsoukas, Michael A., Olivia M. Farr, and Christos S. Mantzoros. 2015. "Leptin in Congenital
491 and HIV-Associated Lipodystrophy." *Metabolism* 64(1):47–59.
492 doi:10.1016/j.metabol.2014.07.017.

493 Varlet, Alice-Anaïs, Emmanuèle Helfer, and Catherine Badens. 2020. "Molecular and
494 Mechanobiological Pathways Related to the Physiopathology of FPLD2." *Cells*
495 9(9):1947. doi:10.3390/cells9091947.

496

Revision Letter

17 Mar, 2026

Dear Editors,

I am writing for the resubmission of the manuscript “Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy”. First, thank you very much for your comments and suggestions, as well as the time and effort you devoted to reviewing my manuscript. The feedback had helped me improve the quality and clarity of the paper. Below, I address the changes made in the manuscript.

Comment: Again, the manuscript currently lacks a methods/search strategy section. As this is a narrative review, it should at the bare minimum state the search strategy, selection criteria, and how evidence was prioritized.

Response: A new paragraph after the introduction is added, addressing the points mentioned.

Comment: Several references could be dated in the future or are otherwise very recent (e.g., 2025 and 2026). Please confirm that these are all published or in press, that DOIs are accurate, and that no placeholder or non-verifiable sources are included.

Response: References included in the paper from 2025 and 2026 have been double-checked, and they are all published. DOIs cited are accurate, and they are all verifiable sources.

Comment: The organization and flow are a bit unclear and repetitive. I would introduce a clearer structural outline (e.g., genetics, pathophysiology, clinical features, treatment, future directions), shorten some of your paragraphs on genetics to not distract as much from the main points, and reduce repetition in your introduction vs. conclusion. You should not have to repeat yourself over and over again to make the point clear. Integration > repetition.

Response: I have made some changes to the overall order of sections. Also, I have added some other information in the conclusion to reduce repetition. Some information in the genetic section is deleted to avoid too much distraction.

Comment: If the figures were made by the author in BioRender, please make this clear, and if not made by the author, they should be properly sourced.

Response: The source is added after each figure/table description in parentheses. All figures were made with Biorender, table one was made with Google Sheet, and table two was adapted from Patni et al. 2024.

Comment: Some language could be made more precise.

- Avoid statements such as “only one treatment” without qualification (what do you mean? what is this treatment?)
- Replace informal or awkward phrasing with precise language (e.g., “a lot of clinical trials.” How many? Do you mean trials or treatments? Do you really need to use this phrasing when you introduce the treatments later on?)
- Some minor grammatical issues (e.g., adipogenesis “ends with apoptosis.” What do you mean? This does not sound correct as-is)

Response: I have made slight changes in response to the suggestions. I highlighted the parts in the manuscript that have been changed. Specifically, I used more precise wordings and deleted or changed parts that might be confusing.

EDITOR COMMENTS AND RECOMMENDATION:

The reviewers commend the author for the depth and breadth of research presented in this manuscript. Both reviewers suggest modifications to the text, specifically more formal, precise language as well as additional elaboration or clarity in the sections detailed below. Special attention should be paid to the "major points" 1-3 from Reviewer 1. In addition to the general feedback provided, Reviewer 2 has also given point by point edits that may be considered for general readability and clarity. Given the reviewer feedback, the editor's recommendation is to accept the manuscript following major revisions.

REVIEWER 1:

Brief Summary

This manuscript provides a narrative review of the genetic, molecular, and clinical aspects of lipodystrophy syndromes, focusing primarily on Congenital Generalized Lipodystrophy (CGL), Familial Partial Lipodystrophy (FPLD), and acquired forms. It explores the metabolic complications arising from these conditions, such as insulin resistance and fatty liver, and evaluates current therapeutic approaches, including metreleptin and potential AAV-mediated gene therapies.

General Impression

The authors have synthesized a broad range of literature to highlight the critical role of adipose tissue as an endocrine and metabolic organ through the lens of rare lipodystrophic disorders. The inclusion of future perspectives, such as gene editing targeting the *BSCL2* gene in mouse models, adds a valuable forward-looking dimension to the manuscript. However, the current draft contains several significant molecular inaccuracies, omits key genetic subtypes in the pathophysiology section, and lacks transparency in its methodological reporting. These issues must be rigorously addressed before the manuscript can be considered suitable for publication.

Major Comments

1. **Mechanistic Inaccuracy in FPLD3 Pathophysiology:** The authors state that mutations in the *PPARG* gene "might cause excess differentiation and growth of adipocytes," leading to cellular stress. This contradicts established molecular biology. Pathogenic variants in *PPARG* associated with FPLD3 are typically loss-of-function or dominant-negative mutations that fundamentally *impair* adipogenesis. This fundamental error should be corrected to accurately reflect the disease's molecular basis.
2. **Omission of CGL2 (BSCL2) in Section 3:** While the authors appropriately discuss *BSCL2* (seipin) in the context of preclinical gene therapy models, they entirely omit CGL2 from the main "Genetics and Pathophysiology" section, focusing only on CGL1 and CGL4. Given that *BSCL2* mutations cause the most severe and globally prevalent form of CGL, a dedicated subsection explaining seipin's role in lipid droplet biogenesis is mandatory.
3. **Conflation of FPLD2 and ZMPSTE24 Pathology:** In Section 3.3, the authors state that *ZMPSTE24* "is also considered to be one of the factors that causes lipodystrophy" in the context of FPLD2. The authors should clarify this distinction: classic FPLD2 is caused by heterozygous missense mutations in the *LMNA* gene itself. Mutations in *ZMPSTE24* (which impair prelamin A processing) cause distinct, more severe syndromic forms of lipodystrophy (e.g., Mandibuloacral Dysplasia). Blurring the lines between these genetic etiologies creates confusion both clinically and molecularly.

4. **Incomplete Methodology Results:** The authors include a "Method" section outlining their literature search strategy, keywords, and inclusion/exclusion criteria. However, they fail to report the actual results of this search. There is no mention of how many articles were initially retrieved, screened, or ultimately included. To ensure scientific rigour and reproducibility, the authors should provide these numbers.
5. **Superficial Explanation of Lipotoxicity:** While the manuscript notes that lipodystrophy leads to metabolic dysfunctions such as insulin resistance and fatty liver, it fails to provide a detailed molecular explanation of lipotoxicity. The paper needs to clearly explain how the inability to store triglycerides in adipocytes leads to ectopic lipid deposition in the liver and skeletal muscle, which directly interferes with insulin receptor signalling pathways.
6. **Clarification of Metreleptin Indications:** The manuscript presents metreleptin as the "primary choice for LD patients", but later notes it is "more efficient in Generalised lipodystrophy patients". The authors should explicitly clarify current clinical guidelines. Metreleptin is strictly indicated and FDA-approved for generalised lipodystrophy; its use in partial lipodystrophy is highly restricted and heavily scrutinised due to varying efficacy and risk profiles.
7. **Omission of APL in Pathophysiology:** The introduction introduces Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome). However, APL is entirely ignored in the subsequent "Genetics and Pathophysiology" section, which only covers AGL. APL should be discussed to provide a comprehensive overview of acquired forms.

Minor Comments

1. **Overuse of Acronyms in Single Paragraphs:** The authors correctly define acronyms such as HAART and NRTI upon their first use. However, since these terms appear only twice and within the same paragraph, introducing the acronyms is unnecessary and clutters the text. It is standard practice to write out the full terms if they are not used frequently throughout the remainder of the manuscript.
2. **Scientific Phrasing and Grammar:** Several sentences lack scientific precision or contain grammatical errors. For instance, the phrases "The storage of adipocytes is limited" and "Except for CGL2, in which patients generally do not acquire both kinds of fat tissues" require language editing for clarity and grammatical correctness.
3. **Unsubstantiated Claims:** The authors state that "around 200 clinical trials are in progress, trying to discover a new way to treat or cure lipodystrophy, especially targeting leptin deficiency". This specific claim requires a reference or a citation from a clinical trial registry to verify the figure.
4. **Figure Formatting:** References to figures within the text should be capitalised for consistency with academic formatting (e.g., change "(figure 1)" and "(figure 2)" to "(Figure 1)" and "(Figure 2)").

Conclusion/Recommendation

Major Revisions. The manuscript addresses a clinically significant and under-researched topic. However, to meet publication standards, the authors should address critical inaccuracies in *PPARG* biology, include comprehensive sections on CGL2 and APL pathophysiology, clearly separate *LMNA* from *ZMPSTE24* pathologies, and transparently report their methodological search results.

REVIEWER 2:

Content: This is a well-researched paper with a strong and thoughtful focus on the molecular and genetic basis of lipodystrophy. The sections on AGPAT2, LMNA, and PPARG are particularly well done and demonstrate a solid understanding of how specific gene mutations affect adipocyte biology. One of the strengths of the paper is its ability to move beyond listing conditions and instead explain underlying mechanisms. In several sections, especially in the genetic discussions, you clearly connect molecular changes to metabolic consequences, which adds real depth to the review. At the same time, there are a few areas where scientific wording could be refined further, particularly in the acquired lipodystrophy section and in some treatment descriptions, to ensure full accuracy and precision.

Grammar and Style: The writing is generally clear and understandable, and the overall flow of ideas is logical. The main issue here is consistency in tone. Some sections are written in a strong academic voice, while others shift into more conversational phrasing. Maintaining a consistent scientific tone throughout will strengthen the professionalism of the manuscript. There are also a few recurring grammar issues, including sentence structure, verb agreement, and phrasing, which can be addressed with a careful final pass.

Scientific Framing: The manuscript shows a good grasp of the literature and includes appropriate gene targets and pathways. A notable strength is the inclusion of both genetic and acquired forms of lipodystrophy, which gives the paper a more complete scope. The paper would become even stronger by more consistently linking molecular mechanisms to clinical presentation. In the strongest sections, this connection is clear and effective, and applying that same level of explanation across all sections would improve overall coherence.

Organization: The overall structure is logical and appropriate for a review article, moving from classification to mechanisms, then to diagnosis and treatment. This organization works well and helps guide the reader through complex material. Some paragraphs, particularly in the introduction and diagnosis sections, are quite dense and would benefit from being divided into smaller sections. The Methods section is functional but could be more clearly organized to match the level of detail seen in the rest of the paper.

Scholarly Tone: The paper demonstrates strong content knowledge and clear effort in engaging with the material. The tone is effective in many sections, particularly in the mechanistic discussions. To elevate the manuscript further, it would help to maintain that same level of academic tone throughout and avoid occasional conversational phrasing. This adjustment would better align the writing with the strength of the scientific content.

Final Assessment: Overall, this is a strong and well-developed review with clear strengths in its mechanistic explanations and topic selection. The paper shows good engagement with the literature and a solid understanding of adipocyte biology. With revisions focused on tone consistency, sentence clarity,

and refinement of scientific phrasing, the manuscript would reach a high level of quality and effectiveness.

Hello Dr. Grive,

I've attached the reviewed manuscript. I went through it for content, grammar, structure, and overall clarity, and added detailed edits to improve it and make it clinically sound. I also included a separate document with more detailed, overall feedback in case that's helpful. Please let me know if you have any questions or if you'd like me to take another pass at anything.

Title page and abstract

- Page 1, Title (“Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy”): The title is clear and appropriate for the paper’s scope. You may want to consider whether “disease progression” is the most precise phrase here, since the paper is centered more on mechanisms, classification, and treatment than on longitudinal progression. A term such as “pathophysiology” may better match the content.
- Page 1, Abstract, opening sentence (“Lipodystrophy syndromes are rare diseases that are often characterized...”): The opening sentence introduces lipodystrophy well, but the wording is somewhat repetitive. “Rare diseases that are often characterized” could be made more concise.
- Page 1, Abstract, sentence beginning “Fat tissues are also known as adipose tissues...”: This reads more like a general definition than part of a scientific abstract. You may want to replace this with a sentence emphasizing the metabolic role of adipose tissue instead.
- Page 1, Abstract, sentence containing “a series of metabolic issues”: This is broad. It would be stronger if it named a few specific complications, such as insulin resistance, hepatic steatosis, or hypertriglyceridemia.
- Page 1, Abstract, sentence beginning “They are all factors that determine...”: This is a bit unclear. It would help to specify whether you mean the clinical phenotype, the molecular defect, or the pattern of adipose loss.
- Page 1, Abstract, sentence beginning “Due to the rarity of this disorder...”: This would read better as “these disorders,” since you are discussing lipodystrophy syndromes rather than a single disease entity. The sentence also becomes somewhat repetitive with “this disease” later in the same thought.
- Page 1, Abstract, sentence beginning “In this article, we first consider...”: This feels more narrative than review style. It may read more professionally if you state the review’s scope directly rather than walking the reader through it step by step.
- Page 1, Abstract, final sentence beginning “Future direction of study...”: This needs a small grammatical correction. The sentence would also benefit from a more precise phrasing of how genetic understanding may inform future therapies.
- Page 1, Abstract, overall: The abstract does a good job covering the paper’s main sections, but it could become stronger by making the connection between gene mutations and metabolic outcomes more

explicit. Right now, the abstract introduces the topics clearly, but it does not fully show the mechanistic thread that becomes important later in the paper.

Introduction and Background

· Page 1–2, Introduction, Paragraph 1, sentence containing “inability to store body fat and excess nutrients”: The introduction establishes the topic clearly, though this phrase could be made more precise. Since one of the key consequences is ectopic lipid storage, naming that directly may strengthen the scientific framing.

· Page 2, Introduction, Paragraph 1, sentence beginning “Adipose tissues are formed through a process called adipogenesis...”: The explanation of adipogenesis is useful, but some of this material reads more like a textbook definition than an introduction to a review article. You may want to move more quickly from defining adipogenesis to explaining why it is relevant to lipodystrophy.

· Page 2, Introduction, Paragraph 1, sentence beginning “This process also includes the triacylglycerol (TAG) fatty acid cycle...”: The TAG cycle discussion is informative, but the sentence is fairly dense and contains several concepts at once. It may help to simplify the structure so the role of lipid storage and mobilization stands out more clearly.

· Page 2, Introduction, Paragraph 1, sentence beginning “It is the process where the lipid droplets...”: This is slightly unclear, as the referent for “It” is not immediately obvious. Clarifying the subject of the sentence may improve readability.

· Page 2, Introduction, Paragraph 1, sentence beginning “However, if a gene mutation...”: The statement about gene mutations affecting adipogenesis is conceptually strong. It may be worth stating more explicitly that these disruptions impair adipocyte differentiation, lipid droplet formation, or adipose maintenance, depending on the gene involved.

· Page 2, Introduction, Paragraph 2, paragraph beginning “LD can be either congenital or acquired...”: This classification paragraph contains important material, but it is doing a great deal at once. It may be easier for the reader if you divide it into one paragraph on congenital versus acquired forms and a second paragraph on subtype distinctions within CGL and FPLD.

· Page 2, Introduction, Paragraph 2, sentence beginning “CGL (also called Berardinelli-Seip syndrome)...”: This sentence is clear, although it may help to define “mechanical and metabolic fat tissues” more carefully. Some readers may not immediately know how you are distinguishing these categories.

· Page 2, Introduction, Paragraph 2, sentence beginning “CGLs are autosomal recessive...”: This is understandable, but the phrasing could be made more formal.

· Page 2, Introduction, Paragraph 2, sentence beginning “Same as CGL...”: This sounds conversational. A more formal transition would improve continuity.

· Page 2, Introduction, Paragraph 2, sentence beginning “Since the body is not able to store excess energy...”: The FPLD description is one of the stronger parts of the introduction because it links adipose

redistribution to metabolic consequences. This would become even stronger if you clarified that the apparent “gain” of fat in other regions often reflects abnormal redistribution rather than normal adipose expansion.

· Page 2, Introduction, Paragraph 2, sentence beginning “Proteins or enzymes that are encoded...”: This is a bit heavy structurally. The main point is good, but the sentence could be made clearer by emphasizing function first.

· Page 2, Introduction, Paragraph 2, phrase “and sometimes idiopathic”: The acquired forms are introduced clearly, although this phrase could be smoothed slightly to fit the tone of the rest of the paragraph.

· Page 3, Introduction, Paragraph 3, paragraph beginning “Not only will the lack of excess energy...”: This paragraph introduces metabolic complications well. The figure reference is useful, and the transition into treatment is natural, though the opening sentence itself is somewhat broad and could be made more concise.

· Page 3, Introduction, Paragraph 3, sentence containing “It currently the only FDA-approved treatment”: The metreleptin discussion is appropriate here, but there is a small grammar issue in this sentence.

· Page 3, Introduction, Paragraph 3, prevalence sentences containing “3/million,” “0.23/ million,” and “2.84/million”: The prevalence numbers are helpful. You may want to make sure units are presented consistently, for example “per million” rather than “/million.”

· Page 3, Introduction, Paragraph 3, sentence beginning “It is also estimated to shorten a patient’s lifespan...”: This is important and strengthens the clinical significance of the review.

· Page 3, Introduction, final sentence beginning “In addition, the treatment developed...”: This could be made slightly more polished. It feels incomplete in structure and would be a good place to state clearly that the review will examine both current therapies and emerging directions.

Methodology

· Page 3, Section title (“2. Method”): Consider changing “Method” to “Methods” to align with standard scientific formatting.

· Page 3, Methods paragraph, sentence beginning “The search included following keywords...”: The literature search description is straightforward, though it would read more smoothly if this were changed to “included the following keywords.”

· Page 3, Methods paragraph, keyword list: The keyword list is useful and appropriately targeted to the paper’s focus.

· Page 3, Methods paragraph, sentence beginning “Only publications in English language were considered”: This would read more naturally as “Only English-language publications were considered.”

- Page 3, Methods paragraph, sentence containing “comprehensive reviews”: The inclusion criteria are generally clear, though this phrase might benefit from a little more specificity if you want to distinguish narrative reviews from systematic reviews.
- Page 3, Methods paragraph, sentence beginning “Case studies with relevant insights...”: This is understandable, though the basis for relevance could be clarified slightly.
- Page 3, Methods paragraph, sentence beginning “Non peer reviewed sources...”: “Non peer reviewed” should be hyphenated. Also, the phrase “case reports with only quantitative data and without further analysis” is a little difficult to interpret. You may want to clarify the reasoning behind that exclusion.
- Page 3, Methods paragraph, final sentence beginning “Full article was reviewed...”: This should be plural.
- Page 3, Methods, overall: This section is functional, but it may become clearer if organized under brief subheadings such as Search Strategy, Inclusion Criteria, and Exclusion Criteria.

Discussion – Section 1: Genetics and Pathophysiology

- Page 4, CGL1, opening paragraph beginning “Type 1 Congenital Generalized Lipodystrophy...”: The AGPAT2 section contains strong mechanistic content. The explanation is scientifically valuable, but the sentence structure is quite dense. Breaking some of the longer sentences may make the biochemical pathway easier to follow.
- Page 4, CGL1, sentence beginning “AGPAT2 is the gene coding for...”: This would be more standard scientifically as a direct statement that the gene encodes the enzyme.
- Page 4, CGL1, sentence beginning “It is an important precursor...”: The explanation of phosphatidic acid synthesis is detailed, which is good for the review’s depth. You may want to make the link to adipocyte dysfunction slightly more explicit at the end of the paragraph so that the reader sees why this biochemical step matters clinically.
- Page 4, CGL1, sentence beginning “The AGPAT family consists of 11 isomers...”: This is useful, though a little hard to follow because several ideas are packed together.
- Page 4, CGL1, sentence beginning “The presence of mechanical adipose tissue...”: The contrast between AGPAT2 and other isomers is interesting and relevant. This may be one place where an extra citation or a more explicit mechanistic link would strengthen the section further.
- Page 4, CGL1, sentence beginning “Defects in AGPAT2 genes also impact insulin signaling...”: This point is important. It may be helpful to clarify whether this effect is direct or secondary to impaired adipocyte function, since the sentence currently reads somewhat definitive.
- Page 4, CGL4, opening sentence beginning “Type four Congenital Generalized Lipodystrophy...”: The opening sentence is clear. The subsection would benefit from more consistent capitalization and formatting in the disease name.

- Page 4, CGL4, sentence beginning “Caveolae are one of the most abundant invaginations...”: The explanation of caveolae is strong, though “lots of mammalian cells” reads conversationally. A more formal phrasing would strengthen tone.
 - Page 4, CGL4, sentence beginning “Cavin-1 starts the whole process...”: This phrasing feels informal. A more academic wording would match the rest of the review.
 - Page 4, CGL4, sentence containing “caveolin 1,2”: The discussion of caveolin isoforms is useful, but the formatting should be standardized.
 - Page 4–5, CGL4, sentence beginning “Absence of caveolae causes the cell...”: The sentence describing cellular consequences would benefit from slightly more precision. Instead of “not be able to develop properly,” you may want to emphasize membrane organization, signal transduction, or adipocyte stability.
 - Page 5, CGL4, paragraph beginning “Some symptoms that are uniquely associated...”: The clinical phenotype discussion is useful and helps connect molecular defects to patient presentation.
 - Page 5, CGL4, final sentence beginning “These symptoms can be explained...”: This could be made more explicit in showing how tissue-specific expression relates to muscle and cardiac findings.
-
- Page 5, FPLD2, opening sentence beginning “The gene LMNA...”: The LMNA subsection is scientifically important, and the topic choice is strong. The first sentence is somewhat heavy structurally and may benefit from division into two shorter sentences.
 - Page 5, FPLD2, sentence beginning “Specifically...”: This appears incomplete and may need revision into a full sentence.
 - Page 5, FPLD2, sentence beginning “One way that Lamin A can affect cell development...”: The ZMPSTE24 discussion is relevant. This would be even stronger if you briefly clarified whether you are describing laminopathy-related processing defects more broadly or specifically FPLD2-associated mechanisms.
 - Page 5, FPLD2, sentence beginning “Not only will the lack of Lamin A...”: The point about prelamin A accumulation is well made and adds mechanistic depth.
 - Page 5, FPLD2, paragraph beginning “A high risk of cardiovascular diseases...”: This paragraph is interesting, though the transition from nuclear structure to epicardial adipose tissue is fairly abrupt. One bridging sentence may help.
 - Page 5, FPLD2, final sentence beginning “Other studies will also need to be done...”: This reads somewhat informal. The idea is good, but the phrasing could be more academic.
-
- Page 5–6, FPLD3, opening sentence beginning “Type 3 Familial Partial Lipodystrophy...”: The PPARG subsection is relevant and well chosen. There is a small phrasing issue with “encodes for.”
 - Page 6, FPLD3, sentence beginning “PPAR γ has three isoforms...”: The mechanism is clearly described and fits well within the paper. Some small reductions in repetition may help readability.

- Page 6, FPLD3, sentence beginning “After binding, PPAR γ induces many targeted genes...”: “induces many targeted genes” might be expressed more precisely, since this is really about transcriptional regulation of downstream targets.
- Page 6, FPLD3, sentence beginning “Mutations in PPARG might cause excess differentiation...”: This appears to be an oversimplification. Many pathogenic PPARG variants impair adipocyte function rather than simply increasing growth, so this phrasing may be misleading and should be reconsidered for accuracy.
- Page 6, FPLD3, paragraph beginning “Compared to FPLD2...”: The comparison with FPLD2 is useful and adds real value to the review. This is a strong section because it moves beyond listing mechanisms and begins comparing phenotypes.
- Page 6, FPLD3, final sentence beginning “However, FPLD3 patients also show...”: This is good, though it may help to clarify why a milder loss of adipose tissue can still be associated with more severe metabolic disease.
- Page 6, AGL, opening sentence beginning “As we can see...”: The opening sentence introduces acquired disease appropriately, but “As we can see” sounds conversational and could be removed.
- Page 6, AGL, paragraph beginning “Adverse effects of highly active antiretroviral therapy...”: The HAART discussion is interesting and clinically relevant. Some of the sentence structure is slightly long, but the content is strong.
- Page 7, AGL, sentence beginning “Proteins such as thymidine analog nucleoside reverse transcriptase inhibitors...”: This is not accurate. NRTIs are pharmacologic agents, not proteins, and this distinction is important for maintaining scientific accuracy. This sentence should be revised to reflect the correct classification and mechanism.
- Page 7, AGL, sentence beginning “It decreases the expression of adiponectin...”: The adiponectin and mitochondrial toxicity points are relevant and help ground the section mechanistically.
- Page 7, AGL, paragraph beginning “Another possible cause of AGL...”: The autoimmune mechanism is a good addition. The perilipin discussion is especially useful because it broadens the review beyond purely genetic forms.
- Page 7, AGL, sentence beginning “It leads to an increase in lipolysis activities...”: This is conceptually good, though it may help to clarify whether you mean uncontrolled lipolysis due to loss of lipid droplet protection.

Diagnosis and Clinical Features

- Page 7–8, Diagnosis, Paragraph 1 beginning “Since lipodystrophy is such a rare disease...”: This paragraph includes important diagnostic material, but it is quite long and would benefit from being divided into smaller units.

- Page 7, Diagnosis, opening phrase “not well known to the public”: This point about underrecognition is important and clinically relevant, though this phrasing may be less useful than a more clinician-focused one.
- Page 7–8, Diagnosis, sentence beginning “Although patients with CGL show symptoms...”: The contrast between CGL and FPLD diagnosis is helpful.
- Page 8, Diagnosis, sentence beginning “It could be easily mixed up with...”: “mixed up with” would benefit from more formal wording.
- Page 8, Diagnosis, paragraph beginning “Some phenotypes that are associated...”: The phenotype paragraph is detailed and generally useful. There is a small typo in “in charge or energy storage.”
- Page 8, Diagnosis, sentence beginning “Metabolic adipose tissues are in charge...”: The explanation of metabolic versus mechanical adipose tissue is useful, but the wording could be made more precise.
- Page 8, Diagnosis, sentence beginning “Although patients still in some degrees lack...”: This is difficult to follow and appears structurally incomplete. This portion may benefit from being rewritten for clarity.
- Page 8, Diagnosis, final sentence beginning “Next, we will be discussing...”: The transition into treatment is smooth and works well, though this phrasing reads somewhat narrative for a review article.

Treatments

- Page 8, Treatments, opening sentence beginning “Currently, there isn’t a definite treatment...”: This sounds somewhat informal. The idea is correct, though the phrasing could be slightly more formal.
- Page 8–9, Metreleptin subsection overall: The metreleptin discussion is one of the strongest applied sections of the paper. It explains the rationale for therapy clearly and appropriately ties it to leptin deficiency.
- Page 9, Metreleptin subsection, sentence beginning “Leptin is a hormone...”: This explanation is useful, though some of this material repeats ideas already implied in the section. You may be able to reduce repetition.
- Page 9, Metreleptin subsection, sentence beginning “This causes patients to show extreme hyperphagia...”: The connection between hypoleptinemia, hyperphagia, and ectopic fat storage is well stated and clinically meaningful.
- Page 9, Metreleptin subsection, sentence beginning “Metreleptin’s main purpose is to mimic...”: This is fine, though it may be worth noting whether the treatment’s benefit is metabolic, symptomatic, or both.
- Page 9, Metreleptin subsection, sentence beginning “Metreleptin is found to be more efficient...”: This might be adjusted slightly to reflect clinical response rather than efficiency.
- Page 9, Metreleptin subsection, sentence beginning “However, the risk of using Metreleptin...”: This contains a subject-verb agreement issue and could be clarified to improve readability.

- Page 9, Metreleptin subsection, final sentence beginning “Other common drugs...”: The closing sentence on adjunctive therapies and cosmetic surgery is appropriate. This gives the treatment section a more complete and realistic scope.
- Page 9, Lifestyle subsection title (“Change in Daily Routine”): This feels somewhat informal as a heading. A more standard heading may fit better with the rest of the paper.
- Page 9, Lifestyle subsection, paragraph beginning “Although Metreleptin can generally help...”: This section is brief but useful. It might be strengthened by explaining why a low-fat or carbohydrate-restricted diet is recommended in metabolic terms, rather than only listing the recommendations.
- Page 9, Lifestyle subsection, sentence containing “doing too much exercise”: This is understandable but may be rephrased more formally.
- Page 9–10, Gene Editing subsection, opening paragraph: This section is forward-looking and adds value to the paper. The discussion of gene therapy is a strong choice for the final treatment subsection.
- Page 10, Gene Editing subsection, sentence beginning “The results of the trials show...”: The mouse model example is useful and helps ground the idea in actual preclinical work.
- Page 10, Gene Editing subsection, sentences containing “AVV”: The acronym “AVV” appears to be used in place of “AAV” (adeno-associated virus). This should be corrected consistently throughout the section. In addition, phrases such as “AVV targets adipocytes” read somewhat absolute and may benefit from more precise wording.
- Page 10, Gene Editing subsection, sentence beginning “Therefore, there isn’t enough evidence...”: The translational caution here is important and scientifically appropriate. This section benefits from the fact that it does not overstate clinical readiness.
- Page 10, Gene Editing subsection, final sentence beginning “Continued research on LD...”: This conclusion is good and appropriately cautious.

Conclusion and Future Directions

- Page 10–11, Conclusion, opening sentence beginning “Although genes involved in lipodystrophy syndromes...”: This contains the paper’s central idea and is conceptually strong, but it is fairly long. Breaking it into two sentences may improve readability.
- Page 11, Conclusion, phrase “common outcome -impaired adipocyte development and function”: This contains a spacing and punctuation issue. It should be corrected for clarity and consistency with standard formatting.
- Page 11, Conclusion, paragraph beginning “LD highlights the essential role...”: This paragraph does a good job emphasizing adipose tissue as an endocrine and metabolic organ. That is one of the manuscript’s central strengths.

- Page 11, Conclusion, sentence beginning “For conditions like lipodystrophy...”: The discussion of awareness and diagnostic delay is relevant and provides a meaningful clinical takeaway.
- Page 11, Conclusion, sentence beginning “Since the discovery of lipodystrophy syndromes...”: “lots of progress has been made” reads somewhat informal.
- Page 11, Conclusion, sentence containing “research have been done”: This is a grammar issue.
- Page 11, Conclusion, final sentence beginning “Having a deep understanding...”: The final sentence is appropriate, though it may be strengthened by tying future therapy more directly to the specific mechanisms discussed earlier.

Figures and Tables

- Table 1 / Page 2: The table is useful and supports the classification section well. Make sure the labeling and formatting remain consistent with the journal’s style.
- Figure 1 / Page 3: The comparison figure is a helpful visual aid. The caption contains multiple grammatical issues, including “The storage of an adipocytes is limited” and “increase glucose level in blood streams.” These should be revised for clarity and correctness.
- Figure 2 / Page 4: The figure is relevant and supports the CGL1 discussion appropriately.
- Figure 3 / Page 5: The caveolae figure is helpful, though the caption could be a bit more precise scientifically. Also, “Biorender” should be standardized to “BioRender.”
- Table 2 / Page 9: This table adds practical value to the treatment section. Make sure the reproduced source and licensing note are formatted exactly as required by the target venue.
- Figure 4 / Page 10: This is one of the stronger figures in the manuscript because it helps unify the review conceptually. The caption is informative and supports the final conclusion well.

1 *Molecular Basis of Lipodystrophy: Gene Mutations, Pathophysiology, and Therapy*

2 *Abstract*

3 Lipodystrophy syndromes are a group of rare diseases characterized by a general
4 or partial absence of body fat, caused by the inability to properly store and utilize adipose
5 tissue. The lack of adipose tissue would lead to serious consequences and the
6 development of a series of metabolic issues, including insulin resistance, leptin deficiency,
7 and hypertriglyceridemia. Lipodystrophy syndromes are genetically and clinically
8 heterogeneous, with different phenotypes influenced by underlying molecular defects.
9 Both fat distribution and the molecular defect play a role in determining the type of
10 lipodystrophy a patient has. Due to the rarity of these disorders, not many studies have
11 been conducted on them. This results in the public's lack of awareness, increasing the
12 difficulty of diagnosing and treating these conditions. This article examines the
13 classification and clinical aspects of lipodystrophy syndromes, covering the onset and the
14 differences in phenotypes of patients. It further discusses the molecular and cellular
15 mechanisms of several types of lipodystrophies and the role they play in the development
16 of adipose tissues. In addition, this review addresses other metabolic dysfunctions caused
17 by lipodystrophy, such as insulin resistance, fatty liver, and hypertriglyceridemia. Lastly, we
18 evaluate therapeutic strategies aimed at improving metabolic control and quality of life in
19 affected patients. Future research and potential therapy may be improved with a deeper
20 and more thorough understanding of the genetic and mechanistic basis of lipodystrophy,
21 as it is critical for identifying key mechanisms and developing a more targeted treatment.

22

23 *Keywords:* Lipodystrophy syndromes, adipose tissue, adipogenesis, gene mutations,
24 metabolic dysfunctions

25

26 1. *Introduction*

27 Lipodystrophy syndromes (LD) are a heterogeneous group of rare disorders
28 characterized by the partial or complete loss of mature adipose tissue in localized or
29 generalized areas. This results in the inability to store body fat, ectopic lipid storage, and
30 excess nutrients (Fourman and Grinspoon 2022). Two main classes of lipodystrophy are
31 Congenital Generalized Lipodystrophy (CGL) and Familial Partial Lipodystrophy (FPLD).

32 For adipose tissues to function normally, adipogenesis is crucial for the
33 differentiation of the precursor cells. Adipogenesis starts with mesenchymal stem cells
34 differentiating into mature adipose tissue. During adipogenesis, lipid storage and
35 mobilization is regulated by the triacylglycerol (TAG) fatty acid cycle. Lipid droplets
36 undergo lipolysis (the breakdown of lipid droplets) and lipogenesis (the synthesis of new
37 lipid droplets)(Poulos et al. 2016). However, if a gene mutation or other factors affect the
38 components involved in the regulation of adipogenesis, this would lead to impaired
39 adipocyte differentiation, lipid droplet formation, and adipocyte functions.

40 LD can be either congenital or acquired. Congenital Lipodystrophy is classified
41 based on the location of lost adipose tissue, and further divided into subtypes according
42 to the gene segment that is mutated (Akinci, Gular, and Oral 2024) (Table 1). Meanwhile,
43 acquired lipodystrophy is caused by external factors or side effects of other treatments.

44 CGL (also called Berardinelli-Seip syndrome) is characterized by the near-complete
45 absence of adipocytes (Oswiecimska n.d.). CGLs are inherited in an autosomal recessive
46 manner, with symptoms typically presenting shortly after birth. It is further divided into
47 CGL1, CGL2, CGL3, and CGL4, which link to four different gene mutations. FPLD presents
48 as an abnormal distribution of adipose tissue, with fat loss around the limbs, torso, and
49 hips. It can be autosomal recessive or dominant depending on the gene involved. Since the
50 body is not able to store excess energy in those areas, other body parts, such as the face,
51 neck, and internal organs like the liver, gain extra adipose tissue (Diagnosis and
52 Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline | The
53 Journal of Clinical Endocrinology & Metabolism | Oxford Academic n.d.). This results in the
54 abnormal distribution of adipose tissues. As with CGL, FPLD is further divided into several
55 subtypes, including FPLD1 (Kobberling-type lipodystrophy), FPLD2 (Dunnigan Variety
56 lipodystrophy), FPLD3, FPLD4, FPLD5, and FPLD6. The development of adipocytes is
57 tightly regulated by various proteins and enzymes. The genes that encode these proteins
58 or enzymes are often the genes associated with lipodystrophy.

59 As for Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and
60 Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome), they have similar
61 symptoms as CGL and FPLD. However, they are caused by autoimmune diseases, side
62 effects of antiretroviral therapy (ART) for HIV patients, or even idiopathic reasons (Misra
63 and Garg 2003).

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/ adolescence.	Palpable "ledge" between normal and lipodystrophic areas
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not affected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

64

65 ▲ Table 1: Classification, clinical features, and molecular basis of lipodystrophies (Made
66 with Google Sheet)

67

68 Not only will the lack of excess body fat affect the body's normal functions, but
69 complications associated with lipodystrophy also have a significant effect on patients' lives.
70 Some common metabolic abnormalities include leptin deficiency, insulin resistance,
71 diabetes, hypertriglyceridemia, and fatty liver disease (Figure 1). Currently, around 200
72 clinical trials are underway to discover a new way to treat or cure lipodystrophy, with a
73 particular focus on leptin deficiency (*Search ClinicalTrials.Gov For*, n.d.).

74 Metreleptin, for example, is a treatment created specifically for acquired or
75 congenital generalized lipodystrophy patients. It is a targeted treatment for leptin
76 deficiency, which is a common metabolic issue associated with LD (Araújo-Vilar & Santini,
77 2019). It is currently the only FDA- approved treatment for generalized lipodystrophy
78 patients. However, conventional treatment, such as special diets, is still optimized before
79 metreleptin (Meehan et al., 2016). Due to the rarity of this disease, limited research has
80 been done, making Metreleptin the primary choice for CGL and AGL patients (Ajluni et al.,
81 2016). As for FPLD patients, the use of Metreleptin is highly restricted. Therefore, they will
82 need to maintain an appropriate diet and require other medications for the metabolic
83 complications.


84 According to studies, only about 3 per million people around the world are affected
85 by some type of lipodystrophy syndrome. While the prevalence of CGL is estimated to be

86 0.23 per million people, the prevalence of FPLD is around 2.84 per million people
87 (Chiquette et al. 2017). It is also estimated to shorten a patient's lifespan by 30 or more
88 years. The main cause of death is shown to be liver diseases and infections caused by
89 adipose tissue dysfunction, but also varies from type to type of lipodystrophy (Lima et al.
90 2018).

91 This literature review aims to highlight the molecular mechanisms underlying
92 lipodystrophy, with a focus on the genetic causes, differences between types of
93 lipodystrophies, and other metabolic conditions caused by adipose tissue abnormalities,
94 as well as the treatment developed and future directions of study, and the possibilities for
95 fundamental treatments.

96

Comparison of adipocyte functions between healthy person and lipodystrophy patient



97

98 ▲ Figure 1: Comparison of adipocyte functions between a healthy person and a
99 lipodystrophy patient. Adipocyte storage is decreased in lipodystrophy patients. Common
100 metabolic abnormalities include leptin deficiency, insulin resistance, and elevated blood
101 glucose levels in the bloodstream. (Made with BioRender)

102

103 2. Methods

104 Search Strategy

105 A literature search was conducted using PubMed and Google Scholar databases.
106 The search included the following keywords: "lipodystrophy genetics", "adipocyte
107 differentiation", "AGPAT2", "PTRF Cavin-1", "LMNA mutation", "PPARγ mutation",
108 "lipodystrophy metabolic abnormalities". Titles and abstracts were first screened for

109 relevance. Full articles were reviewed to see if they met the inclusion criteria. 97 articles
110 were initially screened, and 54 papers were ultimately referenced in this review.

111

112 *Inclusion/Exclusion Criteria*

113 Articles published between 2000 and 2026 were included. Only English language
114 publications were considered. Studies were included if they were peer-reviewed primary
115 research articles or comprehensive reviews, including both narrative reviews and
116 systematic reviews, that focused on the genetic, molecular, or metabolic mechanisms
117 underlying lipodystrophy syndromes. Case studies were included if they provided relevant
118 insights, such as pathological or mutation analyses or clinical findings. Non-peer-reviewed
119 sources and articles published before 2000 are excluded. Case reports that only report
120 descriptive quantitative data, without the discussion of mechanistic interpretation, are also
121 excluded, as clinical data are not the focus of this review.

122

123 *Discussion*


124 *3. Genetics and Pathophysiology*

125 *3.1 Type one Congenital Generalized Lipodystrophy (CGL1)*

126 Type one Congenital Generalized Lipodystrophy (CGL1) is caused by a mutation in
127 the gene AGPAT2. AGPAT2 is the gene that encodes the enzyme 1-acylglycerol-3-phosphate
128 O-acyltransferase 2. It catalyzes the acylation of lysophosphatidic acid
129 (1-acylglycerol-3-phosphate) to phosphatidic acid (1,2 diacylglycerol-3-phosphate)(Gale
130 et al. 2006) (Figure 2). It is an important precursor for the biosynthesis of triacylglycerol
131 (TAG) and phospholipids from glycerol-3-phosphate. This step esterifies a second fatty
132 acyl group at the sn-2 position of the glycerol backbone. Phosphatidic acid is further
133 acylated by other enzymes, creating triacylglycerol and phospholipids. Impaired formation
134 of phosphatidic acid results in the absence of triacylglycerol production, thereby
135 disrupting the normal adipose tissue development.

136 The AGPAT family consists of 11 isomers. Among the isomers, AGPAT2 is expressed
137 at higher levels in adipose tissue than the other isomers. The presence of mechanical
138 adipose tissue can be explained by the increased expression of the other isomers
139 (Broekema et al., 2018). However, studies have shown that the expression of AGPAT2 is
140 required for the accumulation of triacylglycerol, especially in metabolic adipose tissues.
141 Defects in the AGPAT2 gene also impact insulin signaling, which is a direct effect of
142 impaired adipocyte dysfunction (Santoro et al., 2021). This also causes gluconeogenesis
143 to be unrestricted, which leads to the development of hyperglycemia and diabetes(de
144 Melo et al. 2025).

145



146

147 ▲ Figure 2: The process of Triacylglycerol synthesis. In the second step, where LPA is
 148 acylated to PA, AGPAT is the enzyme that catalyzes this reaction. Without it, the reactions
 149 after it will not occur properly, meaning that adipocytes can't develop properly. (Made
 150 with BioRender)

151

152 3.2 Type 2 Congenital Generalized Lipodystrophy (CGL2)

153 Type 2 Congenital Generalized Lipodystrophy (CGL2) is caused by pathogenic
 154 variants of the BSCL2 gene. It encodes the protein seipin, which is found in the
 155 endoplasmic reticulum (ER) (Akinci et al., 2024), Seipin plays an important role in the
 156 regulation of lipid droplet biogenesis. It interacts with proteins involved in TAG synthesis
 157 to facilitate adipogenesis. For instance, it binds with AGPAT2 to regulate PA metabolism.
 158 Seipin deficiency could lead to abnormal accumulation of PA. This increases the surface
 159 tension of the ER and decreases its line tension, disrupting the unidirectional lipid droplet
 160 budding. It causes the accumulation of newly synthesized neutral lipids in the ER, leading
 161 to severe ER stress and potentially being toxic to the cells (Li et al., 2022).

162 CGL2 is the most common type of congenital lipodystrophy. But mutations in the
 163 BSCL2 also lead to the most severe symptoms. Patients are born without any fat, including
 164 mechanical and metabolic adipose tissues. They also have an earlier onset of diabetes
 165 mellitus than other types of lipodystrophies. Other than adipocytes, seipin is also
 166 expressed in the brain and testis. This leads to mild mental disability, developmental
 167 language disorders, and an impaired reproductive system.


168

169 3.2 Type four Congenital Generalized Lipodystrophy (CGL4)

170 Type four Congenital Generalized Lipodystrophy (CGL4) is associated with the
171 gene mutation in the PTRF gene (Polymerase I and Transcript Release
172 Factor) (Salle-Teyssières et al. 2016). The PTRF gene encodes cavin-1, which is one of the
173 essential proteins that is required for the biogenesis of caveolae. Caveolae are the most
174 abundant invaginations of the plasma membrane across a wide range of mammalian cells
175 (Figure 3). Cavin-1 plays a critical role in the initiation of caveolae synthesis through
176 recruiting other structural proteins, such as caveolins. Without it, cells won't be able to
177 produce caveolae. Although it is abundant, its functions have only been understood in the
178 past few decades. It plays a role in signal transduction, endocytosis, and
179 mechanotransduction (Stea and D'Alessio 2025). Cavin-1 binds with the caveolins to form
180 Caveolae. There are three members in the caveolin family: caveolin-1, caveolin-2, and
181 caveolin-3. They are expressed in a variety of cells, like smooth muscle cells, fibroblasts,
182 and adipocytes. Caveolin 3 is expressed exclusively in cardiac and skeletal muscle. It is
183 shown that the lack of PTRF-CAVIN doesn't affect the level of caveolin expressed (Rajab et
184 al. 2010). However, it affects caveolin's ability to localize to the cell's surface, which makes
185 the formation of caveolae impossible. The absence of caveolae causes abnormalities and
186 dysfunctions, including impaired signal transduction and a lack of mechanoprotection.
187 Without the extra membranes acting as a buffer against the force of mechanical stretching,
188 cardiac cells are at a greater risk of rupturing (Grivas et al., 2020).

189 Clinical features uniquely associated with CGL4 include myopathy, which affects
190 skeletal muscle structure, and distal metaphyseal deformation, causing bone stiffness and
191 limited range of motion (Ardissonne et al. 2013). Cardiac arrhythmias are also one of the
192 symptoms caused by the lack of PTRF-CAVIN, and they could be life-threatening, showing
193 the serious consequences of cavin-1 deficiency (Rajab et al. 2010). These symptoms can
194 be explained by the location where caveolins 1, 2, and 3 are expressed.

195



196

197 ▲ Figure 3: Structure and formation of caveolae. Caveolae are invaginations of the
 198 plasma membrane. Cavin-1 first binds with the plasma membrane, initiating caveolae
 199 synthesis. Caveolin 1 binds with cavin-1, which stabilizes its structure and forms caveolae.
 200 (Made with BioRender)

201

202 3.3 Type two Familial Partial Lipodystrophy (FPLD2)

203 The gene LMNA encodes the protein called Lamins. It is the gene that is associated
 204 with Type two Familial Partial Lipodystrophy (FPLD2). FPLD2 is the most common type
 205 of lipodystrophy syndrome (Corsa et al. 2021). In cells, Lamin A and Lamin C are
 206 expressed predominantly. The main functions of Lamin A/C are the regulation of nucleus
 207 shape, providing structural stability to the nuclear envelope and cytoskeleton, and also
 208 controlling gene regulation (Maung et al. 2026):(Bagias et al. 2020). They are important
 209 intermediate filament proteins forming the nuclear lamina. They also play a role in
 210 organizing chromatin. Mutations in Lamin A/C can lead to premature aging syndrome
 211 (Hutchinson-Gilford Progeria Syndrome). The mutated LMNA gene produces a mutant
 212 product called progerin. As progerin accumulates in the nucleus, it destabilizes DNA,
 213 triggers premature senescence, and alters the shape of the nucleus (Gonzalo et al., 2017).

214 The interference with the cleavage step of post-translational regulation of Lamin A
 215 could also affect the patient. ZMPSTE24 plays an important role in this step, and it is also
 216 considered to be one of the factors that causes lipodystrophy. However, mutations in
 217 ZMPSTE24 cause another distinct form of lipodystrophy (mandibuloacral dysplasia),
 218 showing different symptoms and increased severity. Nevertheless, modification is crucial
 219 and ensures that Prelamin A (the precursor of Lamin A before post-translational
 220 regulation) functions normally. Not only will the lack of Lamin A affect cell functions, but

221 the accumulation of Prelamin A could also be toxic to cells (Varlet, Helfer, and Badens
222 2020), which could affect the cell's ability to develop properly.

223 These cellular abnormalities contribute to broader systemic symptoms. This
224 includes a higher risk of cardiovascular diseases. It is found that FPLD2 patients have
225 higher Epicardial adipose tissue (EAT) volume than type two diabetes patients (Talman et
226 al. 2014) (Godoy-Matos et al. 2015). However, it is not related to other metabolic issues
227 that are also presented in lipodystrophy (Lamothe et al. 2025). Additional studies will
228 need to be conducted to gain a clearer insight into this condition and its correlation.

229

230 *3.4 Type three Familial Partial Lipodystrophy (FPLD3)*

231 Type three Familial Partial Lipodystrophy (FPLD3) is caused by pathogenic
232 variants of the PPARG gene. PPARG encodes PPAR γ (Peroxisome proliferator-activated
233 receptor γ), a member of a superfamily of nuclear receptors. PPAR γ is known as the
234 master regulator of adipocyte differentiation, maintenance, and functions (Broekema et al.
235 2019). It has three isoforms: PPAR γ 1, PPAR γ 2, and PPAR γ 3. Among them, PPAR γ 2 is
236 predominantly expressed in adipocytes. PPAR γ acts as a ligand-activated transcription
237 factor. It binds to its target gene as a heterodimer with PPAR-response elements
238 (PPREs) (Madsen et al. 2022). After binding, PPAR γ regulates the transcription of
239 downstream target genes that are involved in the development of adipose tissues.
240 Including the TAG cycle, which is upregulated by PPAR γ for the development of adipocytes.
241 Loss-of-function or dominant-negative mutations in pathogenic variants of PPARG cause
242 excess differentiation and growth in adipocytes, fundamentally impairing adipogenesis.
243 Therefore, leading to increased cellular stress and dysfunctions in adipocytes (Soares et al.
244 2024).

245 Compared to FPLD2, FPLD3 patients show less severe fat loss. One way to explain
246 this is that more large adipocytes are preserved since mutations in PPARG could lead to
247 excess cell growth. Fat accumulation in areas such as the face and neck is also not
248 observed (Bagias et al. 2020). However, FPLD3 patients also show more severe metabolic
249 symptoms, specifically hypertriglyceridemia, diabetes, and insulin resistance. One possible
250 explanation is that although patients still preserve large adipocytes, they only have a few
251 small, insulin-sensitive adipocytes (Soares et al. 2024).

252

253 *3.5 Acquired Lipodystrophy*

254 A wide range of gene mutations that affect different cellular functions could all lead
255 to LD. However, gene mutations are not the only cause of lipodystrophy. Other
256 environmental factors can also trigger the onset of lipodystrophy. Acquired Generalized
257 Lipodystrophy (AGL) and Acquired Partial Lipodystrophy (APL) are forms of
258 lipodystrophy that are not caused by genetic mutations (Al-Jawad et al. 2025). Despite
259 having different mechanisms, they have similar symptoms to congenital lipodystrophy.

260 Acquired lipodystrophy is characterized by the gradual loss of fat tissue starting
261 from childhood or adolescence. AGL patients show a generalized loss of adipose tissue,
262 while APL patients show loss of adipose tissue from the upper body. This includes the
263 face, neck, upper extremities, and upper trunk. They also share similar causes, including
264 autoimmune diseases, panniculitis-associated causes, and idiopathic causes. However,
265 while about 25% of AGL cases are associated with panniculitis, it is rare in APL patients
266 (Hussain & Garg, 2016).

267 Adverse effects of highly active antiretroviral therapy in patients with HIV are
268 among the factors that lead to acquired lipodystrophy. The mechanism by which
269 antiretroviral drugs play a role in the development of lipodystrophy is not fully
270 understood. One possibility is the use of thymidine analog nucleoside reverse
271 transcriptase inhibitors in highly active antiretroviral therapies. They have been shown to
272 disrupt adipose tissue functions (Guzman and Vijayan 2025). It decreases the expression
273 of adiponectin, which regulates the oxidation of glucose and fatty acids. Nucleoside
274 reverse transcriptase inhibitor also induces mitochondrial toxicity, which also plays a role
275 in the development of acquired lipodystrophy. Lipodystrophy in HIV-infected patients is
276 characterized by the loss of subcutaneous fat at the extremities and face.

277 Autoimmune diseases are also a significant cause of acquired lipodystrophy. In
278 particular, perilipin 1 autoantibodies are found in AGL patients (Corvillo et al. 2022).
279 Anti-perilipin is also found in patients with panniculitis-associated AGL. Perilipin is found
280 only in adipose tissue and forms a layer that coats lipid droplets. Under normal conditions,
281 perilipin forms a barrier between lipase and the surface of lipid droplets. However, when
282 the autoantibodies are present, it disrupts the normal function of perilipin. It leads to an
283 increase in lipolysis activities, which contributes to the gradual loss of adipose tissue in
284 AGL patients (Corvillo et al. 2018).

285 In APL patients, the presence of C3 nephritic factor (C3NeF) is commonly
286 associated. It acts as an autoantibody against the body's own complement system,
287 particularly complement component C3. When C3NeF binds with C3 convertase, it
288 stabilizes C3 convertase and prevents its natural decay. Since the function of C3
289 convertase is to cleave C3 into its active fragment, prolonged activation leads to a low level
290 of C3 (*Nephritic Factor - an Overview | ScienceDirect Topics*, n.d.). As the breakdown of C3
291 continues, it activates the terminal pathway. It ultimately leads to the lysis of adipocytes,
292 which explains the fat loss. However, the factor that limits fat loss to the upper body
293 remains unclear (Corvillo & López-Trascasa, 2018).

294

295 4. *Diagnosis and Clinical Features*

296 Since lipodystrophy is so rare, it is often misdiagnosed or left undiagnosed by
297 clinicians. It heavily relies on clinical history and physical examinations that reveal the
298 composition of adipose tissues. Metabolic dysfunctions are also important markers when
299 diagnosing lipodystrophy. Although patients with CGL show symptoms such as a lack of

300 body fat shortly after birth, it is often left undiagnosed until their childhood or adulthood,
301 when they start showing metabolic abnormalities. As for FPLD, it is even more commonly
302 unrecognized due to patients only losing adipose tissue partially. It could be easily
303 misdiagnosed as other types of common metabolic diseases, like obesity or severe
304 diabetes mellitus. Presentations of AGL and APL are generally similar to CGL and FPLD,
305 also including the metabolic issues that come with it (Lima et al. 2025).

306 Lipotoxicity is a direct consequence of adipose tissue dysfunction. Since adipose
307 tissues aren't able to store as many lipid droplets as are produced, excess lipid droplets
308 circulate in the bloodstream as free fatty acids. As the level of circulating free fatty acids
309 elevates, it becomes toxic for non-adipose tissues, resulting in increased oxidative stress
310 (Engin, 2017; Sies, 2020). Since the liver is the major organ that maintains the body's
311 homeostasis, excess fatty acid accumulates at the liver, leading to fatty liver (Kikuchi &
312 Takamura, 2017; Liu et al., 2010). This imbalance of fatty acids in the liver interferes with
313 the insulin signaling pathways. In addition, the body stores excess fat in skeletal muscles,
314 as it is the organ responsible for most of the energy uptake (Merz & Thurmond, 2020).
315 Without skeletal muscles, glucose isn't consumed properly, which also disrupts the insulin
316 signaling pathways.

317 Some phenotypes associated with lipodystrophy include a muscular appearance,
318 prominent veins, and a lack of body fat. Two main types of fat tissue serve different
319 functions in the body: metabolic and mechanical adipose tissue. Metabolic adipose tissue
320 is responsible for energy storage and hormone secretion, while mechanical tissue, also
321 known as subcutaneous fat, is found under the skin and internal organs to provide
322 protection and support. For CGL patients, the loss of metabolic adipose tissues is more
323 severe than the loss of mechanical tissues. Yet patients still, to some degree, lack functional
324 mechanical fat tissues. Only CGL2 patients do not acquire both mechanical and metabolic
325 adipose tissues (Garg 2011).

326 In contrast, FPLD is characterized by the abnormal distribution with a slight loss of
327 adipose tissue, meaning that patients still acquire most of their functional fat tissues. In
328 addition, as mentioned before, the onset of CGL is often shortly after birth, but for FPLDs,
329 its onset is usually around puberty or adolescence. In general, CGL patients lack the ability
330 to build up mature adipose tissue, while FPLD patients can't store or regulate adipose
331 tissue properly. The following section will address potential treatments and their
332 underlying mechanisms.






333

334 5. Treatments

335 5.1 Metreleptin

336 Currently, there isn't a definitive cure for lipodystrophy, but some treatments
337 targeting specific metabolic abnormalities have been developed (Araújo-Vilar and Santini
338 2019). For example, Metreleptin (Recombinant methionyl human leptin) is a drug
339 invented specifically for lipodystrophy. It targets leptin deficiency in patients. Leptin is

secreted by adipose tissue, and it regulates a person's appetite and food intake (Tsoukas, Farr, and Mantzoros 2015). Since lipodystrophy patients lack functional adipose tissue, leptin secretion also decreases. This causes patients to show extreme hyperphagia, which means the excessive intake of food. This worsens insulin resistance and creates excess fat that must be stored in internal organs or muscles. Metreleptin's main purpose is to mimic the naturally occurring leptin hormone, and it must be administered at least once daily (Rodriguez, Mastronardi, and Paz-Filho 2015). It helps reduce patients' appetite and decreases the intake of calories, which contributes to the accumulation of lipid droplets. The use of metreleptin in FPLD patients is not approved by the FDA since it does not work as efficiently in FPLD patients as in CGL patients (Gilio, Foss-Freitas, and Oral 2025). Individual cases of FPLD could be evaluated for whether the requirements for the metreleptin treatment are met. However, the risk of using Metreleptin for special groups of people with generalized lipodystrophy, such as pregnant women, is not certain. Other common drugs, such as insulin or metformin, can also help patients control their symptoms; however, they are not a cure for LD. Cosmetic surgery is also an option for patients to minimize the psychological discomfort and to have a better quality of life (Table 2).

	 Diet and exercise	 Glucose-lowering medications	 Lipid-lowering and CV medications	 LD-specific therapy	 Other
Treatment type	<ul style="list-style-type: none"> Well-balanced, low-fat, low-calorie diet Exercise is encouraged in the absence of specific contraindications 	<ul style="list-style-type: none"> Metformin Insulin Thiazolidinediones GLP-1 receptor agonists SGLT2i 	<ul style="list-style-type: none"> Statins Fibrates Omega-3 fatty acids ACE inhibitors ARBs Beta-blockers 	<ul style="list-style-type: none"> Metreleptin 	<ul style="list-style-type: none"> Cosmetic surgery Counselling
Objectives	<ul style="list-style-type: none"> Cornerstone of LD treatment To help manage weight gain and control calorie and fat intake 	<ul style="list-style-type: none"> Glycemic control 	<ul style="list-style-type: none"> Long-term cardiovascular risk reduction 	<ul style="list-style-type: none"> Only currently approved specific treatment for LD (to treat complications of leptin deficiency adjunct to diet) In PL, often used only once SOC therapies are considered no longer effective 	<ul style="list-style-type: none"> May help patients feel better about their physical appearance and may offer an improved QoL
Challenges and considerations	<ul style="list-style-type: none"> Considered burdensome for patients. Restrictive long-term diets are not easy to maintain Dietary restriction challenging in hyperphagic patients 	<ul style="list-style-type: none"> Patient adherence to therapy High need for careful monitoring especially patients requiring high doses of insulin Challenges with administering in patients with GL due to lack of subcutaneous fat 	<ul style="list-style-type: none"> Patient adherence to therapy 	<ul style="list-style-type: none"> Often used only once SOC therapies are considered no longer effective Challenges with administering in patients with GL due to lack of subcutaneous fat Restricted access in some regions (e.g., REMS program) 	<ul style="list-style-type: none"> Cosmetic surgery rarely mentioned by participants as a treatment option.

358

▲ Table 2: Possible medications to control metabolic issues that arise with lipodystrophy. Including the objectives, possible challenges, and other considerations (Reproduced from (Patni et al., 2024) under the terms of the CC BY license)

362

363 5.2 Lifestyle Modification

364 Although Metreleptin can generally help with metabolic dysfunctions, lifestyle
365 modification also plays a significant role in managing lipodystrophy. A low-fat diet is

366 recommended for patients. Carbohydrate intake is also restricted to control diabetes.
367 Since the body cannot store excess energy properly, it would be beneficial for patients to
368 reduce the intake of food that will be metabolized into excess fat or energy. Physical
369 exercises are also encouraged. However, patients with cardiovascular issues should avoid
370 excessive exercise to prevent further complications (Akinici et al. 2024).

371


372 5.3 Limitations and Possibility of Gene Editing

373 Although Metreleptin is an effective way for LD patients to manage metabolic
374 complications, it is not able to cure them. In the future, gene editing could be applied to
375 treating this disease. Preclinical trials have been conducted on mouse models with CGL2,
376 which has a gene mutation at the BSCL2 gene. Seipin knockout (SKO) mice, which
377 generally show similar metabolic symptoms to CGL2 patients, were generated and injected
378 with adeno-associated virus (AAV) vectors (Sommer et al. 2022). AAV can be engineered
379 to transduce adipocytes, enabling targeted gene therapy for lipodystrophy. The results of
380 the trials show that gene therapy effectively restores adipose tissue development and
381 function (Tiwari et al. 2024). However, even though AAV is commonly used in clinical
382 trials, it hasn't been used to directly target adipose tissue. Novel AAV serotypes that target
383 adipose tissue or an alternative promoter are critical for the development of an improved
384 gene therapy strategy for LD patients. Therefore, there isn't enough evidence currently to
385 suggest that the results from mouse models can be translated to humans. Continued
386 research on LD and advances in gene therapy are necessary to develop a more effective
387 therapeutic strategy for this rare disorder.

388

389 6. Conclusion and the Future

390



391

392 ▲ Figure 4: Steps of adipogenesis. Starting from mesenchymal stem cells, after
393 proliferation and differentiation, it develops into preadipocytes. Then, through lipogenesis,

394 preadipocytes grow into mature adipocytes. When a person is fasting, adipocytes go
395 through lipolysis to produce energy by breaking down triglycerides into glycerol and free
396 fatty acids. The last step is apoptosis, which ultimately leads to cell death. (Made with
397 BioRender)

398

399 Genes involved in lipodystrophy syndromes affect various cellular processes, such
400 as lipid synthesis, signal transduction, and nuclear structure. They all lead to a common
401 outcome: impaired adipocyte development and function. The examples discussed in this
402 review, including CGL1, CGL4, FPLD2, and FPLD3, demonstrate how different stages of
403 adipogenesis and gene mutations that are involved in adipogenesis all lead to similar
404 consequences (Figure 4). In addition to genetic causes, acquired factors can also
405 contribute to adipocyte dysfunctions, as seen in AGL.

406 LD highlights the essential role of adipose tissue as an endocrine and metabolic
407 organ. It not only stores energy but also maintains metabolic homeostasis and regulates
408 hormones. The absence of adipocytes, as shown in this review, could cause
409 life-threatening disorders. Understanding this condition not only helps people recognize
410 the role of adipose tissue in metabolism but also helps raise awareness of rare diseases.
411 For conditions like lipodystrophy, many patients remain undiagnosed throughout their
412 lives. Not only is conducting research with so few samples challenging, but scientists may
413 be less willing to dedicate time to studying rare diseases compared to diseases that affect
414 a larger population. Increased awareness and improved diagnostic tools not only help
415 identify individuals affected by this disease earlier but also give them a chance to manage
416 their condition in a more effective way.

417 Since the discovery of lipodystrophy syndromes in the mid-20th century, significant
418 progress has been made in understanding lipodystrophy. From phenotypes and metabolic
419 abnormalities to underlying genetic causes, research has been conducted to find ways to
420 reduce patients' pain and suffering. Having a deep understanding of lipodystrophy, such
421 as the mechanisms of various genes and their relationship with adipogenesis, will be
422 crucial to the development of a more effective and targeted therapeutic strategy.

423

424 7. References

425

426 Akinci, Baris, Merve Celik Gular, and Elif A. Oral. 2024. "Lipodystrophy Syndromes:
427 Presentation and Treatment." in *Endotext [Internet]*. MDText.com, Inc.

428 Al-Jawad, Mohammad, Lina Mawaldi, Nada Mawaldi, Mariam Krimsty, and Silva Ishkanian.
429 2025. "Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome) with
430 Both-Side Axillary Breasts: A Case Report." *International Journal of Surgery Case
431 Reports* 129:111202. doi:10.1016/j.ijscr.2025.111202.

- 432 Araújo-Vilar, D., and F. Santini. 2019. "Diagnosis and Treatment of Lipodystrophy: A
433 Step-by-Step Approach." *Journal of Endocrinological Investigation* 42(1):61–73.
434 doi:10.1007/s40618-018-0887-z.
- 435 Ardissonne, Anna, Cinzia Bragato, Lorella Caffi, Flavia Blasevich, Sabrina Maestrini, Maria
436 Luisa Bianchi, Lucia Morandi, Isabella Moroni, and Marina Mora. 2013. "Novel
437 PTRF Mutation in a Child with Mild Myopathy and Very Mild Congenital
438 Lipodystrophy." *BMC Medical Genetics* 14(1):89. doi:10.1186/1471-2350-14-89.
- 439 Bagias, Christos, Angeliki Xiarchou, Alexandra Bargiota, and Stelios Tigas. 2020. "Familial
440 Partial Lipodystrophy (FPLD): Recent Insights." *Diabetes, Metabolic Syndrome and
441 Obesity: Targets and Therapy* 13:1531–44. doi:10.2147/DMSO.S206053.
- 442 Broekema, Marjoleine F., Maarten P. G. Massink, Cinzia Donato, Joep De Ligt, Joerg
443 Schaarschmidt, Anouska Borgman, Marieke G. Schooneman, Diana Melchers, Martin
444 N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia, Houshang
445 Monajemi, Gijs W. Van Haaften, Maarten R. Soeters, and Eric Kalkhoven. 2019.
446 "Natural Helix 9 Mutants of PPAR γ Differently Affect Its Transcriptional Activity."
447 *Molecular Metabolism* 20:115–27. doi:10.1016/j.molmet.2018.12.005.
- 448 Chiquette, Elaine, Elif A. Oral, Abhimanyu Garg, David Araújo-Vilar, and Praveen Dhankhar.
449 2017. "Estimating the Prevalence of Generalized and Partial Lipodystrophy:
450 Findings and Challenges." *Diabetes, Metabolic Syndrome and Obesity* 10:375–83.
451 doi:10.2147/DMSO.S130810.
- 452 Corsa, Callie A. S., Carolyn M. Walsh, Devika P. Bagchi, Maria C. Foss Freitas, Ziru Li, Julie
453 Hardij, Katrina Granger, Hiroyuki Mori, Rebecca L. Schill, Kenneth T. Lewis, Jessica
454 N. Maung, Ruth D. Azaria, Amy E. Rothberg, Elif A. Oral, and Ormond A. MacDougald.
455 2021. "Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial
456 Partial Lipodystrophy Type 2." *Diabetes* 70(9):1970–84. doi:10.2337/db20-1001.
- 457 Corvillo, Fernando, Brent S. Abel, Alberto López-Lera, Giovanni Ceccarini, Silvia Magno,
458 Ferruccio Santini, David Araújo-Vilar, Rebecca J. Brown, Pilar Nozal, and Margarita
459 López-Trascasa. 2022. "Characterization and Clinical Association of Autoantibodies
460 Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy." *Diabetes*
461 72(1):71–84. doi:10.2337/db21-1086.
- 462 Corvillo, Fernando, Verónica Aparicio, Alberto López-Lera, Sofía Garrido, David
463 Araújo-Vilar, María P. de Miguel, and Margarita López-Trascasa. 2018.
464 "Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized
465 Lipodystrophy." *Frontiers in Immunology* 9. doi:10.3389/fimmu.2018.02142.

- 466 Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
467 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic.
468 n.d. Retrieved January 19, 2026.
469 <https://academic.oup.com/jcem/article/101/12/4500/2764979>.
- 470 Fourman, Lindsay T, and Steven K. Grinspoon. 2022. "Approach to the Patient With
471 Lipodystrophy." *The Journal of Clinical Endocrinology & Metabolism*
472 107(6):1714–26. doi:10.1210/clinem/dgac079.
- 473 Gale, Sarah E., Andrey Frolov, Xianlin Han, Perry E. Bickel, Li Cao, Anne Bowcock, Jean E.
474 Schaffer, and Daniel S. Ory. 2006. "A Regulatory Role for
475 1-Acylglycerol-3-Phosphate-O-Acyltransferase 2 in Adipocyte Differentiation *."
476 *Journal of Biological Chemistry* 281(16):11082–89. doi:10.1074/jbc.M509612200.
- 477 Garg, Abhimanyu. 2011. "Lipodystrophies: Genetic and Acquired Body Fat Disorders." *The*
478 *Journal of Clinical Endocrinology & Metabolism* 96(11):3313–25.
479 doi:10.1210/jc.2011-1159.
- 480 Gilio, Donatella, Maria Foss-Freitas, and Elif A. Oral. 2025. "Clinical Guidance for
481 Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment." *Current*
482 *Diabetes Reports* 25(1):47. doi:10.1007/s11892-025-01603-4.
- 483 Godoy-Matos, Amélio Fernando, Cynthia M. Valério, Juliana Bonadiman e. Bragança,
484 Ricardo de Andrade Oliveira, Roberto Luis Zagury, Rodolfo de Paula Lustosa,
485 Gabriel Cordeiro Camargo, César Augusto da Silva Nascimento, and Rodrigo O.
486 Moreira. 2015. "Evaluation of Epicardial Adipose Tissue in Familial Partial
487 Lipodystrophy." *Diabetology & Metabolic Syndrome* 7(1):29.
488 doi:10.1186/s13098-015-0024-5.
- 489 Guzman, Nilmarie, and Vini Vijayan. 2025. "HIV-Associated Lipodystrophy." in *StatPearls*.
490 Treasure Island (FL): StatPearls Publishing.
- 491 Lamothe, Sophie, Patricia Ancel, Inès Belalem, Leïla Lecaque, Joris Fournel, Alexis Jacquier,
492 Zouhair Houhou, Jean-Baptiste Julla, Jean-François Gautier, Corinne Vigouroux,
493 Bénédicte Gaborit, and Camille Vatie. 2025. "Increased Epicardial Adipose Tissue Is
494 Part of the Phenotype of *LMNA*-Associated Partial Lipodystrophy and Could
495 Contribute to Increased Cardiovascular Risk." *Diabetes & Metabolism*
496 51(6):101710. doi:10.1016/j.diabet.2025.101710.
- 497 Lima, Josivan Gomes, Lucas Nobrega Lima, Vitor Yan Bezerra Araujo, Lucia Helena Coelho
498 Nobrega, and Julliane Tamara Araújo de Melo Campos. 2025. "Diagnosis of

- 499 Congenital and Acquired Generalized Lipodystrophies—Similarities and
500 Differences.” *Endocrines* 6(4):55. doi:10.3390/endocrines6040055.
- 501 Lima, Josivan Gomes, Lucia Helena C. Nobrega, Natalia Nobrega Lima, Marcel Catão
502 Ferreira dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P. Baracho,
503 Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo
504 Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O. Mendes-Aguiar,
505 and Selma Maria B. Jeronimo. 2018. “Causes of Death in Patients with
506 Berardinelli-Seip Congenital Generalized Lipodystrophy.” *PLOS ONE*
507 13(6):e0199052. doi:10.1371/journal.pone.0199052.
- 508 Madsen, Maria Stahl, Marjoleine F. Broekema, Martin Rønn Madsen, Arjen Koppen,
509 Anouska Borgman, Cathrin Gräwe, Elisabeth G. K. Thomsen, Denise Westland,
510 Mariette E. G. Kranendonk, Marian Groot Koerkamp, Nicole Hamers, Alexandre M. J.
511 J. Bonvin, José M. Ramos Pittol, Kedar Nath Natarajan, Sander Kersten, Frank C. P.
512 Holstege, Houshang Monajemi, Saskia W. C. van Mil, Michiel Vermeulen, Birthe B.
513 Kragelund, David Cassiman, Susanne Mandrup, and Eric Kalkhoven. 2022. “PPAR γ
514 Lipodystrophy Mutants Reveal Intermolecular Interactions Required for Enhancer
515 Activation.” *Nature Communications* 13(1):7090.
516 doi:10.1038/s41467-022-34766-9.
- 517 Maung, Jessica N., Rebecca L. Schill, Akira Nishii, Maria Foss de Freitas, Bonje N. Obua,
518 Marcus Nygård, Maria D. Mendez-Casillas, Isabel D. K. Hermsmeyer, Donatella Gilio,
519 Ozge Besci, Yang Chen, Brian Desrosiers, Rose E. Adler, Anabela D. Gomes, Merve
520 Celik Guler, Hiroyuki Mori, Romina M. Uranga, Ziru Li, Hadla Hariri, Liping Zhang,
521 Anderson de Paula Souza, Keegan S. Hoose, Kenneth T. Lewis, Taryn A. Hetrick, Paul
522 Cederna, Carey N. Lumeng, Susanne Mandrup, Elif A. Oral, and Ormond A.
523 MacDougald. 2026. “Altered Lipid Metabolism and Inflammatory Programs
524 Associate with Adipocyte Loss in Familial Partial Lipodystrophy 2.” *The Journal of*
525 *Clinical Investigation* 136(1). doi:10.1172/JCI198387.
- 526 de Melo, Maria Eduarda Cardoso, Letícia Marques Gomes da Silva, Ana Carolina Costa
527 Cavalcante, Josivan Gomes Lima, and Julliane Tamara Araújo de Melo Campos.
528 2025. “The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital
529 Generalized Lipodystrophy Pathophysiology.” *International Journal of Molecular*
530 *Sciences* 26(11):5416. doi:10.3390/ijms26115416.
- 531 Misra, Anoop, and Abhimanyu Garg. 2003. “Clinical Features and Metabolic Derangements
532 in Acquired Generalized Lipodystrophy: Case Reports and Review of the
533 Literature.” *Medicine* 82(2):129–46. doi:10.1097/00005792-200303000-00007.

- 534 Oswiecimska, Joanna. n.d. "A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2
535 Splicesite Mutation and Concomitant Development of Non-Diabetic Polyneuropathy
536 - Journal of Clinical Research in Pediatric Endocrinology." Retrieved January 19,
537 2026. <https://jcrpe.org/articles/doi/jcrpe.galenos.2018.2018.0227>. doi:
538 10.4274/jcrpe.galenos.2018.2018.0227
- 539 Poulos, Sylvia P, Michael V. Dodson, Melinda F. Culver, and Gary J. Hausman. 2016. "The
540 Increasingly Complex Regulation of Adipocyte Differentiation." *Experimental*
541 *Biology and Medicine* 241(5):449–56. doi:10.1177/1535370215619041.
- 542 Rajab, Anna, Volker Straub, Liza J. McCann, Dominik Seelow, Raymonda Varon, Rita
543 Barresi, Anne Schulze, Barbara Lucke, Susanne Lützkendorf, Mohsen Karbasiyan,
544 Sebastian Bachmann, Simone Spuler, and Markus Schuelke. 2010. "Fatal Cardiac
545 Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized
546 Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations." *PLOS*
547 *Genetics* 6(3):e1000874. doi:10.1371/journal.pgen.1000874.
- 548 Rodriguez, Alexander J., Claudio A. Mastronardi, and Gilberto J. Paz-Filho. 2015. "New
549 Advances in the Treatment of Generalized Lipodystrophy: Role of Metreleptin."
550 *Therapeutics and Clinical Risk Management* 11:1391–1400.
551 doi:10.2147/TCRM.S66521.
- 552 Salle-Teyssières, Laurence, Martine Auclair, Faraj Terro, Mona Nemani, Solaf M. Elsayed,
553 Ezzat Elsobky, Mark Lathrop, Marc Délépine, Olivier Lascols, Jacqueline Capeau,
554 Jocelyne Magré, and Corinne Vigouroux. 2016. "Maladaptative Autophagy Impairs
555 Adipose Function in Congenital Generalized Lipodystrophy Due to Cavin-1
556 Deficiency." *The Journal of Clinical Endocrinology & Metabolism*
557 101(7):2892–2904. doi:10.1210/jc.2016-1086.
- 558 Soares, Reivla Marques Vasconcelos, Monique Alvares da Silva, Julliane Tamara Araújo de
559 Melo Campos, and Josivan Gomes Lima. 2024. "Familial Partial Lipodystrophy
560 Resulting from Loss-of-Function PPAR γ Pathogenic Variants: Phenotypic, Clinical,
561 and Genetic Features." *Frontiers in Endocrinology* 15.
562 doi:10.3389/fendo.2024.1394102.
- 563 Sommer, Nadine, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J. Rochford,
564 and George D. Mcilroy. 2022. "Gene Therapy Restores Adipose Tissue and
565 Metabolic Health in a Pre-Clinical Mouse Model of Lipodystrophy." *Molecular*
566 *Therapy Methods & Clinical Development* 27:206–16.
567 doi:10.1016/j.omtm.2022.09.014.

568 Stea, Dante Maria, and Alessio D'Alessio. 2025. "Caveolae: Metabolic Platforms at the
569 Crossroads of Health and Disease." *International Journal of Molecular Sciences*
570 26(7):2918. doi:10.3390/ijms26072918.

571 Talman, Andrew H., Peter J. Psaltis, James D. Cameron, Ian T. Meredith, Sujith K.
572 Seneviratne, and Dennis T. L. Wong. 2014. "Epicardial Adipose Tissue: Far More
573 than a Fat Depot." *Cardiovascular Diagnosis and Therapy* 4(6):416–29.
574 doi:10.3978/j.issn.2223-3652.2014.11.05.

575 Tiwari, Mansi, Ahlima Roumane, Nadine Sommer, Weiping Han, Mirela Delibegović, Justin J.
576 Rochford, and George D. Mcilroy. 2024. "Preclinical Evaluation of Tissue-Selective
577 Gene Therapies for Congenital Generalised Lipodystrophy." *Gene Therapy*
578 31(9):445–54. doi:10.1038/s41434-024-00471-z.

579 Tsoukas, Michael A., Olivia M. Farr, and Christos S. Mantzoros. 2015. "Leptin in Congenital
580 and HIV-Associated Lipodystrophy." *Metabolism* 64(1):47–59.
581 doi:10.1016/j.metabol.2014.07.017.

582 Varlet, Alice-Anaïs, Emmanuèle Helfer, and Catherine Badens. 2020. "Molecular and
583 Mechanobiological Pathways Related to the Physiopathology of FPLD2." *Cells*
584 9(9):1947. doi:10.3390/cells9091947.

585 Ajluni, N., Dar, M., Xu, J., Neidert, A. H., & Oral, E. A. (2016). Efficacy and Safety of
586 Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded
587 Access Program. *Journal of Diabetes & Metabolism*, 7(3), 659.
588 <https://doi.org/10.4172/2155-6156.1000659>

589 Akinci, B., Gular, M. C., & Oral, E. A. (2024). Lipodystrophy Syndromes: Presentation and
590 Treatment. In *Endotext [Internet]*. MDText.com, Inc.
591 <https://www.ncbi.nlm.nih.gov/sites/books/NBK513130/>

592 Araújo-Vilar, D., & Santini, F. (2019). Diagnosis and treatment of lipodystrophy: A
593 step-by-step approach. *Journal of Endocrinological Investigation*, 42(1), 61–73.
594 <https://doi.org/10.1007/s40618-018-0887-z>

595 Broekema, M. F., Massink, M. P. G., De Ligt, J., Stigter, E. C. A., Monajemi, H., De Ridder, J.,
596 Burgering, B. M. T., van Haaften, G. W., & Kalkhoven, E. (2018). A Single Complex
597 Agpat2 Allele in a Patient With Partial Lipodystrophy. *Frontiers in Physiology*, *9*.
598 <https://doi.org/10.3389/fphys.2018.01363>

599 Corvillo, F., & López-Trascasa, M. (2018). Acquired partial lipodystrophy and C3
600 glomerulopathy: Dysregulation of the complement system as a common
601 mechanism. *Nefrología (English Edition)*, *38*(3), 258–266.
602 <https://doi.org/10.1016/j.nefro.2018.04.002>

603 Engin, A. B. (2017). What Is Lipotoxicity? In A. B. Engin & A. Engin (Eds.), *Obesity and*
604 *Lipotoxicity* (pp. 197–220). Springer International Publishing.
605 https://doi.org/10.1007/978-3-319-48382-5_8

606 Gonzalo, S., Kreienkamp, R., & Askjaer, P. (2017). Hutchinson-Gilford Progeria Syndrome: A
607 premature aging disease caused by LMNA gene mutations. *Ageing Research*
608 *Reviews*, *33*, 18–29. <https://doi.org/10.1016/j.arr.2016.06.007>

609 Grivas, D., González-Rajal, Á., Guerrero Rodríguez, C., Garcia, R., & de la Pompa, J. L. (2020).
610 Loss of Caveolin-1 and caveolae leads to increased cardiac cell stiffness and
611 functional decline of the adult zebrafish heart. *Scientific Reports*, *10*(1), 12816.
612 <https://doi.org/10.1038/s41598-020-68802-9>

613 Hussain, I., & Garg, A. (2016). Lipodystrophy Syndromes. *Endocrinology and Metabolism*
614 *Clinics of North America*, *45*(4), 783–797.
615 <https://doi.org/10.1016/j.ecl.2016.06.012>

616 Kikuchi, A., & Takamura, T. (2017). Where does liver fat go? A possible molecular link
617 between fatty liver and diabetes. *Journal of Diabetes Investigation*, 8(2), 152–154.
618 <https://doi.org/10.1111/jdi.12573>

619 Li, Y., Yang, X., Peng, L., Xia, Q., Zhang, Y., Huang, W., Liu, T., & Jia, D. (2022). Role of Seipin in
620 Human Diseases and Experimental Animal Models. *Biomolecules*, 12(6), 840.
621 <https://doi.org/10.3390/biom12060840>

622 Liu, Q., Bengmark, S., & Qu, S. (2010). The role of hepatic fat accumulation in pathogenesis
623 of non-alcoholic fatty liver disease (NAFLD). *Lipids in Health and Disease*, 9, 42.
624 <https://doi.org/10.1186/1476-511X-9-42>

625 Meehan, C. A., Cochran, E., Kassai, A., Brown, R. J., & Gorden, P. (2016). Metreleptin for
626 injection to treat the complications of leptin deficiency in patients with congenital
627 or acquired generalized lipodystrophy. *Expert Review of Clinical Pharmacology*,
628 9(1), 59–68. <https://doi.org/10.1586/17512433.2016.1096772>

629 Merz, K. E., & Thurmond, D. C. (2020). Role of Skeletal Muscle in Insulin Resistance and
630 Glucose Uptake. *Comprehensive Physiology*, 10(3), 785–809.
631 <https://doi.org/10.1002/cphy.c190029>

632 *Nephritic Factor—An overview | ScienceDirect Topics*. (n.d.). Retrieved May 3, 2026, from
633 <https://www.sciencedirect.com/topics/medicine-and-dentistry/nephritic-factor>

634 Patni, N., Chard, C., Araújo-Vilar, D., Phillips, H., Magee, D. A., & Akinci, B. (2024). Diagnosis,
635 treatment and management of lipodystrophy: The physician perspective on the
636 patient journey. *Orphanet Journal of Rare Diseases*, 19(1), 263.
637 <https://doi.org/10.1186/s13023-024-03245-3>

638 Santoro, A., McGraw, T. E., & Kahn, B. B. (2021). Insulin action in adipocytes, adipose
639 remodeling, and systemic effects. *Cell Metabolism*, 33(4), 748–757.
640 <https://doi.org/10.1016/j.cmet.2021.03.019>

641 *Search ClinicalTrials.gov for: Lipodystrophy | List Results | ClinicalTrials.gov.* (n.d.).
642 Retrieved April 15, 2026, from <https://clinicaltrials.gov/search>

643 Sies, H. (2020). Oxidative Stress: Concept and Some Practical Aspects. *Antioxidants*, 9(9),
644 852. <https://doi.org/10.3390/antiox9090852>

645

1 *Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, Pathophysiology,* 2 *and Therapy*

3 *Abstract*

4 Lipodystrophy syndromes are a group of rare diseases that are often
5 characterized by a general or partial absence of body fat, caused by the inability to
6 properly store and utilize fat tissues, and the lack of adipose tissues, and the
7 of adipose tissues would lead to serious consequences and the development of a series of
8 metabolic issues, including insulin resistance, leptin deficiency, and hypertriglyceridemia.
9 Lipodystrophy These syndromes are genetically and clinically heterogeneous, with
10 different phenotypes influenced by underlying molecular defects. Both fat distribution and
11 the molecular defect play a role in determining the type of
12 lipodystrophy a patient has. Due to the rarity of these disorders, not many studies have
13 been conducted on them. This, which results in the public's lack of
14 knowledge, increasing the difficulty of diagnosing and treating these conditions
15 about this disease and increases the difficulty of treating it. In this article, we first
16 examine the classification and clinical aspects of lipodystrophy syndromes,
17 covering the onset and the differences in phenotypes of patients. Then, we further
18 discuss the molecular and cellular mechanisms of several types of lipodystrophies and
19 the role they play in the development of adipose tissues. In addition, this review
20 addresses other metabolic dysfunctions caused by lipodystrophy, such as
21 insulin resistance, fatty liver, and hypertriglyceridemia. Lastly, we evaluate therapeutic
22 strategies aimed at improving metabolic control and quality of life in affected patients.
23 Future research and potential therapies may be improved with a
24 deeper and more thorough understanding of the genetic and mechanistic basis of
25 lipodystrophy, as it is critical for identifying key mechanisms and developing a more
26 targeted treatment.

27

28 *Keywords:* Lipodystrophy syndromes, adipose tissue, adipogenesis, gene mutations,
29 metabolic dysfunctions

30

31 *1. Introduction*

32 Lipodystrophy syndromes (LD) are a heterogeneous group of rare disorders
33 characterized by the partial or complete loss of mature adipose tissue in localized or
34 generalized areas. This results in the inability to store body fat, ectopic lipid storage, and
35 excess nutrients (Fourman and Grinspoon 2022). Two main classes of lipodystrophy are
36 Congenital Generalized Lipodystrophy (CGL) and Familial Partial Lipodystrophy (FPLD).
37 Adipose tissues are formed through a process called adipogenesis, and it is crucial for the
38 adipose tissue to function normally.

39 For adipose tissues to function normally, adipogenesis is crucial for the
40 differentiation of the precursor cells. Adipogenesis starts with Adipogenesis is the

41 ~~process by which~~ mesenchymal stem cells differentiate into mature adipose tissue.
42 ~~During This adipogenesis process, lipid storage and mobilization is regulated by also~~
43 ~~includes the triacylglycerol (TAG) fatty acid cycle, which regulates lipid storage and~~
44 ~~mobilization in adipocytes. It is the process~~ where the lipid droplets undergo lipolysis
45 (the breakdown of lipid droplets) and lipogenesis (the synthesis of new lipid
46 droplets) (Poulos et al. 2016). However, if a gene mutation or other factors affect the
47 components ~~that play a role~~ involved in the regulation of regulating adipogenesis, ~~this~~
48 would lead to impaired adipocyte differentiation, lipid droplet formation, and adipocyte
49 functions. ~~to serious, life-threatening consequences.~~

50 LD can be either congenital or acquired. Congenital Lipodystrophy, and it is
51 classified based on the location of lost adipose tissue, and further divided into subtypes
52 according to the gene segment that is mutated (Akinci, Gular, and Oral 2024) (Table 1).
53 Meanwhile, acquired lipodystrophy is caused by external factors or side effects of other
54 treatments.

55 CGL (also called Berardinelli-Seip syndrome) is characterized by the near-complete
56 absence of adipocytes, ~~both mechanical and metabolic fat tissues~~ (Oswiecimska n.d.). CGLs
57 are inherited in an autosomal recessive manner, and the with symptoms typically often
58 presenting ~~start showing~~ shortly after birth. It is further divided into CGL1, CGL2, CGL3,
59 and CGL4, which link to four different gene mutations. FPLD presents as an abnormal
60 distribution of adipose tissue, with fat loss around the limbs, torso, and hips. It can be
61 autosomal recessive or dominant depending on the gene ~~that is~~ involved. Since the body
62 is not able to store excess energy in those areas, other body parts, such as the face, neck,
63 and internal organs like the liver, gain extra adipose tissue (Diagnosis and Management of
64 Lipodystrophy Syndromes: A Multi-Society Practice Guideline | The Journal of Clinical
65 Endocrinology & Metabolism | Oxford Academic n.d.). This results in the abnormal
66 distribution of adipose tissues. As with Same as CGL, FPLD it is further also divided into
67 several subtypes, including FPLD1 (Kobberling-type lipodystrophy), FPLD2 (Dunnigan
68 Variety lipodystrophy), FPLD3, FPLD4, FPLD5, and FPLD6. The development of
69 adipocytes is tightly regulated by various proteins and enzymes. The genes that encode
70 these proteins or enzymes are often the genes associated with lipodystrophy. ~~Proteins or~~
71 ~~enzymes that are encoded by the genes associated with any kind of lipodystrophy all play~~
72 ~~important roles in the development of adipocyte.~~

73 As for Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and
74 Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome), they have similar
75 symptoms as CGL and FPLD. However, they are caused by autoimmune diseases, side
76 effects of antiretroviral therapy (ART) for HIV patients, or even idiopathic reasons (Misra
77 and Garg 2003). ~~Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and~~
78 ~~Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome) have similar~~
79 ~~symptoms, respectively, however, they can be caused by autoimmune diseases, the side~~

80 effects of antiretroviral therapy (ART) for HIV patients, and sometimes idiopathic (Misra
81 and Garg 2003).

82

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/ adolescence.	Palpable "ledge" between normal and lipodystrophic areas
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not effected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

83

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/adolescence.	Palpable "ledge" between normal and lipodystrophic areas
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not effected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

84

85 ▲ Table 1: Classification, clinical features, and molecular basis of lipodystrophies (Made
86 with Google Sheet)

87


88 Not only will the lack of excess ~~energy~~ ~~body fat~~ ~~affect~~ ~~affect~~ the body's normal
89 functions, but ~~other~~ complications ~~associated~~ ~~that arise~~ with lipodystrophy also have a
90 ~~significant~~ ~~big~~ effect on patients' lives. Some common metabolic abnormalities include
91 leptin deficiency, insulin resistance, diabetes, hypertriglyceridemia, and fatty liver disease
92 (Figure 1). Currently, around 200 clinical trials are ~~in progress, trying~~ ~~underway~~ to
93 discover a new way to treat or cure lipodystrophy, ~~with a particular focus on~~ ~~especially~~
94 ~~targeting~~ leptin deficiency ~~(Search ClinicalTrials.Gov For, n.d.)~~ ~~ney~~.

95 Metreleptin, for example, is a treatment created specifically for ~~acquired or~~
96 ~~congenital generalized lipodystrophy~~ ~~LD~~ patients. It is a targeted treatment for leptin
97 deficiency, which is a common metabolic issue associated with ~~LDD~~ (Araújo-Vilar &
98 Santini, 2019). ~~(Araújo Vilar e Santini 2019)~~. It is currently the only FDA- approved
99 treatment for ~~generalized lipodystrophy~~ ~~LD~~ patients. ~~However, conventional treatment,~~
100 ~~such as special diets,~~ is ~~still optimized before~~ ~~metreleptin~~ (Meehan et al., 2016). Due to the
101 rarity of this disease, limited research has been done, making Metreleptin the primary
102 choice for ~~CGL and AGL patients~~ ~~LD patients~~ (Ajluni et al., 2016). ~~As for FPLD patients, the~~
103 ~~use of Metreleptin is highly restricted. Therefore, they will need to maintain~~ ~~Patients will~~
104 ~~still need to have an appropriate~~ ~~healthy~~ diet and ~~require~~ other medications for ~~the other~~
105 metabolic ~~complications~~ ~~issues~~.


106 According to studies, only about 3 ~~per~~ ~~/~~ million people around the world are
107 affected by some type of lipodystrophy syndrome. While the prevalence of CGL is
108 estimated to be 0.23 ~~per~~ ~~/~~ million people, the prevalence of FPLD is around 2.84 ~~per~~
109 ~~/~~ million people (Chiquette et al. 2017). It is also estimated to shorten a patient's lifespan
110 by 30 or more years. The main cause of death is shown to be liver diseases and infections
111 caused by adipose tissue dysfunction, but also varies from type to type of lipodystrophy
112 (Lima et al. 2018).

113 This literature review aims to highlight the molecular mechanisms ~~underlying~~ ~~of~~
114 lipodystrophy, ~~focusing~~ ~~with a focus~~ on the genetic causes, differences between types of
115 lipodystrophies, and other metabolic conditions caused by adipose tissue abnormalities,
116 ~~as well as~~ ~~. In addition,~~ the treatment developed and ~~future directions of study, and the~~
117 ~~other~~ possibilities for ~~a~~ ~~fundamental treatments~~ ~~cure~~.

118



119



120

121 ▲ Figure 1: Comparison of adipocyte functions between a healthy person and a
 122 lipodystrophy patient. Adipocyte storage is limited. The storage of adipocytes is limited.
 123 in lipodystrophy patients. Common metabolic abnormalities include leptin deficiency,
 124 insulin resistance, and elevated blood glucose levels in the bloodstream. (Made
 125 with BioRender)

126

127 2. Methods

128 *Search Strategy*

129 A literature search was conducted using PubMed and Google Scholar databases.
130 The search included the following keywords: “lipodystrophy genetics”, “adipocyte
131 differentiation”, “AGPAT2”, “PTRF Cavin-1”, “LMNA mutation”, “PPAR γ mutation”,
132 “lipodystrophy metabolic abnormalities”. Titles and abstracts were first screened for
133 relevance. Full articles were reviewed to see if they met the inclusion criteria. 97 articles
134 were initially screened, and 54 papers were ultimately referenced in this review.

135

136 *Inclusion/Exclusion Criteria*

137 Articles published between 2000 and 2026 were included. Only ~~publications in the~~
138 English language publications were considered. Studies were included if they were
139 peer-reviewed primary research articles or comprehensive reviews, including both
140 narrative reviews and systematic reviews, that focused ~~focusing on~~ the genetic, molecular,
141 or metabolic mechanisms underlying ~~of~~ lipodystrophy syndromes. Case studies were
142 included if they provided ~~with~~ relevant insights ~~and information~~, such as pathological or
143 mutation analyses, or clinical findings ~~were also included~~. Non-peer-reviewed
144 sources and ~~articles published before 2000 are excluded~~; Case reports that only
145 report ~~with~~ descriptive ~~only~~ quantitative data, without the discussion of mechanistic
146 interpretation, are also excluded, as clinical data are not the focus of this review ~~and~~
147 ~~without further analysis were excluded~~. ~~Titles and abstracts were first screened for~~
148 ~~relevance. Full article was reviewed if they met the inclusion criteria.~~

149

150 *Discussion*


151 3. Genetics and Pathophysiology

152 3.1 Type ~~one~~1 Congenital Generalized Lipodystrophy (CGL1)

153 Type ~~one~~1 Congenital Generalized Lipodystrophy (CGL1) is caused by a mutation
154 in the gene AGPAT2. AGPAT2 is the gene ~~that coding for~~ ~~encodes the a specific enzyme~~ ,
155 1-acylglycerol-3-phosphate O-acyltransferase 2. ~~It, which~~ catalyzes the acylation of
156 lysophosphatidic acid (1-acylglycerol-3-phosphate) to phosphatidic acid (1,2
157 diacylglycerol-3-phosphate)(Gale et al. 2006) (Ffigure 2). It is an important precursor
158 ~~for~~ of the biosynthesis of triacylglycerol (TAG) and phospholipids ~~synthesis~~ from
159 glycerol-3-phosphate. This step esterifies a second fatty acyl group at the sn-2 position of
160 the glycerol backbone. Phosphatidic acid is further acylated by other enzymes, creating
161 triacylglycerol and phospholipids. **Impaired formation of phosphatidic acid results in the**
162 **absence of triacylglycerol production, thereby disrupting the normal adipose tissue**
163 **development.**

164 The AGPAT family consists of 11 isomers; ~~Among the isomers, however~~, AGPAT2 is
165 expressed at higher levels in adipose tissue than the other isomers. The presence of

166 mechanical adipose tissue can be explained by the increased expression of the other
167 isomers (Broekema et al., 2018). However, studies have shown that the expression of
168 AGPAT2 is required for the accumulation of triacylglycerol, especially in metabolic adipose
169 tissues. Defects in the AGPAT2 genes also impact insulin signaling, which is a direct effect
170 of impaired adipocyte dysfunction (Santoro et al., 2021). meaning This also causes that
171 gluconeogenesis will be unrestricted, which leads to the development of hyperglycemia
172 and diabetes(de Melo et al. 2025).
173



174
175 ▲ Figure 2: The process of Triacylglycerol synthesis. In the second step, where LPA is
176 acylated to PA, AGPAT is the enzyme that catalyzes this reaction. Without it, the reactions
177 after it will not occur properly, meaning that adipocytes can't develop properly. (Made
178 with BioRender)

179

180 3.2 Type 2 Congenital Generalized Lipodystrophy (CGL2)

181 Type 2 Congenital Generalized Lipodystrophy (CGL2) is caused by pathogenic
182 variants of the BSCL2 gene. It encodes the protein seipin, which is found in the
183 endoplasmic reticulum (ER) (Akinci et al., 2024), Seipin plays an important role in the
184 regulation of lipid droplet biogenesis. It interacts with proteins involved in TAG synthesis
185 to facilitate adipogenesis. For instance, it binds with AGPAT2 to regulate PA metabolism.
186 Seipin deficiency could lead to abnormal accumulation of PA. This increases the surface
187 tension of the ER and decreases its line tension, disrupting the unidirectional lipid droplet

188 budding. It causes the accumulation of newly synthesized neutral lipids in the ER, leading
189 to severe ER stress and potentially being toxic to the cells (Li et al., 2022).

190 CGL2 is the most common type of congenital lipodystrophy. But mutations in the
191 BSCL2 also lead to the most severe symptoms. Patients are born without any fat, including
192 mechanical and metabolic adipose tissues. They also have an earlier onset of diabetes
193 mellitus than other types of lipodystrophies. Other than adipocytes, seipin is also
194 expressed in the brain and testis. This leads to mild mental disability, developmental
195 language disorders, and an impaired reproductive system.


196

197 3.2 Type ~~four~~4 Congenital Generalized Lipodystrophy (CGL4)

198 Type ~~four~~4 Congenital Generalized Lipodystrophy (CGL4) is associated with the
199 gene mutation in the PTRF gene (Polymerase I and Transcript Release
200 Factor) (Salle-Teyssières et al. 2016). The PTRF gene encodes cavin-1, which is one of the
201 essential proteins that is required for the biogenesis of caveolae. Caveolae are ~~one of the~~
202 most abundant invaginations ~~of them in the plasma cell membrane~~ across a wide range of ~~of~~
203 ~~lots of~~ mammalian cells (Figure 3). Cavin-1 ~~plays a critical role in the initiation of caveolae~~
204 ~~starts the whole process of the synthesis of caveolae through~~by recruiting other structural
205 proteins ~~necessary~~, such as caveolins. Without it, cells won't be able to produce caveolae.
206 Although it is abundant, its functions have only been understood in the past few decades.
207 It plays a role in signal transduction, endocytosis, and mechanotransduction (Stea and
208 D'Alessio 2025). Cavin-1 binds with the caveolins to form Caveolae. There are three
209 members in the caveolin family: ~~caveolin-1, caveolin-2, and caveolin-3. They are~~
210 expressed in a ~~variety of cells~~lot of cells, like smooth muscle cells, fibroblasts, and
211 adipocytes. Caveolin 3 is expressed exclusively in cardiac and skeletal muscle. It is shown
212 that the lack of PTRF-CAVIN doesn't affect the level of caveolin expressed (Rajab et al.
213 2010). However, it affects caveolin's ability to localize to the cell's surface, which makes the
214 formation of caveolae impossible. ~~The~~ Absence of caveolae causes ~~the cell to not be able~~
215 ~~to develop properly, causing~~ abnormalities and dysfunctions, including impaired signal
216 transduction and a lack of mechanoprotection. Without the extra membranes acting as a
217 buffer against the force of mechanical stretching, cardiac cells are at a greater risk of
218 rupturing (Grivas et al., 2020).

219 Clinical features ~~Some symptoms that are~~ uniquely associated with CGL4 ~~this type~~
220 ~~of lipodystrophy include~~are myopathy, which affects skeletal muscle structure, and distal
221 metaphyseal deformation, causing bone stiffness and limited range of motion (Ardissone
222 et al. 2013). Cardiac arrhythmias are also one of the symptoms caused by the lack of
223 PTRF-CAVIN, and ~~it~~they could be life-threatening, showing the serious consequences of
224 cavin-1 deficiency (Rajab et al. 2010). These symptoms can be explained by the location
225 where caveolins -1, 2, and 3 are expressed.

226



227

228 ▲ Figure 3: ~~The structure and formation of caveolae. Caveolae are invaginations clusters~~
 229 ~~of in the cell-plasma membrane. Cavin-1 first binds with the plasma membrane, initiating~~
 230 ~~caveolae synthesis. Cavin-1 and caveolin 1 binds with cavin-1, which stabilizes its structure -~~
 231 ~~together and forms caveolae. (Made with BioRender)~~

232

233 3.3 Type ~~two~~2 Familial Partial Lipodystrophy (FPLD2)

234 The gene LMNA, ~~which~~ encodes the protein called Lamins; ~~It is the gene that~~
 235 ~~causes is associated with~~ Type ~~two~~2 Familial Partial Lipodystrophy (FPLD2). ~~It FPLD2 is is-~~
 236 ~~also~~ the most common type of lipodystrophy syndrome (Corsa et al. 2021). In cells, Lamin
 237 A and Lamin C are expressed predominantly. The main functions of Lamin A/C are the
 238 regulation of nucleus shape, providing structural stability to the nuclear envelope and
 239 cytoskeleton, and also controlling gene regulation (Maung et al. 2026) (Bagias et al. 2020).
 240 ~~They are important intermediate filament proteins forming the nuclear lamina. They also~~
 241 ~~play a role in~~ Specifically, ~~organizing the nuclear lamina and chromatin, and the interaction-~~
 242 ~~between them. Mutations in Lamin A/C can lead to premature aging syndrome~~
 243 (Hutchinson-Gilford Progeria Syndrome). The mutated LMNA gene produces a mutant
 244 product called progerin. As progerin accumulates in the nucleus, it destabilizes DNA,
 245 triggers premature senescence, and alters the shape of the nucleus (Gonzalo et al., 2017).

246

~~One way that Lamin A can affect cell development is -~~ The interference with the
 247 cleavage step of post-translational regulation of Lamin A could also affect the patient. ~~-~~
 248 ZMPSTE24 plays an important role in this step, and it is also considered to be one of the
 249 factors that causes lipodystrophy. However, mutations in ZMPSTE24 cause another distinct
 250 form of lipodystrophy (mandibuloacral dysplasia), showing different symptoms and
 251 increased severity. ~~This -~~ Nevertheless, modification is crucial and ensures that Prelamin
 252 A (the precursor of Lamin A before ~~the~~ post-translational regulation) ~~will-~~

253 function functions normally. Not only will the lack of Lamin A affect cell functions, but the
254 accumulation of Prelamin A could also be toxic to cells (Varlet, Helfer, and Badens 2020),
255 which could affect the cell's ability to develop properly.

256 These cellular abnormalities contribute to broader systemic symptoms. This
257 includes a higher risk of cardiovascular diseases is also associated with FPLD2. It is
258 found that FPLD2 patients have higher Epicardial adipose tissue (EAT) volume than type
259 two diabetes patients (Talman et al. 2014) (Godoy-Matos et al. 2015). However, it is not
260 related to other metabolic issues that are also presented in lipodystrophy (Lamothe et al.
261 2025). Other-Additional studies will also need to be conducted done to gain have a
262 clearer insight into this condition and the its correlation between them.

263

264 3.4 Type ~~three~~3 Familial Partial Lipodystrophy (FPLD3)

265 Type ~~three~~3 Familial Partial Lipodystrophy (FPLD3) is caused by pathogenic
266 variants of the PPARG gene. PPARG encodes for PPAR γ (Peroxisome proliferator-activated
267 receptor γ), a member of a superfamily of nuclear receptors. PPAR γ is known as the
268 master regulator of adipocyte differentiation, maintenance, and functions (Broekema et al.
269 2019). It PPAR γ has three isoforms: PPAR γ 1, PPAR γ 2, and PPAR γ 3. Among them, PPAR γ 2
270 is predominantly expressed in adipocytes. PPAR γ acts as a ligand-activated transcription
271 factor. It binds to its target gene as a heterodimer with PPAR-response elements
272 (PPREs) (Madsen et al. 2022). After binding, PPAR γ regulates the transcription of
273 downstream target genes induces many targeted genes that are involved in the
274 development of adipose tissues. Including the TAG cycle, which is also upregulated by
275 PPAR γ for the development of adipocytes. Loss-of-function or dominant-negative
276 mutations in pathogenic variants of PPARG might cause excess differentiation and
277 growth in of adipocytes, fundamentally impairing adipogenesis. Therefore, leading it leads
278 to increased cellular stress and dysfunctions in adipocytes (Soares et al. 2024).

279 Compared to FPLD2, FPLD3 patients show less severe fat loss. One way to explain
280 this is that more large adipocytes are preserved since mutations in PPARG could lead to
281 excess cell growth. Fat accumulation in areas such as the face and neck are is also not
282 observed (Bagias et al. 2020). However, FPLD3 patients also show more severe metabolic
283 symptoms, specifically hypertriglyceridemia, diabetes, and insulin resistance. One possible
284 explanation is that although patients still preserve large adipocytes, they only have a few
285 small, insulin-sensitive adipocytes (Soares et al. 2024).

286

287 3.5 Acquired ~~Generalized~~ Lipodystrophy (AGL)

288 As we can see, a wide variety range of gene mutations that affect different cellular
289 functions could all lead to LD. However, gene mutations are not the only cause of
290 lipodystrophy. Other environmental factors can also trigger the onset of lipodystrophy.
291 Acquired Generalized Lipodystrophy (AGL, also called Lawrence Syndrome) and Acquired
292 Partial Lipodystrophy (APL) are forms is another form of lipodystrophy, which has similar

293 symptoms to CGL but is that are not caused by genetic mutations (Al-Jawad et al. 2025).
294 Despite having different mechanisms, they have similar symptoms to congenital
295 lipodystrophy.

296 ¶

297 Acquired lipodystrophy is characterized by the gradual loss of fat tissue starting from
298 childhood or adolescence. AGL patients show a generalized loss of adipose tissue, while
299 APL patients show loss of adipose tissue from the upper body. This includes the face, neck,
300 upper extremities, and upper trunk. They also share similar causes, including autoimmune
301 diseases, panniculitis-associated causes, and idiopathic causes. However, while about 25%
302 of AGL cases are associated with panniculitis, it is rare in APL patients (Hussain & Garg,
303 2016).

304 — Adverse effects of highly active antiretroviral therapy (HAART) in patients
305 with HIV are among one of the factors that lead to acquired lipodystrophy AGL. The
306 mechanism by which antiretroviral drugs play a role in the development of lipodystrophy
307 is not fully understood completely. One possibility is Proteins such as the use of
308 thymidine analog nucleoside reverse transcriptase inhibitors (NRTI), which are used in
309 highly active antiretroviral therapies HAART. They, are have been shown to disrupt adipose
310 tissue functions (Guzman and Vijayan 2025). It decreases the expression of adiponectin,
311 which regulates the oxidation of glucose and fatty acids. Nucleoside reverse transcriptase
312 inhibitor NRTI also induces mitochondrial toxicity, which also plays a role in the
313 development of AGL acquired lipodystrophy. Lipodystrophy in HIV-infected patients is
314 characterized by the loss of subcutaneous fat at the extremities and face. ¶

315

316 ~~Another possible cause of AGL is A~~ autoimmune diseases are also a significant
317 cause of acquired lipodystrophy: Specifically In particular, perilipin 1 (PLIN1)
318 autoantibodies are found in AGL AGL patients (Corvillo et al. 2022). Anti-perilipin is also
319 found in patients with ~~panniculitis-associated~~ panniculitis-associated AGL AGL. Perilipin is
320 found only in adipose tissue and forms a layer that coats lipid droplets. Under normal
321 conditions, perilipin forms a barrier between lipase and the surface of lipid droplets.
322 However, when the autoantibodies are present, it disrupts the normal function of perilipin.
323 It leads to an increase in lipolysis activities, which ~~decreases~~ contributes to the gradual
324 loss of adipose tissue in the fat storage in t AGL patients he body (Corvillo et al. 2018).

325 In APL patients, the presence of C3 nephritic factor (C3NeF) is commonly
326 associated. It acts as an autoantibody against the body's own complement system,
327 particularly complement component C3. When C3NeF binds with C3 convertase, it
328 stabilizes C3 convertase and prevents its natural decay. Since the function of C3
329 convertase is to cleave C3 into its active fragment, prolonged activation leads to a low level
330 of C3 (*Nephritic Factor - an Overview | ScienceDirect Topics*, n.d.). As the breakdown of C3
331 continues, it activates the terminal pathway. It ultimately leads to the lysis of adipocytes,

332 which explains the fat loss. However, the factor that limits fat loss to the upper body
333 remains unclear (Corvillo & López-Trascasa, 2018).

334 ¶

335

336 4. *Diagnosis and Clinical Features*

337 Since lipodystrophy is ~~such a rare disease and not well known to the public~~, it is
338 often misdiagnosed or ~~left~~ undiagnosed by clinicians. It heavily relies on clinical history
339 and physical examinations that reveal the composition of adipose tissues. Metabolic
340 dysfunctions are also important markers when diagnosing lipodystrophy. Although
341 patients with CGL show symptoms such as a lack of body fat shortly after birth, it is often
342 left undiagnosed until their childhood or adulthood, when they start showing metabolic
343 abnormalities. As for FPLD, it is even more commonly unrecognized due to patients only
344 losing adipose tissue partially. It could ~~be easily mixed up with~~ **be easily misdiagnosed as**
345 other types of common metabolic diseases, like obesity or severe diabetes mellitus.
346 Presentations of AGL and APL are generally similar to CGL and FPLD, also including the
347 metabolic issues that come with it (Lima et al. 2025). -

348 **Lipotoxicity is a direct consequence of adipose tissue dysfunction. Since adipose**
349 **tissues aren't able to store as many lipid droplets as are produced, excess lipid droplets**
350 **circulate in the bloodstream as free fatty acids. As the level of circulating free fatty acids**
351 **elevates, it becomes toxic for non-adipose tissues, resulting in increased oxidative stress**
352 **(Engin, 2017; Sies, 2020). Since the liver is the major organ that maintains the body's**
353 **homeostasis, excess fatty acid accumulates at the liver, leading to fatty liver (Kikuchi &**
354 **Takamura, 2017; Liu et al., 2010). This imbalance of fatty acids in the liver interferes with**
355 **the insulin signaling pathways. In addition, the body stores excess fat in skeletal muscles,**
356 **as it is the organ responsible for most of the energy uptake (Merz & Thurmond, 2020).**
357 **Without skeletal muscles, glucose isn't consumed properly, which also disrupts the insulin**
358 **signaling pathways.**

359 Some phenotypes ~~that are~~ associated with lipodystrophy ~~are~~ **include a muscular**
360 **appearance, prominent veins, and the a lack of body fat. Two main types of fat tissue serve**
361 **different functions in the body: metabolic and mechanical adipose tissue. Metabolic**
362 **adipose tissue is responsible for energy storage and hormone secretion, while mechanical**
363 **tissue, also known as subcutaneous fat, is found under the skin and internal organs to**
364 **provide protection and support. For CGL patients, the absence-loss of metabolic adipose**
365 **tissues is more severe** ~~common~~ **than the loss of mechanical tissues. Yet. Although patients**
366 **still, to in some degree, lack functional mechanical fat tissues. Metabolic adipose tissues**
367 ~~are in charge of energy storage and hormone secretion, while the mechanical tissues, also~~
368 ~~known as subcutaneous fat tissue, are found under the skin and internal organs to~~
369 ~~provide protection and support. Although patients still in some degrees lack functional~~
370 ~~mechanical fat tissues. Only CGL2 patients~~ **Except for CGL2, in which patients generally do**

371 not acquire both ~~mechanical and metabolic~~ adipose tissues ~~kinds of fat tissues~~ (Garg
372 2011).

373 In contrast, FPLD is ~~characterized~~ characterized by the abnormal distribution with a
374 slight loss of adipose tissue, meaning that patients still acquire most of their functional fat
375 tissues. In addition, as mentioned before, the onset of CGL is often shortly after birth, but
376 for FPLDs, its onset is usually around puberty or adolescence. In general, CGL patients
377 lack the ability to build up mature adipose tissues, while FPLD patients can't store or
378 regulate adipose tissue properly. ~~Next, we~~ The following section will address potential
379 treatments and their underlying mechanisms. ~~will be discussing some potential treatments~~
380 ~~for lipodystrophy and the mechanisms behind them.~~






381

382 5. Treatments

383 5.1 Metreleptin

384 Currently, there isn't a definitive ~~treatment~~ cure for lipodystrophy, but some
385 treatments ~~targeting~~ for specific metabolic abnormalities ~~are~~ have been developed ~~being~~
386 ~~invented~~ (Araújo-Vilar and Santini 2019). For example, Metreleptin (Recombinant
387 methionyl human leptin) is a drug invented specifically for lipodystrophy. It targets leptin
388 deficiency in patients. ~~Leptin is a hormone that regulates energy metabolism. Leptin~~ It is
389 secreted by adipose tissue, and it regulates a person's appetite and food intake (Tsoukas,
390 Farr, and Mantzoros 2015). Since lipodystrophy patients lack functional adipose tissue,
391 leptin secretion also decreases. This causes patients to show extreme hyperphagia, which
392 means the excessive intake of food. This worsens insulin resistance and creates excess fat
393 that must be stored in internal organs or muscles. Metreleptin's main purpose is to mimic
394 the naturally occurring leptin hormone, and it must be administered at least once daily
395 (Rodriguez, Mastronardi, and Paz-Filho 2015). ~~It helps reduce patients' appetite and~~
396 ~~decreases the intake of calories, which contributes to the accumulation of lipid droplets.~~
397 The use of metreleptin in FPLD patients is not approved by the FDA since it does not work
398 ~~as efficiently in FPLD patients as in CGL patients. Metreleptin is found to be more efficient~~
399 ~~in Generalized lipodystrophy patients due to the low levels of leptin that are~~
400 ~~produced~~ (Gilio, Foss-Freitas, and Oral 2025). ~~Individual cases of FPLD could be evaluated~~
401 ~~for whether the requirements for the metreleptin treatment are met.~~ However, the risk of
402 using Metreleptin for special groups of people ~~with generalized lipodystrophy~~, such as
403 pregnant women, ~~are~~ is not certain. Other common drugs, such as insulin or metformin,
404 can also help patients control their symptoms; however, they are not a cure for LDD. ~~■~~
405 Cosmetic surgery is also an option for patients to minimize the psychological discomfort
406 and to have a better quality of life (Table 2).

407

	 Diet and exercise	 Glucose-lowering medications	 Lipid-lowering and CV medications	 LD-specific therapy	 Other
Treatment type	<ul style="list-style-type: none"> Well-balanced, low-fat, low-calorie diet Exercise is encouraged in the absence of specific contraindications 	<ul style="list-style-type: none"> Metformin Insulin Thiazolidinediones GLP-1 receptor agonists SGLT2i 	<ul style="list-style-type: none"> Statins Fibrates Omega-3 fatty acids ACE inhibitors ARBs Beta-blockers 	<ul style="list-style-type: none"> Metreleptin 	<ul style="list-style-type: none"> Cosmetic surgery Counselling
Objectives	<ul style="list-style-type: none"> Cornerstone of LD treatment To help manage weight gain and control calorie and fat intake 	<ul style="list-style-type: none"> Glycemic control 	<ul style="list-style-type: none"> Long-term cardiovascular risk reduction 	<ul style="list-style-type: none"> Only currently approved specific treatment for LD (to treat complications of leptin deficiency adjunct to diet) In PL, often used only once SOC therapies are considered no longer effective 	<ul style="list-style-type: none"> May help patients feel better about their physical appearance and may offer an improved QoL
Challenges and considerations	<ul style="list-style-type: none"> Considered burdensome for patients. Restrictive long-term diets are not easy to maintain Dietary restriction challenging in hyperphagic patients 	<ul style="list-style-type: none"> Patient adherence to therapy High need for careful monitoring especially patients requiring high-doses of insulin Challenges with administering in patients with GL due to lack of subcutaneous fat 	<ul style="list-style-type: none"> Patient adherence to therapy 	<ul style="list-style-type: none"> Often used only once SOC therapies are considered no longer effective Challenges with administering in patients with GL due to lack of subcutaneous fat Restricted access in some regions (e.g., REMS program) 	<ul style="list-style-type: none"> Cosmetic surgery rarely mentioned by participants as a treatment option.

408

409 ▲ Table 2: Possible medications to control metabolic issues that arises with
 410 lipodystrophy. Including the objectives, possible challenges, and other considerations
 411 (Reproduced from (Patni et al., 2024) (~~Patni et al. 2024~~) under the terms of the CC BY
 412 license)

413

414 5.2 Lifestyle Modification ~~Change in Daily Routine~~

415 Although Metreleptin can generally help with metabolic dysfunctions, lifestyle
 416 modification also plays a significant role in managing lipodystrophy. A low-fat diet is
 417 recommended for patients. Carbohydrate intake is also restricted to control diabetes.
 418 Since the body cannot store excess energy properly, it would be beneficial for patients to
 419 reduce the intake of food that will be metabolized into excess fat or energy. Physical
 420 exercises are also encouraged. However, patients with cardiovascular issues should avoid
 421 ~~doing too much excessive~~ exercise to prevent the development of other serious further
 422 complications (Akinci et al. 2024).

423

424 5.3 Limitations and Possibility of Gene Editing


425 Although Metreleptin is an effective way for LD patients to manage metabolic
 426 complications, it is not able to cure ~~it~~ them. In the future, gene editing could be applied to
 427 ~~treating the treatment of~~ this disease. Preclinical trials have been conducted on mouse
 428 models with CGL2, which has a gene mutation at the BSCL2 gene. Seipin knockout (SKO)
 429 mice, which generally show similar metabolic symptoms to CGL2 patients, were generated;
 430 and ~~were~~ injected with adeno-associated virus (AAV) vectors (Sommer et al. 2022). ~~AAV~~
 431 can be engineered to ~~transduce~~ targets adipocytes, ~~enabling which act as a targeted in~~
 432 gene therapy for lipodystrophy. The results of the trials show that gene therapy effectively
 433 restores adipose tissue development and function (Tiwari et al. 2024). However, even

434 though AAV is commonly used in clinical trials, it hasn't been used to directly target
 435 adipose tissue. Novel AAV serotypes that targets adipose tissue or an alternative
 436 promoter are critical for the development of an improved gene therapy strategy for LD
 437 patients. Therefore, there isn't enough evidence currently to suggest that the results from
 438 mouse models can be translated to humans. Continued research on LD and advances in
 439 gene therapy are necessary to develop a more effective therapeutic strategy for this rare
 440 disorder.

441

442 6. Conclusion and the Future

443



444

445 ▲ Figure 4: Steps of adipogenesis. Starting from mesenchymal stem cells, after
 446 proliferation and differentiation, it develops into preadipocytes. Then, through lipogenesis,
 447 preadipocytes grow into mature adipocytes. When a person is fasting, adipocytes go
 448 through lipolysis to produce energy by breaking down triglycerides into glycerol and free
 449 fatty acids. The last step is apoptosis, which ultimately leads to cell death. (Made with
 450 BioRender)

451

452 ~~Although~~ genes involved in lipodystrophy syndromes affect various cellular
 453 processes, such as lipid synthesis, signal transduction, and nuclear structure. ~~They, they~~ all
 454 lead to a common outcome: impaired adipocyte development and function. The examples
 455 discussed in this review, including CGL1, CGL4, FPLD2, and FPLD3, demonstrate how
 456 different stages of adipogenesis and gene mutations that are involved in adipogenesis all
 457 lead to similar consequences (Figure 4). In addition to genetic causes, acquired factors
 458 can also contribute to adipocyte dysfunctions, as seen in AGL.

459

LD highlights the essential role of adipose tissue as an endocrine and metabolic
 460 organ. It not only stores energy but also maintains metabolic homeostasis and regulates
 461 hormones. The absence of adipocytes, as shown in this review, could cause

462 life-threatening disorders. Understanding this condition not only helps people recognize
463 the role of adipose tissue in metabolism but also helps raise awareness of rare diseases.
464 For conditions like lipodystrophy, many patients remain undiagnosed throughout their
465 lives. Not only is conducting research with so few samples challenging, but scientists may
466 be less willing to dedicate time to studying rare diseases compared to diseases that affect
467 a larger population. Increased awareness and improved diagnostic tools not only help
468 identify individuals affected by this disease earlier but also give them a chance to manage
469 their condition in a more effective way.

470 Since the discovery of lipodystrophy syndromes ~~in around~~ the mid-20th century, ~~lots~~
471 ~~of, significant~~ progress has been made ~~in to get a better~~ understanding of lipodystrophy.
472 ~~From the phenotypes and to the~~ metabolic abnormalities ~~to and the~~ underlying genetic
473 causes, research ~~have has~~ been ~~conducted done to find~~ ~~seek for~~ ways to reduce patients'
474 pain and suffering. Having a deep understanding of lipodystrophy, ~~such as the~~
475 ~~mechanisms of various genes and their relationship with adipogenesis,~~ will be crucial to
476 the development of a more effective and targeted therapeutic strategy.

477

478 7. References

479

480 Akinci, Baris, Merve Celik Gular, and Elif A. Oral. 2024. "Lipodystrophy Syndromes:
481 Presentation and Treatment." in *Endotext [Internet]*. MDText.com, Inc.

482 Al-Jawad, Mohammad, Lina Mawaldi, Nada Mawaldi, Mariam Krimsty, and Silva Ishkanian.
483 2025. "Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome) with
484 Both-Side Axillary Breasts: A Case Report." *International Journal of Surgery Case*
485 *Reports* 129:111202. doi:10.1016/j.ijscr.2025.111202.

486 Araújo-Vilar, D., and F. Santini. 2019. "Diagnosis and Treatment of Lipodystrophy: A
487 Step-by-Step Approach." *Journal of Endocrinological Investigation* 42(1):61–73.
488 doi:10.1007/s40618-018-0887-z.

489 Ardisson, Anna, Cinzia Bragato, Lorella Caffi, Flavia Blasevich, Sabrina Maestrini, Maria
490 Luisa Bianchi, Lucia Morandi, Isabella Moroni, and Marina Mora. 2013. "Novel
491 PTRF Mutation in a Child with Mild Myopathy and Very Mild Congenital
492 Lipodystrophy." *BMC Medical Genetics* 14(1):89. doi:10.1186/1471-2350-14-89.

493 Bagias, Christos, Angeliki Xiarchou, Alexandra Bargiota, and Stelios Tigas. 2020. "Familial
494 Partial Lipodystrophy (FPLD): Recent Insights." *Diabetes, Metabolic Syndrome and*
495 *Obesity: Targets and Therapy* 13:1531–44. doi:10.2147/DMSO.S206053.

496 Broekema, Marjoleine F., Maarten P. G. Massink, Cinzia Donato, Joep De Ligt, Joerg
497 Schaarschmidt, Anouska Borgman, Marieke G. Schooneman, Diana Melchers, Martin

- 498 N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia, Houshang
499 Monajemi, Gijs W. Van Haaften, Maarten R. Soeters, and Eric Kalkhoven. 2019.
500 “Natural Helix 9 Mutants of PPAR γ Differently Affect Its Transcriptional Activity.”
501 *Molecular Metabolism* 20:115–27. doi:10.1016/j.molmet.2018.12.005.
- 502 Chiquette, Elaine, Elif A. Oral, Abhimanyu Garg, David Araújo-Vilar, and Praveen Dhankhar.
503 2017. “Estimating the Prevalence of Generalized and Partial Lipodystrophy:
504 Findings and Challenges.” *Diabetes, Metabolic Syndrome and Obesity* 10:375–83.
505 doi:10.2147/DMSO.S130810.
- 506 Corsa, Callie A. S., Carolyn M. Walsh, Devika P. Bagchi, Maria C. Foss Freitas, Ziru Li, Julie
507 Hardij, Katrina Granger, Hiroyuki Mori, Rebecca L. Schill, Kenneth T. Lewis, Jessica
508 N. Maung, Ruth D. Azaria, Amy E. Rothberg, Elif A. Oral, and Ormond A. MacDougald.
509 2021. “Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial
510 Partial Lipodystrophy Type 2.” *Diabetes* 70(9):1970–84. doi:10.2337/db20-1001.
- 511 Corvillo, Fernando, Brent S. Abel, Alberto López-Lera, Giovanni Ceccarini, Silvia Magno,
512 Ferruccio Santini, David Araújo-Vilar, Rebecca J. Brown, Pilar Nozal, and Margarita
513 López-Trascasa. 2022. “Characterization and Clinical Association of Autoantibodies
514 Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy.” *Diabetes*
515 72(1):71–84. doi:10.2337/db21-1086.
- 516 Corvillo, Fernando, Verónica Aparicio, Alberto López-Lera, Sofia Garrido, David
517 Araújo-Vilar, María P. de Miguel, and Margarita López-Trascasa. 2018.
518 “Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized
519 Lipodystrophy.” *Frontiers in Immunology* 9. doi:10.3389/fimmu.2018.02142.
- 520 Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
521 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic.
522 n.d. Retrieved January 19, 2026.
523 <https://academic.oup.com/jcem/article/101/12/4500/2764979>.
- 524 Fourman, Lindsay T, and Steven K. Grinspoon. 2022. “Approach to the Patient With
525 Lipodystrophy.” *The Journal of Clinical Endocrinology & Metabolism*
526 107(6):1714–26. doi:10.1210/clinem/dgac079.
- 527 Gale, Sarah E., Andrey Frolov, Xianlin Han, Perry E. Bickel, Li Cao, Anne Bowcock, Jean E.
528 Schaffer, and Daniel S. Ory. 2006. “A Regulatory Role for
529 1-Acylglycerol-3-Phosphate-O-Acyltransferase 2 in Adipocyte Differentiation *.”
530 *Journal of Biological Chemistry* 281(16):11082–89. doi:10.1074/jbc.M509612200.

- 531 Garg, Abhimanyu. 2011. "Lipodystrophies: Genetic and Acquired Body Fat Disorders." *The*
532 *Journal of Clinical Endocrinology & Metabolism* 96(11):3313–25.
533 doi:10.1210/jc.2011-1159.
- 534 Gilio, Donatella, Maria Foss-Freitas, and Elif A. Oral. 2025. "Clinical Guidance for
535 Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment." *Current*
536 *Diabetes Reports* 25(1):47. doi:10.1007/s11892-025-01603-4.
- 537 Godoy-Matos, Amélio Fernando, Cynthia M. Valério, Juliana Bonadiman e. Bragança,
538 Ricardo de Andrade Oliveira, Roberto Luis Zagury, Rodolfo de Paula Lustosa,
539 Gabriel Cordeiro Camargo, César Augusto da Silva Nascimento, and Rodrigo O.
540 Moreira. 2015. "Evaluation of Epicardial Adipose Tissue in Familial Partial
541 Lipodystrophy." *Diabetology & Metabolic Syndrome* 7(1):29.
542 doi:10.1186/s13098-015-0024-5.
- 543 Guzman, Nilmarie, and Vini Vijayan. 2025. "HIV-Associated Lipodystrophy." in *StatPearls*.
544 Treasure Island (FL): StatPearls Publishing.
- 545 Lamothe, Sophie, Patricia Ancel, Inès Belalem, Leïla Lecaque, Joris Fournel, Alexis Jacquier,
546 Zouhair Houhou, Jean-Baptiste Julla, Jean-François Gautier, Corinne Vigouroux,
547 Bénédicte Gaborit, and Camille Vatie. 2025. "Increased Epicardial Adipose Tissue Is
548 Part of the Phenotype of *LMNA*-Associated Partial Lipodystrophy and Could
549 Contribute to Increased Cardiovascular Risk." *Diabetes & Metabolism*
550 51(6):101710. doi:10.1016/j.diabet.2025.101710.
- 551 Lima, Josivan Gomes, Lucas Nobrega Lima, Vitor Yan Bezerra Araujo, Lucia Helena Coelho
552 Nobrega, and Julliane Tamara Araújo de Melo Campos. 2025. "Diagnosis of
553 Congenital and Acquired Generalized Lipodystrophies—Similarities and
554 Differences." *Endocrines* 6(4):55. doi:10.3390/endocrines6040055.
- 555 Lima, Josivan Gomes, Lucia Helena C. Nobrega, Natalia Nobrega Lima, Marcel Catão
556 Ferreira dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P. Baracho,
557 Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo
558 Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O. Mendes-Aguiar,
559 and Selma Maria B. Jeronimo. 2018. "Causes of Death in Patients with
560 Berardinelli-Seip Congenital Generalized Lipodystrophy." *PLOS ONE*
561 13(6):e0199052. doi:10.1371/journal.pone.0199052.
- 562 Madsen, Maria Stahl, Marjoleine F. Broekema, Martin Rønn Madsen, Arjen Koppen,
563 Anouska Borgman, Cathrin Gräwe, Elisabeth G. K. Thomsen, Denise Westland,
564 Mariette E. G. Kranendonk, Marian Groot Koerkamp, Nicole Hamers, Alexandre M. J.

- 565 J. Bonvin, José M. Ramos Pittol, Kedar Nath Natarajan, Sander Kersten, Frank C. P.
566 Holstege, Houshang Monajemi, Saskia W. C. van Mil, Michiel Vermeulen, Birthe B.
567 Kragelund, David Cassiman, Susanne Mandrup, and Eric Kalkhoven. 2022. "PPAR γ
568 Lipodystrophy Mutants Reveal Intermolecular Interactions Required for Enhancer
569 Activation." *Nature Communications* 13(1):7090.
570 doi:10.1038/s41467-022-34766-9.
- 571 Maung, Jessica N., Rebecca L. Schill, Akira Nishii, Maria Foss de Freitas, Bonje N. Obua,
572 Marcus Nygård, Maria D. Mendez-Casillas, Isabel D. K. Hermsmeyer, Donatella Gilio,
573 Ozge Besci, Yang Chen, Brian Desrosiers, Rose E. Adler, Anabela D. Gomes, Merve
574 Celik Guler, Hiroyuki Mori, Romina M. Uranga, Ziru Li, Hadla Hariri, Liping Zhang,
575 Anderson de Paula Souza, Keegan S. Hoose, Kenneth T. Lewis, Taryn A. Hetrick, Paul
576 Cederna, Carey N. Lumeng, Susanne Mandrup, Elif A. Oral, and Ormond A.
577 MacDougald. 2026. "Altered Lipid Metabolism and Inflammatory Programs
578 Associate with Adipocyte Loss in Familial Partial Lipodystrophy 2." *The Journal of*
579 *Clinical Investigation* 136(1). doi:10.1172/JCI198387.
- 580 de Melo, Maria Eduarda Cardoso, Letícia Marques Gomes da Silva, Ana Carolina Costa
581 Cavalcante, Josivan Gomes Lima, and Julliane Tamara Araújo de Melo Campos.
582 2025. "The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital
583 Generalized Lipodystrophy Pathophysiology." *International Journal of Molecular*
584 *Sciences* 26(11):5416. doi:10.3390/ijms26115416.
- 585 Misra, Anoop, and Abhimanyu Garg. 2003. "Clinical Features and Metabolic Derangements
586 in Acquired Generalized Lipodystrophy: Case Reports and Review of the
587 Literature." *Medicine* 82(2):129–46. doi:10.1097/00005792-200303000-00007.
- 588 Oswiecimska, Joanna. n.d. "A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2
589 Splicesite Mutation and Concomitant Development of Non-Diabetic Polyneuropathy
590 - Journal of Clinical Research in Pediatric Endocrinology." Retrieved January 19,
591 2026. <https://jcrpe.org/articles/doi/jcrpe.galenos.2018.2018.0227>. doi:
592 10.4274/jcrpe.galenos.2018.2018.0227
- 593 Poulos, Sylvia P., Michael V. Dodson, Melinda F. Culver, and Gary J. Hausman. 2016. "The
594 Increasingly Complex Regulation of Adipocyte Differentiation." *Experimental*
595 *Biology and Medicine* 241(5):449–56. doi:10.1177/1535370215619041.
- 596 Rajab, Anna, Volker Straub, Liza J. McCann, Dominik Seelow, Raymonda Varon, Rita
597 Barresi, Anne Schulze, Barbara Lucke, Susanne Lützkendorf, Mohsen Karbasiyan,
598 Sebastian Bachmann, Simone Spuler, and Markus Schuelke. 2010. "Fatal Cardiac
599 Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized

- 600 Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations." *PLOS*
601 *Genetics* 6(3):e1000874. doi:10.1371/journal.pgen.1000874.
- 602 Rodriguez, Alexander J., Claudio A. Mastronardi, and Gilberto J. Paz-Filho. 2015. "New
603 Advances in the Treatment of Generalized Lipodystrophy: Role of Metreleptin."
604 *Therapeutics and Clinical Risk Management* 11:1391–1400.
605 doi:10.2147/TCRM.S66521.
- 606 Salle-Teyssières, Laurence, Martine Auclair, Faraj Terro, Mona Nemani, Solaf M. Elsayed,
607 Ezzat Elsobky, Mark Lathrop, Marc Délépine, Olivier Lascols, Jacqueline Capeau,
608 Jocelyne Magré, and Corinne Vigouroux. 2016. "Maladaptative Autophagy Impairs
609 Adipose Function in Congenital Generalized Lipodystrophy Due to Cavin-1
610 Deficiency." *The Journal of Clinical Endocrinology & Metabolism*
611 101(7):2892–2904. doi:10.1210/jc.2016-1086.
- 612 Soares, Reivla Marques Vasconcelos, Monique Alvares da Silva, Julliane Tamara Araújo de
613 Melo Campos, and Josivan Gomes Lima. 2024. "Familial Partial Lipodystrophy
614 Resulting from Loss-of-Function PPAR γ Pathogenic Variants: Phenotypic, Clinical,
615 and Genetic Features." *Frontiers in Endocrinology* 15.
616 doi:10.3389/fendo.2024.1394102.
- 617 Sommer, Nadine, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J. Rochford,
618 and George D. Mcilroy. 2022. "Gene Therapy Restores Adipose Tissue and
619 Metabolic Health in a Pre-Clinical Mouse Model of Lipodystrophy." *Molecular*
620 *Therapy Methods & Clinical Development* 27:206–16.
621 doi:10.1016/j.omtm.2022.09.014.
- 622 Stea, Dante Maria, and Alessio D'Alessio. 2025. "Caveolae: Metabolic Platforms at the
623 Crossroads of Health and Disease." *International Journal of Molecular Sciences*
624 26(7):2918. doi:10.3390/ijms26072918.
- 625 Talman, Andrew H., Peter J. Psaltis, James D. Cameron, Ian T. Meredith, Sujith K.
626 Seneviratne, and Dennis T. L. Wong. 2014. "Epicardial Adipose Tissue: Far More
627 than a Fat Depot." *Cardiovascular Diagnosis and Therapy* 4(6):416–29.
628 doi:10.3978/j.issn.2223-3652.2014.11.05.
- 629 Tiwari, Mansi, Ahlima Roumane, Nadine Sommer, Weiping Han, Mirela Delibegović, Justin J.
630 Rochford, and George D. Mcilroy. 2024. "Preclinical Evaluation of Tissue-Selective
631 Gene Therapies for Congenital Generalised Lipodystrophy." *Gene Therapy*
632 31(9):445–54. doi:10.1038/s41434-024-00471-z.

633 Tsoukas, Michael A., Olivia M. Farr, and Christos S. Mantzoros. 2015. "Leptin in Congenital
634 and HIV-Associated Lipodystrophy." *Metabolism* 64(1):47–59.
635 doi:10.1016/j.metabol.2014.07.017.

636 Varlet, Alice-Anaïs, Emmanuèle Helfer, and Catherine Badens. 2020. "Molecular and
637 Mechanobiological Pathways Related to the Physiopathology of FPLD2." *Cells*
638 9(9):1947. doi:10.3390/cells9091947.

639 Ajluni, N., Dar, M., Xu, J., Neidert, A. H., & Oral, E. A. (2016). Efficacy and Safety of
640 Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded
641 Access Program. *Journal of Diabetes & Metabolism*, 7(3), 659.
642 <https://doi.org/10.4172/2155-6156.1000659>

643 Akinci, B., Gular, M. C., & Oral, E. A. (2024). Lipodystrophy Syndromes: Presentation and
644 Treatment. In *Endotext [Internet]*. MDText.com, Inc.
645 <https://www.ncbi.nlm.nih.gov/sites/books/NBK513130/>

646 Araújo-Vilar, D., & Santini, F. (2019). Diagnosis and treatment of lipodystrophy: A
647 step-by-step approach. *Journal of Endocrinological Investigation*, 42(1), 61–73.
648 <https://doi.org/10.1007/s40618-018-0887-z>

649 Broekema, M. F., Massink, M. P. G., De Ligt, J., Stigter, E. C. A., Monajemi, H., De Ridder, J.,
650 Burgering, B. M. T., van Haaften, G. W., & Kalkhoven, E. (2018). A Single Complex
651 Agpat2 Allele in a Patient With Partial Lipodystrophy. *Frontiers in Physiology*, 9.
652 <https://doi.org/10.3389/fphys.2018.01363>

653 Corvillo, F., & López-Trascasa, M. (2018). Acquired partial lipodystrophy and C3
654 glomerulopathy: Dysregulation of the complement system as a common
655 mechanism. *Nefrología (English Edition)*, 38(3), 258–266.
656 <https://doi.org/10.1016/j.nefro.2018.04.002>

657 Engin, A. B. (2017). What Is Lipotoxicity? In A. B. Engin & A. Engin (Eds.), *Obesity and*
658 *Lipotoxicity* (pp. 197–220). Springer International Publishing.
659 https://doi.org/10.1007/978-3-319-48382-5_8

660 Gonzalo, S., Kreienkamp, R., & Askjaer, P. (2017). Hutchinson-Gilford Progeria Syndrome: A
661 premature aging disease caused by LMNA gene mutations. *Ageing Research*
662 *Reviews*, 33, 18–29. <https://doi.org/10.1016/j.arr.2016.06.007>

663 Grivas, D., González-Rajal, Á., Guerrero Rodríguez, C., Garcia, R., & de la Pompa, J. L. (2020).
664 Loss of Caveolin-1 and caveolae leads to increased cardiac cell stiffness and
665 functional decline of the adult zebrafish heart. *Scientific Reports*, 10(1), 12816.
666 <https://doi.org/10.1038/s41598-020-68802-9>

667 Hussain, I., & Garg, A. (2016). Lipodystrophy Syndromes. *Endocrinology and Metabolism*
668 *Clinics of North America*, 45(4), 783–797.
669 <https://doi.org/10.1016/j.ecl.2016.06.012>

670 Kikuchi, A., & Takamura, T. (2017). Where does liver fat go? A possible molecular link
671 between fatty liver and diabetes. *Journal of Diabetes Investigation*, 8(2), 152–154.
672 <https://doi.org/10.1111/jdi.12573>

673 Li, Y., Yang, X., Peng, L., Xia, Q., Zhang, Y., Huang, W., Liu, T., & Jia, D. (2022). Role of Seipin in
674 Human Diseases and Experimental Animal Models. *Biomolecules*, 12(6), 840.
675 <https://doi.org/10.3390/biom12060840>

676 Liu, Q., Bengmark, S., & Qu, S. (2010). The role of hepatic fat accumulation in pathogenesis
677 of non-alcoholic fatty liver disease (NAFLD). *Lipids in Health and Disease*, 9, 42.
678 <https://doi.org/10.1186/1476-511X-9-42>

679 Meehan, C. A., Cochran, E., Kassai, A., Brown, R. J., & Gorden, P. (2016). Metreleptin for
680 injection to treat the complications of leptin deficiency in patients with congenital
681 or acquired generalized lipodystrophy. *Expert Review of Clinical Pharmacology*,
682 9(1), 59–68. <https://doi.org/10.1586/17512433.2016.1096772>

683 Merz, K. E., & Thurmond, D. C. (2020). Role of Skeletal Muscle in Insulin Resistance and
684 Glucose Uptake. *Comprehensive Physiology*, 10(3), 785–809.
685 <https://doi.org/10.1002/cphy.c190029>

686 *Nephritic Factor—An overview | ScienceDirect Topics*. (n.d.). Retrieved May 3, 2026, from
687 <https://www.sciencedirect.com/topics/medicine-and-dentistry/nephritic-factor>

688 Patni, N., Chard, C., Araújo-Vilar, D., Phillips, H., Magee, D. A., & Akinci, B. (2024). Diagnosis,
689 treatment and management of lipodystrophy: The physician perspective on the
690 patient journey. *Orphanet Journal of Rare Diseases*, 19(1), 263.
691 <https://doi.org/10.1186/s13023-024-03245-3>

692 Santoro, A., McGraw, T. E., & Kahn, B. B. (2021). Insulin action in adipocytes, adipose
693 remodeling, and systemic effects. *Cell Metabolism*, 33(4), 748–757.
694 <https://doi.org/10.1016/j.cmet.2021.03.019>

695 *Search ClinicalTrials.gov for: Lipodystrophy | List Results | ClinicalTrials.gov*. (n.d.).
696 Retrieved April 15, 2026, from <https://clinicaltrials.gov/search>

697 Sies, H. (2020). Oxidative Stress: Concept and Some Practical Aspects. *Antioxidants*, 9(9),
698 852. <https://doi.org/10.3390/antiox9090852>

699

Dear reviewer,

Thank you very much for your meaningful insights, thoughtful comments, and suggestions on my manuscript “Molecular Basis of Lipodystrophy: Gene Mutations, Pathophysiology, and Therapy”. Below, I address the comments point by point.

Major Comments

1. Mechanistic Inaccuracy in FPLD3 Pathophysiology: The authors state that mutations in the PPARG gene “might cause excess differentiation and growth of adipocytes,” leading to cellular stress. This contradicts established molecular biology. Pathogenic variants in PPARG associated with FPLD3 are typically loss-of-function or dominant-negative mutations that fundamentally impair adipogenesis. This fundamental error should be corrected to accurately reflect the disease’s molecular basis.

Response: I thank the reviewer for this thoughtful suggestion. I agree that fixing this error is important for the accuracy of the molecular mechanisms. I have revised the manuscript as requested to ensure the accuracy of this section.

2. Omission of CGL2 (BSCL2) in Section 3: While the authors appropriately discuss BSCL2 (seipin) in the context of preclinical gene therapy models, they entirely omit CGL2 from the main “Genetics and Pathophysiology” section, focusing only on CGL1 and CGL4. Given that BSCL2 mutations cause the most severe and globally prevalent form of CGL, a dedicated subsection explaining seipin’s role in lipid droplet biogenesis is mandatory.

Response: I appreciate this helpful comment. I agree that adding a section explaining CGL2 strengthens the overall scope of the manuscript. Therefore, I have added a section in the discussion dedicated to CGL2.

3. Conflation of FPLD2 and ZMPSTE24 Pathology: In Section 3.3, the authors state that ZMPSTE24 “is also considered to be one of the factors that causes lipodystrophy” in the context of FPLD2. The authors should clarify this distinction: classic FPLD2 is caused by heterozygous missense mutations in the LMNA gene itself. Mutations in ZMPSTE24 (which impair prelamin A processing) cause distinct, more severe syndromic forms of lipodystrophy (e.g., Mandibuloacral Dysplasia). Blurring the lines between these genetic etiologies creates confusion both clinically and molecularly.

Response: I thank the reviewer for this valuable insight. I agree that distinguishing the difference between them is important. I have added details addressing their difference.

4. Incomplete Methodology Results: The authors include a “Method” section outlining their literature search strategy, keywords, and inclusion/exclusion criteria. However, they fail to report the actual results of this search. There is no mention of how many articles were initially retrieved, screened, or

ultimately included. To ensure scientific rigour and reproducibility, the authors should provide these numbers.

Response: I appreciate the thoughtful comment about the completeness of the method section. I agree that this helps with the overall clarity and scientific rigour. I have added details on the number of articles retrieved, screened, and included.

5. Superficial Explanation of Lipotoxicity: While the manuscript notes that lipodystrophy leads to metabolic dysfunctions such as insulin resistance and fatty liver, it fails to provide a detailed molecular explanation of lipotoxicity. The paper needs to clearly explain how the inability to store triglycerides in adipocytes leads to ectopic lipid deposition in the liver and skeletal muscle, which directly interferes with insulin receptor signalling pathways.

Response: I appreciate this helpful feedback. To improve clarity of the relationship between insulin resistance and lipotoxicity, I have added a paragraph to the diagnosis and clinical features section explaining the underlying mechanisms.

6. Clarification of Metreleptin Indications: The manuscript presents metreleptin as the "primary choice for LD patients", but later notes it is "more efficient in Generalised lipodystrophy patients". The authors should explicitly clarify current clinical guidelines. Metreleptin is strictly indicated and FDA-approved for generalised lipodystrophy; its use in partial lipodystrophy is highly restricted and heavily scrutinised due to varying efficacy and risk profiles.

Response: Thank you for pointing out this mistake. I agree that addressing this error improves the quality of the manuscript. I have fixed the problem mentioned above to improve the accuracy of the information regarding metreleptin.

7. Omission of APL in Pathophysiology: The introduction introduces Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome). However, APL is entirely ignored in the subsequent "Genetics and Pathophysiology" section, which only covers AGL. APL should be discussed to provide a comprehensive overview of acquired forms.

Response: Thank you for this valuable feedback. I agree that adding APL provides a more complete review of lipodystrophy. Therefore, I added details about APL to the "acquired lipodystrophy" section, which discusses both AGL and APL.

Minor Comments

1. Overuse of Acronyms in Single Paragraphs: The authors correctly define acronyms such as HAART and NRTI upon their first use. However, since these terms appear only twice and within the same

paragraph, introducing the acronyms is unnecessary and clutters the text. It is standard practice to write out the full terms if they are not used frequently throughout the remainder of the manuscript.

Response: I thank the reviewer for this helpful insight. I agree that the use of acronyms is excessive in this paragraph. Therefore, I have replaced the acronyms with their full terms to improve the paragraph's flow.

2. Scientific Phrasing and Grammar: Several sentences lack scientific precision or contain grammatical errors. For instance, the phrases "The storage of adipocytes is limited" and "Except for CGL2, in which patients generally do not acquire both kinds of fat tissues" require language editing for clarity and grammatical correctness.

Response: I appreciate this considerate comment. I agree that fixing the grammar errors will improve the clarity of the paper as a whole. Therefore, I have fixed the issues mentioned above and other phrases that also need clarification.

3. Unsubstantiated Claims: The authors state that "around 200 clinical trials are in progress, trying to discover a new way to treat or cure lipodystrophy, especially targeting leptin deficiency". This specific claim requires a reference or a citation from a clinical trial registry to verify the figure.

Response: I appreciate this helpful suggestion. I have included a citation to the website [ClinicalTrials.gov](https://clinicaltrials.gov)

4. Figure Formatting: References to figures within the text should be capitalised for consistency with academic formatting (e.g., change "(figure 1)" and "(figure 2)" to "(Figure 1)" and "(Figure 2)").

Response: Thank you for noticing this minor detail. I have fixed them as required.

Dear reviewer,

Thank you very much for your meaningful insights, thoughtful comments, and suggestions on my manuscript “Molecular Basis of Lipodystrophy: Gene Mutations, Pathophysiology, and Therapy”. Below, I address the comments point by point.

Grammar and Style: The writing is generally clear and understandable, and the overall flow of ideas is logical. The main issue here is consistency in tone. Some sections are written in a strong academic voice, while others shift into more conversational phrasing. Maintaining a consistent scientific tone throughout will strengthen the professionalism of the manuscript. There are also a few recurring grammar issues, including sentence structure, verb agreement, and phrasing, which can be addressed with a careful final pass.

Response: Thank you for this thoughtful suggestion. I agree that maintaining a consistent tone and fixing the grammatical mistakes would help the readability of this manuscript. Therefore, I have revised some sections to improve the quality and readability.

Scientific Framing: The manuscript shows a good grasp of the literature and includes appropriate gene targets and pathways. A notable strength is the inclusion of both genetic and acquired forms of lipodystrophy, which gives the paper a more complete scope. The paper would become even stronger by more consistently linking molecular mechanisms to clinical presentation. In the strongest sections, this connection is clear and effective, and applying that same level of explanation across all sections would improve overall coherence.

Response: I appreciate this helpful feedback. I agree that linking molecular mechanisms to clinical phenotypes would improve the quality of this review. I have revised parts of the manuscript that would benefit from adding the connection between them.

Organization: The overall structure is logical and appropriate for a review article, moving from classification to mechanisms, then to diagnosis and treatment. This organization works well and helps guide the reader through complex material. Some paragraphs, particularly in the introduction and diagnosis sections, are quite dense and would benefit from being divided into smaller sections. The Methods section is functional but could be more clearly organized to match the level of detail seen in the rest of the paper.

Response: I appreciate this helpful comment. I agree that dividing those sections into smaller paragraphs will improve clarity, and that the method section would benefit from adding more details to it. I have reorganized the introduction and diagnosis section. As for the method section, I have added the results of my search and reorganized it to improve clarity.

Scholarly Tone: The paper demonstrates strong content knowledge and clear effort in engaging with the material. The tone is effective in many sections, particularly in the mechanistic discussions. To elevate the manuscript further, it would help to maintain that same level of academic tone throughout and avoid occasional conversational phrasing. This adjustment would better align the writing with the strength of the scientific content.

Response: Thank you for this thoughtful insight. I agree that maintaining a consistent tone throughout the paper is important. Therefore, I have revised the parts of the manuscript that show conversational phrasing to improve consistency.

Dear Reviewer,

Thank you for your thorough and valuable suggestions. These detailed editorial corrections helped me improve the overall quality of this review. Below, I respond to the comments by sections.

Title page and abstract

· Page 1, Title (“Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy”): The title is clear and appropriate for the paper’s scope. You may want to consider whether “disease progression” is the most precise phrase here, since the paper is centered more on mechanisms, classification, and treatment than on longitudinal progression. A term such as “pathophysiology” may better match the content.

· Page 1, Abstract, opening sentence (“Lipodystrophy syndromes are rare diseases that are often characterized...”): The opening sentence introduces lipodystrophy well, but the wording is somewhat repetitive. “Rare diseases that are often characterized” could be made more concise.

· Page 1, Abstract, sentence beginning “Fat tissues are also known as adipose tissues...”: This reads more like a general definition than part of a scientific abstract. You may want to replace this with a sentence emphasizing the metabolic role of adipose tissue instead.

· Page 1, Abstract, sentence containing “a series of metabolic issues”: This is broad. It would be stronger if it named a few specific complications, such as insulin resistance, hepatic steatosis, or hypertriglyceridemia.

· Page 1, Abstract, sentence beginning “They are all factors that determine...”: This is a bit unclear. It would help to specify whether you mean the clinical phenotype, the molecular defect, or the pattern of adipose loss.

· Page 1, Abstract, sentence beginning “Due to the rarity of this disorder...”: This would read better as “these disorders,” since you are discussing lipodystrophy syndromes rather than a single disease entity. The sentence also becomes somewhat repetitive with “this disease” later in the same thought.

· Page 1, Abstract, sentence beginning “In this article, we first consider...”: This feels more narrative than review style. It may read more professionally if you state the review’s scope directly rather than walking the reader through it step by step.

· Page 1, Abstract, final sentence beginning “Future direction of study...”: This needs a small grammatical correction. The sentence would also benefit from a more precise phrasing of how genetic understanding may inform future therapies.

· Page 1, Abstract, overall: The abstract does a good job covering the paper’s main sections, but it could become stronger by making the connection between gene mutations and metabolic outcomes more explicit. Right now, the abstract introduces the topics clearly, but it does not fully show the mechanistic thread that becomes important later in the paper.

Response for comments on the title page and abstract: I appreciate these thoughtful suggestions. I have implemented the corrections suggested.

Introduction and Background

· Page 1–2, Introduction, Paragraph 1, sentence containing “inability to store body fat and excess nutrients”: The introduction establishes the topic clearly, though this phrase could be made more precise. Since one of the key consequences is ectopic lipid storage, naming that directly may strengthen the scientific framing.

· Page 2, Introduction, Paragraph 1, sentence beginning “Adipose tissues are formed through a process called adipogenesis...”: The explanation of adipogenesis is useful, but some of this material reads more like a textbook definition than an introduction to a review article. You may want to move more quickly from defining adipogenesis to explaining why it is relevant to lipodystrophy.

· Page 2, Introduction, Paragraph 1, sentence beginning “This process also includes the triacylglycerol (TAG) fatty acid cycle...”: The TAG cycle discussion is informative, but the sentence is fairly dense and contains several concepts at once. It may help to simplify the structure so the role of lipid storage and mobilization stands out more clearly.

· Page 2, Introduction, Paragraph 1, sentence beginning “It is the process where the lipid droplets...”: This is slightly unclear, as the referent for “It” is not immediately obvious. Clarifying the subject of the sentence may improve readability.

· Page 2, Introduction, Paragraph 1, sentence beginning “However, if a gene mutation...”: The statement about gene mutations affecting adipogenesis is conceptually strong. It may be worth stating more explicitly that these disruptions impair adipocyte differentiation, lipid droplet formation, or adipose maintenance, depending on the gene involved.

· Page 2, Introduction, Paragraph 2, paragraph beginning “LD can be either congenital or acquired...”: This classification paragraph contains important material, but it is doing a great deal at once. It may be easier for the reader if you divide it into one paragraph on congenital versus acquired forms and a second paragraph on subtype distinctions within CGL and FPLD.

· Page 2, Introduction, Paragraph 2, sentence beginning “CGL (also called Berardinelli-Seip syndrome)...”: This sentence is clear, although it may help to define “mechanical and metabolic fat tissues” more carefully. Some readers may not immediately know how you are distinguishing these categories.

· Page 2, Introduction, Paragraph 2, sentence beginning “CGLs are autosomal recessive...”: This is understandable, but the phrasing could be made more formal.

· Page 2, Introduction, Paragraph 2, sentence beginning “Same as CGL...”: This sounds conversational. A more formal transition would improve continuity.

· Page 2, Introduction, Paragraph 2, sentence beginning “Since the body is not able to store excess energy...”: The FPLD description is one of the stronger parts of the introduction because it links adipose redistribution to metabolic consequences. This would become even stronger if you clarified that the

apparent “gain” of fat in other regions often reflects abnormal redistribution rather than normal adipose expansion.

· Page 2, Introduction, Paragraph 2, sentence beginning “Proteins or enzymes that are encoded...”: This is a bit heavy structurally. The main point is good, but the sentence could be made clearer by emphasizing function first.

· Page 2, Introduction, Paragraph 2, phrase “and sometimes idiopathic”: The acquired forms are introduced clearly, although this phrase could be smoothed slightly to fit the tone of the rest of the paragraph.

· Page 3, Introduction, Paragraph 3, paragraph beginning “Not only will the lack of excess energy...”: This paragraph introduces metabolic complications well. The figure reference is useful, and the transition into treatment is natural, though the opening sentence itself is somewhat broad and could be made more concise.

· Page 3, Introduction, Paragraph 3, sentence containing “It currently the only FDA-approved treatment”: The metreleptin discussion is appropriate here, but there is a small grammar issue in this sentence.

· Page 3, Introduction, Paragraph 3, prevalence sentences containing “3/million,” “0.23/ million,” and “2.84/million”: The prevalence numbers are helpful. You may want to make sure units are presented consistently, for example “per million” rather than “/million.”

· Page 3, Introduction, Paragraph 3, sentence beginning “It is also estimated to shorten a patient’s lifespan...”: This is important and strengthens the clinical significance of the review.

· Page 3, Introduction, final sentence beginning “In addition, the treatment developed...”: This could be made slightly more polished. It feels incomplete in structure and would be a good place to state clearly that the review will examine both current therapies and emerging directions.

Response for comments on Introduction and background: Thank you for the helpful feedbacks. I have corrected them as requested.

Methodology

· Page 3, Section title (“2. Method”): Consider changing “Method” to “Methods” to align with standard scientific formatting.

· Page 3, Methods paragraph, sentence beginning “The search included following keywords...”: The literature search description is straightforward, though it would read more smoothly if this were changed to “included the following keywords.”

· Page 3, Methods paragraph, keyword list: The keyword list is useful and appropriately targeted to the paper’s focus.

· Page 3, Methods paragraph, sentence beginning “Only publications in English language were considered”: This would read more naturally as “Only English-language publications were considered.”

· Page 3, Methods paragraph, sentence containing “comprehensive reviews”: The inclusion criteria are generally clear, though this phrase might benefit from a little more specificity if you want to distinguish narrative reviews from systematic reviews.

· Page 3, Methods paragraph, sentence beginning “Case studies with relevant insights...”: This is understandable, though the basis for relevance could be clarified slightly.

· Page 3, Methods paragraph, sentence beginning “Non peer reviewed sources...”: “Non peer reviewed” should be hyphenated. Also, the phrase “case reports with only quantitative data and without further analysis” is a little difficult to interpret. You may want to clarify the reasoning behind that exclusion.

· Page 3, Methods paragraph, final sentence beginning “Full article was reviewed...”: This should be plural.

· Page 3, Methods, overall: This section is functional, but it may become clearer if organized under brief subheadings such as Search Strategy, Inclusion Criteria, and Exclusion Criteria.

Response to comments on methodology: I thank the reviewer for the valuable comments. I have revised the manuscript as requested.

Discussion – Section 1: Genetics and Pathophysiology

· Page 4, CGL1, opening paragraph beginning “Type 1 Congenital Generalized Lipodystrophy...”: The AGPAT2 section contains strong mechanistic content. The explanation is scientifically valuable, but the sentence structure is quite dense. Breaking some of the longer sentences may make the biochemical pathway easier to follow.

· Page 4, CGL1, sentence beginning “AGPAT2 is the gene coding for...”: This would be more standard scientifically as a direct statement that the gene encodes the enzyme.

· Page 4, CGL1, sentence beginning “It is an important precursor...”: The explanation of phosphatidic acid synthesis is detailed, which is good for the review’s depth. You may want to make the link to adipocyte dysfunction slightly more explicit at the end of the paragraph so that the reader sees why this biochemical step matters clinically.

· Page 4, CGL1, sentence beginning “The AGPAT family consists of 11 isomers...”: This is useful, though a little hard to follow because several ideas are packed together.

· Page 4, CGL1, sentence beginning “The presence of mechanical adipose tissue...”: The contrast between AGPAT2 and other isomers is interesting and relevant. This may be one place where an extra citation or a more explicit mechanistic link would strengthen the section further.

· Page 4, CGL1, sentence beginning “Defects in AGPAT2 genes also impact insulin signaling...”: This point is important. It may be helpful to clarify whether this effect is direct or secondary to impaired adipocyte function, since the sentence currently reads somewhat definitive.

· Page 4, CGL4, opening sentence beginning “Type four Congenital Generalized Lipodystrophy...”:

The opening sentence is clear. The subsection would benefit from more consistent capitalization and formatting in the disease name.

· Page 4, CGL4, sentence beginning “Caveolae are one of the most abundant invaginations...”: The explanation of caveolae is strong, though “lots of mammalian cells” reads conversationally. A more formal phrasing would strengthen tone.

· Page 4, CGL4, sentence beginning “Cavin-1 starts the whole process...”: This phrasing feels informal. A more academic wording would match the rest of the review.

· Page 4, CGL4, sentence containing “caveolin 1,2”: The discussion of caveolin isoforms is useful, but the formatting should be standardized.

· Page 4–5, CGL4, sentence beginning “Absence of caveolae causes the cell...”: The sentence describing cellular consequences would benefit from slightly more precision. Instead of “not be able to develop properly,” you may want to emphasize membrane organization, signal transduction, or adipocyte stability.

· Page 5, CGL4, paragraph beginning “Some symptoms that are uniquely associated...”: The clinical phenotype discussion is useful and helps connect molecular defects to patient presentation.

· Page 5, CGL4, final sentence beginning “These symptoms can be explained...”: This could be made more explicit in showing how tissue-specific expression relates to muscle and cardiac findings.

· Page 5, FPLD2, opening sentence beginning “The gene LMNA...”: The LMNA subsection is scientifically important, and the topic choice is strong. The first sentence is somewhat heavy structurally and may benefit from division into two shorter sentences.

· Page 5, FPLD2, sentence beginning “Specifically...”: This appears incomplete and may need revision into a full sentence.

· Page 5, FPLD2, sentence beginning “One way that Lamin A can affect cell development...”: The ZMPSTE24 discussion is relevant. This would be even stronger if you briefly clarified whether you are describing laminopathy-related processing defects more broadly or specifically FPLD2-associated mechanisms.

· Page 5, FPLD2, sentence beginning “Not only will the lack of Lamin A...”: The point about prelamin A accumulation is well made and adds mechanistic depth.

· Page 5, FPLD2, paragraph beginning “A high risk of cardiovascular diseases...”: This paragraph is interesting, though the transition from nuclear structure to epicardial adipose tissue is fairly abrupt. One bridging sentence may help.

· Page 5, FPLD2, final sentence beginning “Other studies will also need to be done...”: This reads somewhat informal. The idea is good, but the phrasing could be more academic.

· Page 5–6, FPLD3, opening sentence beginning “Type 3 Familial Partial Lipodystrophy...”: The

PPARG subsection is relevant and well chosen. There is a small phrasing issue with “encodes for.”

· Page 6, FPLD3, sentence beginning “PPAR γ has three isoforms...”: The mechanism is clearly described and fits well within the paper. Some small reductions in repetition may help readability.

· Page 6, FPLD3, sentence beginning “After binding, PPAR γ induces many targeted genes...”: “induces many targeted genes” might be expressed more precisely, since this is really about transcriptional regulation of downstream targets.

· Page 6, FPLD3, sentence beginning “Mutations in PPARG might cause excess differentiation...”: This appears to be an oversimplification. Many pathogenic PPARG variants impair adipocyte function rather than simply increasing growth, so this phrasing may be misleading and should be reconsidered for accuracy.

· Page 6, FPLD3, paragraph beginning “Compared to FPLD2...”: The comparison with FPLD2 is useful and adds real value to the review. This is a strong section because it moves beyond listing mechanisms and begins comparing phenotypes.

· Page 6, FPLD3, final sentence beginning “However, FPLD3 patients also show...”: This is good, though it may help to clarify why a milder loss of adipose tissue can still be associated with more severe metabolic disease.

· Page 6, AGL, opening sentence beginning “As we can see...”: The opening sentence introduces acquired disease appropriately, but “As we can see” sounds conversational and could be removed.

· Page 6, AGL, paragraph beginning “Adverse effects of highly active antiretroviral therapy...”: The HAART discussion is interesting and clinically relevant. Some of the sentence structure is slightly long, but the content is strong.

· Page 7, AGL, sentence beginning “Proteins such as thymidine analog nucleoside reverse transcriptase inhibitors...”: This is not accurate. NRTIs are pharmacologic agents, not proteins, and this distinction is important for maintaining scientific accuracy. This sentence should be revised to reflect the correct classification and mechanism.

· Page 7, AGL, sentence beginning “It decreases the expression of adiponectin...”: The adiponectin and mitochondrial toxicity points are relevant and help ground the section mechanistically.

· Page 7, AGL, paragraph beginning “Another possible cause of AGL...”: The autoimmune mechanism is a good addition. The perilipin discussion is especially useful because it broadens the review beyond purely genetic forms.

· Page 7, AGL, sentence beginning “It leads to an increase in lipolysis activities...”: This is conceptually good, though it may help to clarify whether you mean uncontrolled lipolysis due to loss of lipid droplet protection.

Response for discussion section 1: I appreciate the thoughtful comments. I have fixed the mistakes mentioned to improve quality and clarity.

Diagnosis and Clinical Features

- Page 7–8, Diagnosis, Paragraph 1 beginning “Since lipodystrophy is such a rare disease...”: This paragraph includes important diagnostic material, but it is quite long and would benefit from being divided into smaller units.
- Page 7, Diagnosis, opening phrase “not well known to the public”: This point about underrecognition is important and clinically relevant, though this phrasing may be less useful than a more clinician-focused one.
- Page 7–8, Diagnosis, sentence beginning “Although patients with CGL show symptoms...”: The contrast between CGL and FPLD diagnosis is helpful.
- Page 8, Diagnosis, sentence beginning “It could be easily mixed up with...”: “mixed up with” would benefit from more formal wording.
- Page 8, Diagnosis, paragraph beginning “Some phenotypes that are associated...”: The phenotype paragraph is detailed and generally useful. There is a small typo in “in charge or energy storage.”
- Page 8, Diagnosis, sentence beginning “Metabolic adipose tissues are in charge...”: The explanation of metabolic versus mechanical adipose tissue is useful, but the wording could be made more precise.
- Page 8, Diagnosis, sentence beginning “Although patients still in some degrees lack...”: This is difficult to follow and appears structurally incomplete. This portion may benefit from being rewritten for clarity.
- Page 8, Diagnosis, final sentence beginning “Next, we will be discussing...”: The transition into treatment is smooth and works well, though this phrasing reads somewhat narrative for a review article.

Response for Diagnosis and Clinical Features: I thank the reviewer for these helpful feedbacks. I have revised this section as mentioned.

Treatments

- Page 8, Treatments, opening sentence beginning “Currently, there isn’t a definite treatment...”: This sounds somewhat informal. The idea is correct, though the phrasing could be slightly more formal.
- Page 8–9, Metreleptin subsection overall: The metreleptin discussion is one of the strongest applied sections of the paper. It explains the rationale for therapy clearly and appropriately ties it to leptin deficiency.
- Page 9, Metreleptin subsection, sentence beginning “Leptin is a hormone...”: This explanation is useful, though some of this material repeats ideas already implied in the section. You may be able to reduce repetition.
- Page 9, Metreleptin subsection, sentence beginning “This causes patients to show extreme hyperphagia...”: The connection between hypoleptinemia, hyperphagia, and ectopic fat storage is

well stated and clinically meaningful.

· Page 9, Metreleptin subsection, sentence beginning “Metreleptin’s main purpose is to mimic...”: This is fine, though it may be worth noting whether the treatment’s benefit is metabolic, symptomatic, or both.

· Page 9, Metreleptin subsection, sentence beginning “Metreleptin is found to be more efficient...”: This might be adjusted slightly to reflect clinical response rather than efficiency.

· Page 9, Metreleptin subsection, sentence beginning “However, the risk of using Metreleptin...”: This contains a subject-verb agreement issue and could be clarified to improve readability.

· Page 9, Metreleptin subsection, final sentence beginning “Other common drugs...”: The closing sentence on adjunctive therapies and cosmetic surgery is appropriate. This gives the treatment section a more complete and realistic scope.

· Page 9, Lifestyle subsection title (“Change in Daily Routine”): This feels somewhat informal as a heading. A more standard heading may fit better with the rest of the paper.

· Page 9, Lifestyle subsection, paragraph beginning “Although Metreleptin can generally help...”: This section is brief but useful. It might be strengthened by explaining why a low-fat or carbohydrate-restricted diet is recommended in metabolic terms, rather than only listing the recommendations.

· Page 9, Lifestyle subsection, sentence containing “doing too much exercise”: This is understandable but may be rephrased more formally.

· Page 9–10, Gene Editing subsection, opening paragraph: This section is forward-looking and adds value to the paper. The discussion of gene therapy is a strong choice for the final treatment subsection.

· Page 10, Gene Editing subsection, sentence beginning “The results of the trials show...”: The mouse model example is useful and helps ground the idea in actual preclinical work.

· Page 10, Gene Editing subsection, sentences containing “AVV”: The acronym “AVV” appears to be used in place of “AAV” (adeno-associated virus). This should be corrected consistently throughout the section. In addition, phrases such as “AVV targets adipocytes” read somewhat absolute and may benefit from more precise wording.

· Page 10, Gene Editing subsection, sentence beginning “Therefore, there isn’t enough evidence...”: The translational caution here is important and scientifically appropriate. This section benefits from the fact that it does not overstate clinical readiness.

· Page 10, Gene Editing subsection, final sentence beginning “Continued research on LD...”: This conclusion is good and appropriately cautious.

Response for Treatments: Thank you for these helpful feedbacks. I have implemented these suggestions as requested.

Conclusion and Future Directions

- Page 10–11, Conclusion, opening sentence beginning “Although genes involved in lipodystrophy syndromes...”: This contains the paper’s central idea and is conceptually strong, but it is fairly long. Breaking it into two sentences may improve readability.
- Page 11, Conclusion, phrase “common outcome -impaired adipocyte development and function”: This contains a spacing and punctuation issue. It should be corrected for clarity and consistency with standard formatting.
- Page 11, Conclusion, paragraph beginning “LD highlights the essential role...”: This paragraph does a good job emphasizing adipose tissue as an endocrine and metabolic organ. That is one of the manuscript’s central strengths.
- Page 11, Conclusion, sentence beginning “For conditions like lipodystrophy...”: The discussion of awareness and diagnostic delay is relevant and provides a meaningful clinical takeaway.
- Page 11, Conclusion, sentence beginning “Since the discovery of lipodystrophy syndromes...”: “lots of progress has been made” reads somewhat informal.
- Page 11, Conclusion, sentence containing “research have been done”: This is a grammar issue.
- Page 11, Conclusion, final sentence beginning “Having a deep understanding...”: The final sentence is appropriate, though it may be strengthened by tying future therapy more directly to the specific mechanisms discussed earlier.

Response for Conclusion and Future Directions: I thank the reviewer for the thoughtful comments. I have revised the conclusion as requested.

Figures and Tables

- Table 1 / Page 2: The table is useful and supports the classification section well. Make sure the labeling and formatting remain consistent with the journal’s style.
- Figure 1 / Page 3: The comparison figure is a helpful visual aid. The caption contains multiple grammatical issues, including “The storage of an adipocytes is limited” and “increase glucose level in blood streams.” These should be revised for clarity and correctness.
- Figure 2 / Page 4: The figure is relevant and supports the CGL1 discussion appropriately.
- Figure 3 / Page 5: The caveolae figure is helpful, though the caption could be a bit more precise scientifically. Also, “Biorender” should be standardized to “BioRender.”
- Table 2 / Page 9: This table adds practical value to the treatment section. Make sure the reproduced source and licensing note are formatted exactly as required by the target venue.
- Figure 4 / Page 10: This is one of the stronger figures in the manuscript because it helps unify the review conceptually. The caption is informative and supports the final conclusion well.

Response for Figures and Tables: I appreciate these helpful comments. I have fixed the details that are mentioned above.

The student has clearly put a lot of effort into addressing our comments, and the paper is in a much stronger position now.

Because the student has made such substantial improvements, I do not think we need to send this out for another full round of peer review. I recommend **acceptance with minor edits**, provided the student addresses a few final, specific critiques outlined below.

Here is my post-review critical feedback.

Strengths and improvements:

The author did an excellent job expanding the scope and scientific rigour of the review. The addition of the CGL2/seipin section provides crucial context for the most severe form of congenital lipodystrophy. Furthermore, the newly added explanation of lipotoxicity (specifically how excess free fatty acids accumulate in the liver and skeletal muscle to disrupt insulin signalling) bridges a major mechanistic gap that was missing in the first draft. The methodological transparency has also been appropriately addressed with the inclusion of screening numbers, and the clinical indications for metreleptin are now accurately represented.

Constructive critiques and areas for final polish:

While the manuscript is vastly improved, there are a few remaining scientific and structural issues that need to be resolved before publication:

1. Biologically contradictory sentence in FPLD3. In an attempt to address my previous comment on FPLD3, the author merged their original flawed premise with my correction, resulting in a contradictory sentence: "*Loss-of-function or dominant-negative mutations in pathogenic variants of PPARG cause excess differentiation and growth in adipocytes, fundamentally impairing adipogenesis.*" The author should delete the phrase "*cause excess differentiation and growth in adipocytes*" entirely. Impaired adipogenesis means the cells *fail* to differentiate and grow; they cannot do both simultaneously.
2. Missing link in the APL/C3NeF mechanism: The addition of the APL section is great, but the explanation of the C3NeF pathway misses a vital physiological link. The author states that continuous C3 breakdown activates the terminal pathway, leading to adipocyte lysis. To deepen this manuscript, the author should briefly mention *why* adipocytes are targeted: adipose tissue produces high levels of Factor D (adipsin), making it uniquely susceptible to localised alternative complement pathway activation.
3. Numbering and formatting typos: The author added the new CGL2 section but accidentally duplicated the numbering. There is currently "3.2 Type 2 Congenital Generalised Lipodystrophy (CGL2)" followed immediately by "3.2 Type four Congenital Generalised Lipodystrophy (CGL4)". This needs to be corrected to 3.2, 3.3, 3.4, etc.
4. Awkward phrasing in the diagnosis section: The sentence, "*Only CGL2 patients do not acquire both mechanical and metabolic adipose tissues*", remains awkwardly phrased. In a medical context, "acquire" implies catching an infectious disease. This should be rephrased to "*Only CGL2 patients fail to develop both...*" or "*Only CGL2 patients are born without...*" to maintain a strict academic tone.

Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, and Therapy- Accept with minor edits.

The revised manuscript shows clear improvement in organization, clarity, and overall scientific presentation. Many of the earlier concerns were addressed thoughtfully, particularly in the areas of structure, terminology, and explanation of key concepts. The paper now reads more cohesively, and the progression between sections is easier to follow. The introduction and abstract are both stronger in this version and do a better job establishing the scope and clinical relevance of the review from the beginning.

One of the stronger aspects of the revision is the improved discussion of the molecular and metabolic basis of lipodystrophy. Several sections now provide clearer explanations of how disruptions in adipocyte biology contribute to disease development and metabolic complications. The paper also does a better job balancing scientific detail with readability, which helps the review feel more focused and organized overall. The inclusion of both genetic and acquired forms of lipodystrophy continues to strengthen the scope of the manuscript and gives the review broader clinical relevance.

The treatment section has improved as well and now feels more integrated into the overall discussion of disease mechanisms and patient outcomes. The figures and tables also contribute more effectively to the manuscript in this version and support the written discussion more clearly than before. Overall, the paper now reads more like a complete review article rather than a collection of summarized information.

There are still a few smaller areas that could continue to be refined. Some sentences remain slightly long or dense, particularly in sections discussing molecular pathways, and simplifying a few of these sentences may further improve readability. In a few places, mechanistic explanations could also be phrased somewhat more cautiously to avoid sounding overly definitive when discussing pathways that are still under investigation. Adding a small number of additional citations in sections with more detailed mechanistic discussion may also help strengthen scientific support in those areas.

Overall, this is a strong revision that reflects clear effort and attention to feedback. The manuscript is substantially more polished, better organized, and more scientifically focused than the earlier version. Following revision, the manuscript is scientifically sound, well organized, and appropriate for publication pending minor editorial refinement.

1 *Molecular Basis of Lipodystrophy: Gene Mutations, Disease Progression, Pathophysiology,* 2 *and Therapy*

3 *Abstract*

4 Lipodystrophy syndromes are a group of rare diseases that are often
5 characterized by a general or partial absence of body fat, caused by the inability to
6 properly store and utilize fat tissues, and the lack of adipose tissues, and the
7 of adipose tissues would lead to serious consequences and the development of a series of
8 metabolic issues, including insulin resistance, leptin deficiency, and hypertriglyceridemia.
9 Lipodystrophy These syndromes are genetically and clinically heterogeneous, with
10 different phenotypes influenced by underlying molecular defects. Both fat distribution and
11 the molecular defect play a role in determining the type of
12 lipodystrophy a patient has. Due to the rarity of these disorders, not many studies have
13 been conducted on them. This, which results in the public's lack of
14 knowledge, increasing the difficulty of diagnosing and treating these conditions
15 about this disease and increases the difficulty of treating it. In this article, we first
16 examine the classification and clinical aspects of lipodystrophy syndromes,
17 covering the onset and the differences in phenotypes of patients. Then, we further
18 discuss the molecular and cellular mechanisms of several types of lipodystrophies and
19 the role they play in the development of adipose tissues. In addition, this review
20 addresses other metabolic dysfunctions caused by lipodystrophy, such as
21 insulin resistance, fatty liver, and hypertriglyceridemia. Lastly, we evaluate therapeutic
22 strategies aimed at improving metabolic control and quality of life in affected patients.
23 Future direction of research and potential therapies may be improved with a
24 deeper and more thorough understanding of the genetic and mechanistic basis of
25 lipodystrophy, as it is critical for identifying key mechanisms and developing a more
26 targeted treatment.

27

28 *Keywords:* Lipodystrophy syndromes, adipose tissue, adipogenesis, gene mutations,
29 metabolic dysfunctions

30

31 *1. Introduction*

32 Lipodystrophy syndromes (LD) are a heterogeneous group of rare disorders
33 characterized by the partial or complete loss of mature adipose tissue in localized or
34 generalized areas. This results in the inability to store body fat, ectopic lipid storage, and
35 excess nutrients (Fourman and Grinspoon 2022). Two main classes of lipodystrophy are
36 Congenital Generalized Lipodystrophy (CGL) and Familial Partial Lipodystrophy (FPLD).
37 Adipose tissues are formed through a process called adipogenesis, and it is crucial for the
38 adipose tissue to function normally.

39 For adipose tissues to function normally, adipogenesis is crucial for the
40 differentiation of the precursor cells. Adipogenesis starts with Adipogenesis is the

41 ~~process by which~~ mesenchymal stem cells differentiating into mature adipose tissue.
42 ~~During This adipogenesis process, lipid storage and mobilization is regulated by also~~
43 ~~includes the triacylglycerol (TAG) fatty acid cycle, which regulates lipid storage and~~
44 ~~mobilization in adipocytes. It is the process~~ where the lipid droplets undergo lipolysis
45 (the breakdown of lipid droplets) and lipogenesis (the synthesis of new lipid
46 droplets) (Poulos et al. 2016). However, if a gene mutation or other factors affect the
47 components ~~that play a role~~ involved in the regulation of regulating adipogenesis, ~~this~~
48 would lead to impaired adipocyte differentiation, lipid droplet formation, and adipocyte
49 functions. ~~to serious, life-threatening consequences.~~

50 LD can be either congenital or acquired. Congenital Lipodystrophy, and it is
51 classified based on the location of lost adipose tissue, and further divided into subtypes
52 according to the gene segment that is mutated (Akinci, Gular, and Oral 2024) (Table 1).
53 Meanwhile, acquired lipodystrophy is caused by external factors or side effects of other
54 treatments.

55 CGL (also called Berardinelli-Seip syndrome) is characterized by the near-complete
56 absence of adipocytes, ~~both mechanical and metabolic fat tissues~~ (Oswiecimska n.d.). CGLs
57 are inherited in an autosomal recessive manner, ~~and the~~ with symptoms typically often
58 presenting ~~start showing~~ shortly after birth. It is further divided into CGL1, CGL2, CGL3,
59 and CGL4, which link to four different gene mutations. FPLD presents as an abnormal
60 distribution of adipose tissue, with fat loss around the limbs, torso, and hips. It can be
61 autosomal recessive or dominant depending on the gene ~~that is~~ involved. Since the body
62 is not able to store excess energy in those areas, other body parts, such as the face, neck,
63 and internal organs like the liver, gain extra adipose tissue (Diagnosis and Management of
64 Lipodystrophy Syndromes: A Multi-Society Practice Guideline | The Journal of Clinical
65 Endocrinology & Metabolism | Oxford Academic n.d.). This results in the abnormal
66 distribution of adipose tissues. As with ~~Same as~~ CGL, FPLD ~~it is further also~~ divided into
67 several subtypes, including FPLD1 (Kobberling-type lipodystrophy), FPLD2 (Dunnigan
68 Variety lipodystrophy), FPLD3, FPLD4, FPLD5, and FPLD6. The development of
69 adipocytes is tightly regulated by various proteins and enzymes. The genes that encode
70 these proteins or enzymes are often the genes associated with lipodystrophy. ~~Proteins or~~
71 ~~enzymes that are encoded by the genes associated with any kind of lipodystrophy all play~~
72 ~~important roles in the development of adipocyte.~~

73 As for Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and
74 Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome), they have similar
75 symptoms as CGL and FPLD. However, they are caused by autoimmune diseases, side
76 effects of antiretroviral therapy (ART) for HIV patients, or even idiopathic reasons (Misra
77 and Garg 2003). ~~Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) and~~
78 ~~Acquired Partial Lipodystrophy (APL, Barraquer-Simons syndrome) have similar~~
79 ~~symptoms, respectively, however, they can be caused by autoimmune diseases, the side~~

80 effects of antiretroviral therapy (ART) for HIV patients, and sometimes idiopathic (Misra
81 and Garg 2003).

82

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/ adolescence.	Palpable "ledge" between normal and lipodystrophic areas
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not effected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

83

Type	Subtype	Gene Involved	Inheritance	Clinical Phenotype	Commonly associated Features
Generalized Lipodystrophy Syndrome					
Congenital Generalized Lipodystrophy (Berardinelli-Seip syndrome)	CGL1	AGPAT2	Autosomal recessive	Near total absence of adipose tissue, generalized muscularity, metabolic abnormalities. Starts showing symptoms shortly after birth.	Loss of metabolic fat, retains mechanical fat tissues
	CGL2	BSCL2	Autosomal recessive		Mild mental retardation
	CGL3	CAV1	Autosomal recessive		Vitamin D resistance
	CGL4	PTRF	Autosomal recessive		Myopathy, pyloric stenosis
Acquired Generalized Lipodystrophy (Lawrence Syndrome)	NA	NA	NA	Near total absence of adipose tissue, metabolic issues. Develops during childhood/ puberty.	Could be caused by autoimmune diseases, panniculitis, idiopathic or immunotherapy
Partial lipodystrophy syndromes					
Familial Partial Lipodystrophy	FPLD1 (Kobbering)	Unknown	Polygenic	Absence of fat around the limbs and buttock, excess adipose tissues around face, neck, and abdomen. Also shows sign of metabolic issues. Develops during puberty/adolescence.	Palpable "ledge" between normal and lipodystrophic areas
	FPLD2 (Dunnigan)	LMNA	Autosomal dominant		High risks of cardiovascular diseases
	FPLD3	PPARG	Autosomal dominant		Less severe and distal fat loss
	FPLD4	PLIN1	Autosomal dominant		Increased fibrosis of adipose tissue, small lipid droplets in adipocytes
	FPLD5	CIDEA	Autosomal recessive		
	FPLD6	LIPE	Autosomal recessive		Increased visceral fat
Acquired Partial Lipodystrophy (Barraquer-Simons syndrome)	NA	NA	NA	Loss of subcutaneous fat around the face, neck, upper limbs and abdomen. Low limbs are not effected.	Causes could be autoimmune, MPGN-associated, immunotherapy or idiopathic

84

85 ▲ Table 1: Classification, clinical features, and molecular basis of lipodystrophies (Made
86 with Google Sheet)

87


88 Not only will the lack of excess ~~energy~~ ~~body fat~~ ~~affect~~ ~~affect~~ the body's normal
89 functions, but ~~other~~ complications ~~associated~~ ~~that arise~~ with lipodystrophy also have a
90 ~~significant~~ ~~big~~ effect on patients' lives. Some common metabolic abnormalities include
91 leptin deficiency, insulin resistance, diabetes, hypertriglyceridemia, and fatty liver disease
92 (Figure 1). Currently, around 200 clinical trials are ~~in progress, trying~~ ~~underway~~ to
93 discover a new way to treat or cure lipodystrophy, ~~with a particular focus on~~ ~~especially~~
94 ~~targeting~~ leptin deficiency ~~(Search ClinicalTrials.Gov For, n.d.)~~ ~~ney~~.

95 Metreleptin, for example, is a treatment created specifically for ~~acquired or~~
96 ~~congenital generalized lipodystrophy~~ ~~LD~~ patients. It is a targeted treatment for leptin
97 deficiency, which is a common metabolic issue associated with ~~LDD~~ (Araújo-Vilar &
98 Santini, 2019). ~~(Araújo Vilar e Santini 2019)~~. It is currently the only FDA- approved
99 treatment for ~~generalized lipodystrophy~~ ~~LD~~ patients. ~~However, conventional treatment,~~
100 ~~such as special diets,~~ is ~~still optimized before~~ ~~metreleptin~~ (Meehan et al., 2016). Due to the
101 rarity of this disease, limited research has been done, making Metreleptin the primary
102 choice for ~~CGL and AGL patients~~ ~~LD patients~~ (Ajluni et al., 2016). ~~As for FPLD patients, the~~
103 ~~use of Metreleptin is highly restricted. Therefore, they will need to maintain~~ ~~Patients will~~
104 ~~still need to have an appropriate~~ ~~healthy~~ diet and ~~require~~ other medications for ~~the other~~
105 metabolic ~~complications~~ ~~issues~~.


106 According to studies, only about 3 ~~per~~ ~~/~~ million people around the world are
107 affected by some type of lipodystrophy syndrome. While the prevalence of CGL is
108 estimated to be 0.23 ~~per~~ ~~/~~ million people, the prevalence of FPLD is around 2.84 ~~per~~
109 ~~/~~ million people (Chiquette et al. 2017). It is also estimated to shorten a patient's lifespan
110 by 30 or more years. The main cause of death is shown to be liver diseases and infections
111 caused by adipose tissue dysfunction, but also varies from type to type of lipodystrophy
112 (Lima et al. 2018).

113 This literature review aims to highlight the molecular mechanisms ~~underlying~~ ~~of~~
114 lipodystrophy, ~~focusing~~ ~~with a focus~~ on the genetic causes, differences between types of
115 lipodystrophies, and other metabolic conditions caused by adipose tissue abnormalities,
116 ~~as well as~~ ~~. In addition,~~ the treatment developed and ~~future directions of study, and the~~
117 ~~other~~ possibilities for ~~a~~ ~~fundamental treatments~~ ~~cure~~.

118



119



120

121 ▲ Figure 1: Comparison of adipocyte functions between a healthy person and a
 122 lipodystrophy patient. Adipocyte storage is limited. The storage of adipocytes is limited.
 123 in lipodystrophy patients. Common metabolic abnormalities include leptin deficiency,
 124 insulin resistance, and elevated blood glucose levels in the bloodstream. (Made
 125 with BioRender)

126

127 2. Methods

128 *Search Strategy*

129 A literature search was conducted using PubMed and Google Scholar databases.
130 The search included the following keywords: “lipodystrophy genetics”, “adipocyte
131 differentiation”, “AGPAT2”, “PTRF Cavin-1”, “LMNA mutation”, “PPAR γ mutation”,
132 “lipodystrophy metabolic abnormalities”. Titles and abstracts were first screened for
133 relevance. Full articles were reviewed to see if they met the inclusion criteria. 97 articles
134 were initially screened, and 55 papers were ultimately referenced in this review.

135

136 *Inclusion/Exclusion Criteria*

137 Articles published between 2000 and 2026 were included. Only ~~publications in the~~
138 English language publications were considered. Studies were included if they were
139 peer-reviewed primary research articles or comprehensive reviews, including both
140 narrative reviews and systematic reviews, that focused ~~focusing on~~ the genetic, molecular,
141 or metabolic mechanisms underlying ~~of~~ lipodystrophy syndromes. Case studies were
142 included if they provided ~~with~~ relevant insights, such as pathological or mutation analyses
143 or clinical findings ~~were also included~~. Non-peer-reviewed sources and ~~articles~~
144 published before 2000 are excluded. Case reports that only report ~~with~~ descriptive ~~only~~
145 quantitative data, without the discussion of mechanistic interpretation, are also excluded,
146 as clinical data are not the focus of this review ~~and without further analysis were excluded~~.
147 ~~Titles and abstracts were first screened for relevance. Full article was reviewed if they met~~
148 ~~the inclusion criteria.~~

149

150 3. Discussion

151 *Genetics and Pathophysiology*


152 *3.1 Type 1 ~~1~~ Congenital Generalized Lipodystrophy (CGL1)*

153 Type ~~one~~ ~~1~~ Congenital Generalized Lipodystrophy (CGL1) is caused by a mutation
154 in the gene AGPAT2. AGPAT2 is the gene ~~that coding for~~ ~~encodes the a specific enzyme~~ ,
155 1-acylglycerol-3-phosphate O-acyltransferase 2. ~~It, which~~ catalyzes the acylation of
156 lysophosphatidic acid (1-acylglycerol-3-phosphate) to phosphatidic acid (1,2
157 diacylglycerol-3-phosphate)(Gale et al. 2006) (Ffigure 2). It is an important precursor
158 ~~for~~ of the biosynthesis of triacylglycerol (TAG) and phospholipids ~~synthesis~~ from
159 glycerol-3-phosphate. This step esterifies a second fatty acyl group at the sn-2 position of
160 the glycerol backbone. Phosphatidic acid is further acylated by other enzymes, creating
161 triacylglycerol and phospholipids. **Impaired formation of phosphatidic acid results in the**
162 **absence of triacylglycerol production, thereby disrupting the normal adipose tissue**
163 **development.**

164

165 The AGPAT family consists of 11 isomers. ~~Among the isomers, however,~~ AGPAT2 is
expressed at higher levels in adipose tissue than the other isomers. The presence of

166 mechanical adipose tissue can be explained by the increased expression of the other
167 isomers (Broekema et al., 2018). However, studies have shown that the expression of
168 AGPAT2 is required for the accumulation of triacylglycerol, especially in metabolic adipose
169 tissues. Defects in the AGPAT2 genes also impact insulin signaling, which is a direct effect
170 of impaired adipocyte dysfunction (Santoro et al., 2021). meaning This also causes that
171 gluconeogenesis will be unrestricted, which leads to the development of hyperglycemia
172 and diabetes(de Melo et al. 2025).
173



174
175 ▲ Figure 2: The process of Triacylglycerol synthesis. In the second step, where LPA is
176 acylated to PA, AGPAT is the enzyme that catalyzes this reaction. Without it, the reactions
177 after it will not occur properly, meaning that adipocytes can't develop properly. (Made
178 with BioRender)

179

180 3.2 Type 2 Congenital Generalized Lipodystrophy (CGL2)

181 Type 2 Congenital Generalized Lipodystrophy (CGL2) is caused by pathogenic
182 variants of the BSCL2 gene. It encodes the protein seipin, which is found in the
183 endoplasmic reticulum (ER) (Akinçi et al., 2024), Seipin plays an important role in the
184 regulation of lipid droplet biogenesis. It interacts with proteins involved in TAG synthesis
185 to facilitate adipogenesis. For instance, it binds with AGPAT2 to regulate PA metabolism.
186 Seipin deficiency could lead to abnormal accumulation of PA. This increases the surface
187 tension of the ER and decreases its line tension, disrupting the unidirectional lipid droplet

188 budding. It causes the accumulation of newly synthesized neutral lipids in the ER, leading
189 to severe ER stress and potentially being toxic to the cells (Li et al., 2022).

190 CGL2 is the most common type of congenital lipodystrophy. But mutations in the
191 BSCL2 also lead to the most severe symptoms. Patients are born without any fat, including
192 mechanical and metabolic adipose tissues. They also have an earlier onset of diabetes
193 mellitus than other types of lipodystrophies. Other than adipocytes, seipin is also
194 expressed in the brain and testis. This leads to mild mental disability, developmental
195 language disorders, and an impaired reproductive system.


196

197 3.3 Type ~~four~~4 Congenital Generalized Lipodystrophy (CGL4)

198 Type ~~four~~four Congenital Generalized Lipodystrophy (CGL4) is associated with the
199 gene mutation in the PTRF gene (Polymerase I and Transcript Release
200 Factor) (Salle-Teyssières et al. 2016). The PTRF gene encodes cavin-1, which is one of the
201 essential proteins that is required for the biogenesis of caveolae. Caveolae are ~~one of the~~
202 most abundant invaginations ~~of them in the plasma cell membrane~~ across a wide range of ~~of~~
203 ~~lots of~~ mammalian cells (Figure 3). Cavin-1 ~~plays a critical role in the initiation of caveolae~~
204 ~~starts the whole process of the synthesis of caveolae through~~by recruiting other structural
205 proteins ~~necessary~~, such as caveolins. Without it, cells won't be able to produce caveolae.
206 Although it is abundant, its functions have only been understood in the past few decades.
207 It plays a role in signal transduction, endocytosis, and mechanotransduction (Stea and
208 D'Alessio 2025). Cavin-1 binds with the caveolins to form Caveolae. There are three
209 members in the caveolin family: ~~caveolin-1, caveolin-2, and caveolin-3. They are~~
210 expressed in a ~~variety of cells~~lot of cells, like smooth muscle cells, fibroblasts, and
211 adipocytes. Caveolin 3 is expressed exclusively in cardiac and skeletal muscle. It is shown
212 that the lack of PTRF-CAVIN doesn't affect the level of caveolin expressed (Rajab et al.
213 2010). However, it affects caveolin's ability to localize to the cell's surface, which makes the
214 formation of caveolae impossible. ~~The~~ Absence of caveolae causes ~~the cell to not be able~~
215 ~~to develop properly, causing~~ abnormalities and dysfunctions, including impaired signal
216 transduction and a lack of mechanoprotection. Without the extra membranes acting as a
217 buffer against the force of mechanical stretching, cardiac cells are at a greater risk of
218 rupturing (Grivas et al., 2020).

219 Clinical features ~~Some symptoms that are~~ uniquely associated with CGL4 ~~this type~~
220 ~~of lipodystrophy include~~are myopathy, which affects skeletal muscle structure, and distal
221 metaphyseal deformation, causing bone stiffness and limited range of motion (Ardissone
222 et al. 2013). Cardiac arrhythmias are also one of the symptoms caused by the lack of
223 PTRF-CAVIN, and ~~it~~they could be life-threatening, showing the serious consequences of
224 cavin-1 deficiency (Rajab et al. 2010). These symptoms can be explained by the location
225 where caveolins -1, 2, and 3 are expressed.

226



227

228 ▲ Figure 3: ~~The structure and formation of caveolae. Caveolae are invaginations clusters~~
 229 ~~of in the cell-plasma membrane. Cavin-1 first binds with the plasma membrane, initiating~~
 230 ~~caveolae synthesis. Cavin-1 and caveolin 1 binds with cavin-1, which stabilizes its structure -~~
 231 ~~together and forms caveolae. (Made with BioRender)~~

232

233 3.4 Type ~~two~~ Familial Partial Lipodystrophy (FPLD2)

234 The gene LMNA, ~~which~~ encodes the protein called Lamins; ~~It is the gene that~~
 235 ~~causes is associated with~~ Type ~~two~~ Familial Partial Lipodystrophy (FPLD2). ~~It FPLD2 is is-~~
 236 ~~also~~ the most common type of lipodystrophy syndrome (Corsa et al. 2021). In cells, Lamin
 237 A and Lamin C are expressed predominantly. The main functions of Lamin A/C are the
 238 regulation of nucleus shape, providing structural stability to the nuclear envelope and
 239 cytoskeleton, and also controlling gene regulation (Maung et al. 2026) (Bagias et al. 2020).
 240 ~~They are important intermediate filament proteins forming the nuclear lamina. They also~~
 241 ~~play a role in~~ Specifically, ~~organizing the nuclear lamina and chromatin, and the interaction-~~
 242 ~~between them. Mutations in Lamin A/C can lead to premature aging syndrome~~
 243 (Hutchinson-Gilford Progeria Syndrome). The mutated LMNA gene produces a mutant
 244 product called progerin. As progerin accumulates in the nucleus, it destabilizes DNA,
 245 triggers premature senescence, and alters the shape of the nucleus (Gonzalo et al., 2017).

246

~~One way that Lamin A can affect cell development is~~ The interference with the
 247 cleavage step of post-translational regulation of Lamin A could also affect the patient. ~~-~~
 248 ZMPSTE24 plays an important role in this step, and it is also considered to be one of the
 249 factors that causes lipodystrophy. However, mutations in ZMPSTE24 cause another distinct
 250 form of lipodystrophy (mandibuloacral dysplasia), showing different symptoms and
 251 increased severity. ~~This m~~ Nevertheless, modification is crucial and ensures that Prelamin
 252 A (the precursor of Lamin A before ~~the~~ post-translational regulation) ~~will~~

253 function functions normally. Not only will the lack of Lamin A affect cell functions, but the
254 accumulation of Prelamin A could also be toxic to cells (Varlet, Helfer, and Badens 2020),
255 which could affect the cell's ability to develop properly.

256 These cellular abnormalities contribute to broader systemic symptoms. This
257 includes a higher risk of cardiovascular diseases is also associated with FPLD2. It is
258 found that FPLD2 patients have higher Epicardial adipose tissue (EAT) volume than type
259 two diabetes patients (Talman et al. 2014) (Godoy-Matos et al. 2015). However, it is not
260 related to other metabolic issues that are also presented in lipodystrophy (Lamothe et al.
261 2025). Other-Additional studies will also need to be conducted done to gain have a
262 clearer insight into this condition and the its correlation between them.

263

264 3.5 Type ~~three~~3 Familial Partial Lipodystrophy (FPLD3)

265 Type ~~three~~3 Familial Partial Lipodystrophy (FPLD3) is caused by pathogenic
266 variants of the PPARG gene. PPARG encodes for PPAR γ (Peroxisome proliferator-activated
267 receptor γ), a member of a superfamily of nuclear receptors. PPAR γ is known as the
268 master regulator of adipocyte differentiation, maintenance, and functions (Broekema et al.
269 2019). It PPAR γ has three isoforms: PPAR γ 1, PPAR γ 2, and PPAR γ 3. Among them, PPAR γ 2
270 is predominantly expressed in adipocytes. PPAR γ acts as a ligand-activated transcription
271 factor. It binds to its target gene as a heterodimer with PPAR-response elements
272 (PPREs) (Madsen et al. 2022). After binding, PPAR γ regulates the transcription of
273 downstream target genes induces many targeted genes involved in the development of
274 adipose tissue. Including the TAG cycle, which is also upregulated by PPAR γ for the
275 development of adipocytes. Loss-of-function or dominant-negative mutations in
276 pathogenic variants of PPARG might fundamentally impair adipogenesis. Therefore, leading
277 it leads to increased cellular stress and dysfunctions in adipocytes (Soares et al. 2024).

278 Compared to FPLD2, FPLD3 patients show less severe fat loss. One way to explain
279 this is that more large adipocytes are preserved since mutations in PPARG could lead to
280 excess cell growth. Fat accumulation in areas such as the face and neck are is also not
281 observed (Bagias et al. 2020). However, FPLD3 patients also show more severe metabolic
282 symptoms, specifically hypertriglyceridemia, diabetes, and insulin resistance. One possible
283 explanation is that although patients still preserve large adipocytes, they only have a few
284 small, insulin-sensitive adipocytes (Soares et al. 2024).

285

286 3.6 Acquired ~~Generalized~~ Lipodystrophy (AGL)

287 A ~~we can see, a wide variety~~ range of gene mutations that affect different cellular
288 functions could all lead to LD. However, gene mutations are not the only cause of
289 lipodystrophy. Other environmental factors can also trigger the onset of lipodystrophy.
290 Acquired Generalized Lipodystrophy (AGL, ~~also called Lawrence Syndrome~~) and Acquired
291 Partial Lipodystrophy (APL) are forms is another form of lipodystrophy, which has similar
292 symptoms to ~~CGL~~ but is that are not caused by genetic mutations (Al-Jawad et al. 2025).

293 Despite having different mechanisms, they have similar symptoms to congenital
294 lipodystrophy.

295 ¶

296 Acquired lipodystrophy is characterized by the gradual loss of fat tissue starting from
297 childhood or adolescence. AGL patients show a generalized loss of adipose tissue, while
298 APL patients show loss of adipose tissue from the upper body. This includes the face, neck,
299 upper extremities, and upper trunk. They also share similar causes, including autoimmune
300 diseases, panniculitis-associated causes, and idiopathic causes. However, while about 25%
301 of AGL cases are associated with panniculitis, it is rare in APL patients (Hussain & Garg,
302 2016).

303 ~~Adverse effects of highly active antiretroviral therapy (HAART) in patients~~
304 with HIV are ~~among one of the factors that lead to acquired lipodystrophy~~AGL. The
305 mechanism by which antiretroviral drugs play a role in the development of lipodystrophy
306 is not fully understood (Giralt et al., 2025) ~~ed completely. One possibility is~~ Proteins such
307 ~~as the use of thymidine analog nucleoside reverse transcriptase inhibitors (NRTI), which~~
308 ~~are used in highly active antiretroviral therapies~~HAART. They, ~~are~~ have been shown to
309 disrupt adipose tissue functions (Guzman and Vijayan 2025). It decreases the expression
310 of adiponectin, which regulates the oxidation of glucose and fatty acids. Nucleoside
311 reverse transcriptase inhibitor ~~NRTI~~ also induces mitochondrial toxicity, which also plays
312 a role in the development of ~~AGL~~acquired lipodystrophy. Lipodystrophy in HIV-infected
313 patients is characterized by the loss of subcutaneous fat at the extremities and face.¶

314

315 ~~Another possible cause of AGL is~~ Autoimmune diseases ~~are also a significant~~
316 cause of acquired lipodystrophy. Specifically ~~In particular,~~ perilipin 1 (~~PLIN1~~)
317 autoantibodies are found in ~~AGL~~AGL patients (Corvillo et al. 2022). Anti-perilipin is also
318 found in patients with ~~panniculitis-associated~~panniculitis-associated ~~AGL~~AGL. Perilipin is
319 found only in adipose tissue and forms a layer that coats lipid droplets. Under normal
320 conditions, perilipin forms a barrier between lipase and the surface of lipid droplets.
321 However, when the autoantibodies are present, it disrupts the normal function of perilipin.
322 It leads to an increase in lipolysis activities, which ~~decreases~~ contributes to the gradual
323 loss of adipose tissue in ~~the fat storage in~~AGL patients ~~he body~~(Corvillo et al. 2018).

324 In APL patients, the presence of C3 nephritic factor (C3NeF) is commonly
325 associated. It acts as an autoantibody against the body's own complement system,
326 particularly complement component C3. When C3NeF binds with C3 convertase, it
327 stabilizes the C3 convertase and prevents its natural decay. Since the function of C3
328 convertase is to cleave C3 into its active fragment, prolonged activation leads to a low level
329 of C3 (*Nephritic Factor - an Overview | ScienceDirect Topics*, n.d.). In adipose tissues, the
330 production of Factor D (adipsin) makes them more susceptible to the activation of the
331 alternative pathway. Factor D plays an important role in the cleavage of factor B (C3bB),
332 resulting in fragments Ba and Bb. The fragment Bb then forms the enzyme C3 convertase,

333 also known as C3bBb. As the breakdown of C3 continues, it activates the terminal pathway.
334 It ultimately leads to the lysis of adipocytes, which explains the fat loss. However, the factor
335 that limits fat loss to the upper body remains unclear (Corvillo & López-Trascasa, 2018).

336 ¶

337

338 4. *Diagnosis and Clinical Features*

339 Since lipodystrophy is ~~such a rare disease and not well known to the public~~, it is
340 often misdiagnosed or ~~left~~ undiagnosed by clinicians. It heavily relies on clinical history
341 and physical examinations that reveal the composition of adipose tissues. Metabolic
342 dysfunctions are also important markers when diagnosing lipodystrophy. Although
343 patients with CGL show symptoms such as a lack of body fat shortly after birth, it is often
344 left undiagnosed until their childhood or adulthood, when they start showing metabolic
345 abnormalities. As for FPLD, it is even more commonly unrecognized due to patients only
346 losing adipose tissue partially. It could ~~be easily mixed up with~~ ~~be easily~~ misdiagnosed as
347 other types of common metabolic diseases, like obesity or severe diabetes mellitus.
348 Presentations of AGL and APL are generally similar to CGL and FPLD, also including the
349 metabolic issues that come with it (Lima et al. 2025). -

350 Lipotoxicity is a direct consequence of adipose tissue dysfunction. Since adipose
351 tissues aren't able to store as many lipid droplets as are produced, excess lipid droplets
352 circulate in the bloodstream as free fatty acids. As the level of circulating free fatty acids
353 elevates, it becomes toxic for non-adipose tissues, resulting in increased oxidative stress
354 (Engin, 2017; Sies, 2020). Since the liver is the major organ that maintains the body's
355 homeostasis, excess fatty acid accumulates at the liver, leading to fatty liver (Kikuchi &
356 Takamura, 2017; Liu et al., 2010). This imbalance of fatty acids in the liver interferes with
357 the insulin signaling pathways. In addition, the body stores excess fat in skeletal muscles,
358 as it is the organ responsible for most of the energy uptake (Merz & Thurmond, 2020).
359 Without skeletal muscles, glucose isn't consumed properly, which also disrupts the insulin
360 signaling pathways.

361 Some phenotypes ~~that are~~ associated with lipodystrophy ~~are~~ include a muscular
362 appearance, prominent veins, and ~~the~~ a lack of body fat. Two main types of fat tissue serve
363 different functions in the body: metabolic and mechanical adipose tissue. Metabolic
364 adipose tissue is responsible for energy storage and hormone secretion, while mechanical
365 tissue, also known as subcutaneous fat, is found under the skin and internal organs to
366 provide protection and support. For CGL patients, the ~~absence~~ loss of metabolic adipose
367 tissues is more ~~severe~~ common than the loss of mechanical tissues. ~~Yet. Although~~ patients
368 still, ~~to~~ in some degree, ~~lack functional mechanical fat tissues.~~ Metabolic adipose tissues
369 ~~are in charge of energy storage and hormone secretion, while the mechanical tissues, also~~
370 ~~known as subcutaneous fat tissue, are found under the skin and internal organs to~~
371 ~~provide protection and support. Although patients still in some degrees lack functional~~

372 ~~mechanical fat tissues. Only CGL2 patients~~ Except for CGL2, in which patients generally are
373 born without ~~mechanical and metabolic adipose tissues~~ kinds of fat tissues (Garg 2011).

374 In contrast, FPLD is ~~characterized~~ characterized by the abnormal distribution with a
375 slight loss of adipose tissue, meaning that patients still acquire most of their functional fat
376 tissues. In addition, as mentioned before, the onset of CGL is often shortly after birth, but
377 for FPLDs, its onset is usually around puberty or adolescence. In general, CGL patients
378 lack the ability to build up mature adipose tissues, while FPLD patients can't store or
379 regulate adipose tissue properly. ~~Next, we~~ The following section will address potential
380 treatments and their underlying mechanisms. ~~will be discussing some potential treatments~~
381 ~~for lipodystrophy and the mechanisms behind them.~~






382

383 5. Treatments

384 5.1 Metreleptin

385 Currently, there isn't a definitive ~~treatment~~ cure for lipodystrophy, but some
386 treatments ~~targeting~~ for specific metabolic abnormalities ~~are~~ have been developed ~~being~~
387 ~~invented~~ (Araújo-Vilar and Santini 2019). For example, Metreleptin (Recombinant
388 methionyl human leptin) is a drug invented specifically for lipodystrophy. It targets leptin
389 deficiency in patients. ~~Leptin is a hormone that regulates energy metabolism. Leptin~~ It is
390 secreted by adipose tissue, and it regulates a person's appetite and food intake (Tsoukas,
391 Farr, and Mantzoros 2015). Since lipodystrophy patients lack functional adipose tissue,
392 leptin secretion also decreases. This causes patients to show extreme hyperphagia, which
393 means the excessive intake of food. This worsens insulin resistance and creates excess fat
394 that must be stored in internal organs or muscles. Metreleptin's main purpose is to mimic
395 the naturally occurring leptin hormone, and it must be administered at least once daily
396 (Rodriguez, Mastronardi, and Paz-Filho 2015). ~~It helps reduce patients' appetite and~~
397 ~~decreases the intake of calories, which contributes to the accumulation of lipid droplets.~~
398 The use of metreleptin in FPLD patients is not approved by the FDA since it does not work
399 ~~as efficiently in FPLD patients as in CGL patients. Metreleptin is found to be more efficient~~
400 ~~in Generalized lipodystrophy patients due to the low levels of leptin that are~~
401 ~~produced~~ (Gilio, Foss-Freitas, and Oral 2025). ~~Individual cases of FPLD could be evaluated~~
402 ~~for whether the requirements for the metreleptin treatment are met.~~ However, the risk of
403 using Metreleptin for special groups of people ~~with generalized lipodystrophy~~, such as
404 pregnant women, ~~are~~ is not certain. Other common drugs, such as insulin or metformin,
405 can also help patients control their symptoms; however, they are not a cure for LDD. ~~■~~
406 Cosmetic surgery is also an option for patients to minimize the psychological discomfort
407 and to have a better quality of life (Table 2).

408

	 Diet and exercise	 Glucose-lowering medications	 Lipid-lowering and CV medications	 LD-specific therapy	 Other
Treatment type	<ul style="list-style-type: none"> Well-balanced, low-fat, low-calorie diet Exercise is encouraged in the absence of specific contraindications 	<ul style="list-style-type: none"> Metformin Insulin Thiazolidinediones GLP-1 receptor agonists SGLT2i 	<ul style="list-style-type: none"> Statins Fibrates Omega-3 fatty acids ACE inhibitors ARBs Beta-blockers 	<ul style="list-style-type: none"> Metreleptin 	<ul style="list-style-type: none"> Cosmetic surgery Counselling
Objectives	<ul style="list-style-type: none"> Cornerstone of LD treatment To help manage weight gain and control calorie and fat intake 	<ul style="list-style-type: none"> Glycemic control 	<ul style="list-style-type: none"> Long-term cardiovascular risk reduction 	<ul style="list-style-type: none"> Only currently approved specific treatment for LD (to treat complications of leptin deficiency adjunct to diet) In PL, often used only once SOC therapies are considered no longer effective 	<ul style="list-style-type: none"> May help patients feel better about their physical appearance and may offer an improved QoL
Challenges and considerations	<ul style="list-style-type: none"> Considered burdensome for patients. Restrictive long-term diets are not easy to maintain Dietary restriction challenging in hyperphagic patients 	<ul style="list-style-type: none"> Patient adherence to therapy High need for careful monitoring especially patients requiring high-doses of insulin Challenges with administering in patients with GL due to lack of subcutaneous fat 	<ul style="list-style-type: none"> Patient adherence to therapy 	<ul style="list-style-type: none"> Often used only once SOC therapies are considered no longer effective Challenges with administering in patients with GL due to lack of subcutaneous fat Restricted access in some regions (e.g., REMS program) 	<ul style="list-style-type: none"> Cosmetic surgery rarely mentioned by participants as a treatment option.

409

410 ▲ Table 2: Possible medications to control metabolic issues that arises with
 411 lipodystrophy. Including the objectives, possible challenges, and other considerations
 412 (Reproduced from (Patni et al., 2024) (~~Patni et al. 2024~~) under the terms of the CC BY
 413 license)

414

415 5.2 Lifestyle Modification ~~Change in Daily Routine~~

416 Although Metreleptin can generally help with metabolic dysfunctions, lifestyle
 417 modification also plays a significant role in managing lipodystrophy. A low-fat diet is
 418 recommended for patients. Carbohydrate intake is also restricted to control diabetes.
 419 Since the body cannot store excess energy properly, it would be beneficial for patients to
 420 reduce the intake of food that will be metabolized into excess fat or energy. Physical
 421 exercises are also encouraged. However, patients with cardiovascular issues should avoid
 422 doing too much excessive exercise to prevent the development of other serious further
 423 complications (Akinci et al. 2024).

424

425 5.3 Limitations and Possibility of Gene Editing


426 Although Metreleptin is an effective way for LD patients to manage metabolic
 427 complications, it is not able to cure ~~it~~ them. In the future, gene editing could be applied to
 428 ~~treating the treatment of~~ this disease. Preclinical trials have been conducted on mouse
 429 models with CGL2, which has a gene mutation at the BSCL2 gene. Seipin knockout (SKO)
 430 mice, which generally show similar metabolic symptoms to CGL2 patients, were generated,
 431 and ~~were~~ injected with adeno-associated virus (AAV) vectors (Sommer et al. 2022). ~~AAV~~
 432 can be engineered to ~~transduce~~ targets adipocytes, ~~enabling which act as a targeted in~~
 433 gene therapy for lipodystrophy. The results of the trials show that gene therapy effectively
 434 restores adipose tissue development and function (Tiwari et al. 2024). However, even

435 though AAV is commonly used in clinical trials, it hasn't been used to directly target
 436 adipose tissue. Novel AAV serotypes that targets adipose tissue or an alternative
 437 promoter are critical for the development of an improved gene therapy strategy for LD
 438 patients. Therefore, there isn't enough evidence currently to suggest that the results from
 439 mouse models can be translated to humans. Continued research on LD and advances in
 440 gene therapy are necessary to develop a more effective therapeutic strategy for this rare
 441 disorder.

442

443 6. Conclusion and the Future

444



445

446 ▲ Figure 4: Steps of adipogenesis. Starting from mesenchymal stem cells, after
 447 proliferation and differentiation, it develops into preadipocytes. Then, through lipogenesis,
 448 preadipocytes grow into mature adipocytes. When a person is fasting, adipocytes go
 449 through lipolysis to produce energy by breaking down triglycerides into glycerol and free
 450 fatty acids. The last step is apoptosis, which ultimately leads to cell death. (Made with
 451 BioRender)

452

453 ~~Although~~ genes involved in lipodystrophy syndromes affect various cellular
 454 processes, such as lipid synthesis, signal transduction, and nuclear structure. ~~They, they~~ all
 455 lead to a common outcome: impaired adipocyte development and function. The examples
 456 discussed in this review, including CGL1, CGL4, FPLD2, and FPLD3, demonstrate how
 457 different stages of adipogenesis and gene mutations that are involved in adipogenesis all
 458 lead to similar consequences (Figure 4). In addition to genetic causes, acquired factors
 459 can also contribute to adipocyte dysfunctions, as seen in AGL.

460

LD highlights the essential role of adipose tissue as an endocrine and metabolic
 461 organ. It not only stores energy but also maintains metabolic homeostasis and regulates
 462 hormones. The absence of adipocytes, as shown in this review, could cause

463 life-threatening disorders. Understanding this condition not only helps people recognize
464 the role of adipose tissue in metabolism but also helps raise awareness of rare diseases.
465 For conditions like lipodystrophy, many patients remain undiagnosed throughout their
466 lives. Not only is conducting research with so few samples challenging, but scientists may
467 be less willing to dedicate time to studying rare diseases compared to diseases that affect
468 a larger population. Increased awareness and improved diagnostic tools not only help
469 identify individuals affected by this disease earlier but also give them a chance to manage
470 their condition in a more effective way.

471 Since the discovery of lipodystrophy syndromes ~~in around~~ the mid-20th century, ~~lots~~
472 ~~of,~~ **significant** progress has been made ~~in to get a better~~ understanding of lipodystrophy.
473 ~~From the phenotypes and to the~~ metabolic abnormalities ~~to and the~~ underlying genetic
474 causes, research ~~have has~~ been **conducted** ~~done to find~~ ~~seek for~~ ways to reduce patients'
475 pain and suffering. Having a deep understanding of lipodystrophy, **such as the**
476 **mechanisms of various genes and their relationship with adipogenesis**, will be crucial to
477 the development of a more effective and targeted therapeutic strategy.

478

479 7. References

480

481 Al-Jawad, Mohammad, Lina Mawaldi, Nada Mawaldi, Mariam Krimsty, and Silva Ishkanian.
482 2025. "Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome) with
483 Both-Side Axillary Breasts: A Case Report." *International Journal of Surgery Case*
484 *Reports* 129:111202. doi:10.1016/j.ijscr.2025.111202.

485 Araújo-Vilar, D., and F. Santini. 2019. "Diagnosis and Treatment of Lipodystrophy: A
486 Step-by-Step Approach." *Journal of Endocrinological Investigation* 42(1):61–73.
487 doi:10.1007/s40618-018-0887-z.

488 Ardissonne, Anna, Cinzia Bragato, Lorella Caffi, Flavia Blasevich, Sabrina Maestrini, Maria
489 Luisa Bianchi, Lucia Morandi, Isabella Moroni, and Marina Mora. 2013. "Novel
490 PTRF Mutation in a Child with Mild Myopathy and Very Mild Congenital
491 Lipodystrophy." *BMC Medical Genetics* 14(1):89. doi:10.1186/1471-2350-14-89.

492 Bagias, Christos, Angeliki Xiarchou, Alexandra Bargiota, and Stelios Tigas. 2020. "Familial
493 Partial Lipodystrophy (FPLD): Recent Insights." *Diabetes, Metabolic Syndrome and*
494 *Obesity: Targets and Therapy* 13:1531–44. doi:10.2147/DMSO.S206053.

495 Broekema, Marjoleine F., Maarten P. G. Massink, Cinzia Donato, Joep De Ligt, Joerg
496 Schaarschmidt, Anouska Borgman, Marieke G. Schooneman, Diana Melchers, Martin
497 N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia, Houshang
498 Monajemi, Gijs W. Van Haften, Maarten R. Soeters, and Eric Kalkhoven. 2019.

499 "Natural Helix 9 Mutants of PPAR γ Differently Affect Its Transcriptional Activity."
500 *Molecular Metabolism* 20:115–27. doi:10.1016/j.molmet.2018.12.005.

501 Chiquette, Elaine, Elif A. Oral, Abhimanyu Garg, David Araújo-Vilar, and Praveen Dhankhar.
502 2017. "Estimating the Prevalence of Generalized and Partial Lipodystrophy:
503 Findings and Challenges." *Diabetes, Metabolic Syndrome and Obesity* 10:375–83.
504 doi:10.2147/DMSO.S130810.

505 Corsa, Callie A. S., Carolyn M. Walsh, Devika P. Bagchi, Maria C. Foss Freitas, Ziru Li, Julie
506 Hardij, Katrina Granger, Hiroyuki Mori, Rebecca L. Schill, Kenneth T. Lewis, Jessica
507 N. Maung, Ruth D. Azaria, Amy E. Rothberg, Elif A. Oral, and Ormond A. MacDougald.
508 2021. "Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial
509 Partial Lipodystrophy Type 2." *Diabetes* 70(9):1970–84. doi:10.2337/db20-1001.

510 Corvillo, Fernando, Brent S. Abel, Alberto López-Lera, Giovanni Ceccarini, Silvia Magno,
511 Ferruccio Santini, David Araújo-Vilar, Rebecca J. Brown, Pilar Nozal, and Margarita
512 López-Trascasa. 2022. "Characterization and Clinical Association of Autoantibodies
513 Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy." *Diabetes*
514 72(1):71–84. doi:10.2337/db21-1086.

515 Corvillo, Fernando, Verónica Aparicio, Alberto López-Lera, Sofía Garrido, David
516 Araújo-Vilar, María P. de Miguel, and Margarita López-Trascasa. 2018.
517 "Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized
518 Lipodystrophy." *Frontiers in Immunology* 9. doi:10.3389/fimmu.2018.02142.

519 Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice
520 Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic.
521 n.d. Retrieved January 19, 2026.
522 <https://academic.oup.com/jcem/article/101/12/4500/2764979>.

523 Fourman, Lindsay T, and Steven K. Grinspoon. 2022. "Approach to the Patient With
524 Lipodystrophy." *The Journal of Clinical Endocrinology & Metabolism*
525 107(6):1714–26. doi:10.1210/clinem/dgac079.

526 Gale, Sarah E., Andrey Frolov, Xianlin Han, Perry E. Bickel, Li Cao, Anne Bowcock, Jean E.
527 Schaffer, and Daniel S. Ory. 2006. "A Regulatory Role for
528 1-Acylglycerol-3-Phosphate-O-Acyltransferase 2 in Adipocyte Differentiation *."
529 *Journal of Biological Chemistry* 281(16):11082–89. doi:10.1074/jbc.M509612200.

530 Garg, Abhimanyu. 2011. "Lipodystrophies: Genetic and Acquired Body Fat Disorders." *The*
531 *Journal of Clinical Endocrinology & Metabolism* 96(11):3313–25.
532 doi:10.1210/jc.2011-1159.

- 533 Gilio, Donatella, Maria Foss-Freitas, and Elif A. Oral. 2025. "Clinical Guidance for
534 Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment." *Current*
535 *Diabetes Reports* 25(1):47. doi:10.1007/s11892-025-01603-4.
- 536 Godoy-Matos, Amélio Fernando, Cynthia M. Valério, Juliana Bonadiman e. Bragança,
537 Ricardo de Andrade Oliveira, Roberto Luis Zagury, Rodolfo de Paula Lustosa,
538 Gabriel Cordeiro Camargo, César Augusto da Silva Nascimento, and Rodrigo O.
539 Moreira. 2015. "Evaluation of Epicardial Adipose Tissue in Familial Partial
540 Lipodystrophy." *Diabetology & Metabolic Syndrome* 7(1):29.
541 doi:10.1186/s13098-015-0024-5.
- 542 Guzman, Nilmarie, and Vini Vijayan. 2025. "HIV-Associated Lipodystrophy." in *StatPearls*.
543 Treasure Island (FL): StatPearls Publishing.
- 544 Lamothe, Sophie, Patricia Ancel, Inès Belalem, Leïla Lecaque, Joris Fournel, Alexis Jacquier,
545 Zouhair Houhou, Jean-Baptiste Julla, Jean-François Gautier, Corinne Vigouroux,
546 Bénédicte Gaborit, and Camille Vatie. 2025. "Increased Epicardial Adipose Tissue Is
547 Part of the Phenotype of *LMNA*-Associated Partial Lipodystrophy and Could
548 Contribute to Increased Cardiovascular Risk." *Diabetes & Metabolism*
549 51(6):101710. doi:10.1016/j.diabet.2025.101710.
- 550 Lima, Josivan Gomes, Lucas Nobrega Lima, Vitor Yan Bezerra Araujo, Lucia Helena Coelho
551 Nobrega, and Julliane Tamara Araújo de Melo Campos. 2025. "Diagnosis of
552 Congenital and Acquired Generalized Lipodystrophies—Similarities and
553 Differences." *Endocrines* 6(4):55. doi:10.3390/endocrines6040055.
- 554 Lima, Josivan Gomes, Lucia Helena C. Nobrega, Natalia Nobrega Lima, Marcel Catão
555 Ferreira dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P. Baracho,
556 Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo
557 Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O. Mendes-Aguiar,
558 and Selma Maria B. Jeronimo. 2018. "Causes of Death in Patients with
559 Berardinelli-Seip Congenital Generalized Lipodystrophy." *PLOS ONE*
560 13(6):e0199052. doi:10.1371/journal.pone.0199052.
- 561 Madsen, Maria Stahl, Marjoleine F. Broekema, Martin Rønn Madsen, Arjen Koppen,
562 Anouska Borgman, Cathrin Gräwe, Elisabeth G. K. Thomsen, Denise Westland,
563 Mariette E. G. Kranendonk, Marian Groot Koerkamp, Nicole Hamers, Alexandre M. J.
564 J. Bonvin, José M. Ramos Pittol, Kedar Nath Natarajan, Sander Kersten, Frank C. P.
565 Holstege, Houshang Monajemi, Saskia W. C. van Mil, Michiel Vermeulen, Birthe B.
566 Kragelund, David Cassiman, Susanne Mandrup, and Eric Kalkhoven. 2022. "PPAR γ
567 Lipodystrophy Mutants Reveal Intermolecular Interactions Required for Enhancer

568 Activation." *Nature Communications* 13(1):7090.
569 doi:10.1038/s41467-022-34766-9.

570 Maung, Jessica N., Rebecca L. Schill, Akira Nishii, Maria Foss de Freitas, Bonje N. Obua,
571 Marcus Nygård, Maria D. Mendez-Casillas, Isabel D. K. Hermsmeyer, Donatella Gilio,
572 Ozge Besci, Yang Chen, Brian Desrosiers, Rose E. Adler, Anabela D. Gomes, Merve
573 Celik Guler, Hiroyuki Mori, Romina M. Uranga, Ziru Li, Hadla Hariri, Liping Zhang,
574 Anderson de Paula Souza, Keegan S. Hoose, Kenneth T. Lewis, Taryn A. Hetrick, Paul
575 Cederna, Carey N. Lumeng, Susanne Mandrup, Elif A. Oral, and Ormond A.
576 MacDougald. 2026. "Altered Lipid Metabolism and Inflammatory Programs
577 Associate with Adipocyte Loss in Familial Partial Lipodystrophy 2." *The Journal of*
578 *Clinical Investigation* 136(1). doi:10.1172/JCI198387.

579 de Melo, Maria Eduarda Cardoso, Letícia Marques Gomes da Silva, Ana Carolina Costa
580 Cavalcante, Josivan Gomes Lima, and Julliane Tamara Araújo de Melo Campos.
581 2025. "The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital
582 Generalized Lipodystrophy Pathophysiology." *International Journal of Molecular*
583 *Sciences* 26(11):5416. doi:10.3390/ijms26115416.

584 Misra, Anoop, and Abhimanyu Garg. 2003. "Clinical Features and Metabolic Derangements
585 in Acquired Generalized Lipodystrophy: Case Reports and Review of the
586 Literature." *Medicine* 82(2):129–46. doi:10.1097/00005792-200303000-00007.

587 Oswiecimska, Joanna. n.d. "A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2
588 Splicesite Mutation and Concomitant Development of Non-Diabetic Polyneuropathy
589 - Journal of Clinical Research in Pediatric Endocrinology." Retrieved January 19,
590 2026. <https://jcrpe.org/articles/doi/jcrpe.galenos.2018.2018.0227>. doi:
591 10.4274/jcrpe.galenos.2018.2018.0227

592 Poulos, Sylvia P., Michael V. Dodson, Melinda F. Culver, and Gary J. Hausman. 2016. "The
593 Increasingly Complex Regulation of Adipocyte Differentiation." *Experimental*
594 *Biology and Medicine* 241(5):449–56. doi:10.1177/1535370215619041.

595 Rajab, Anna, Volker Straub, Liza J. McCann, Dominik Seelow, Raymonda Varon, Rita
596 Barresi, Anne Schulze, Barbara Lucke, Susanne Lützkendorf, Mohsen Karbasiyan,
597 Sebastian Bachmann, Simone Spuler, and Markus Schuelke. 2010. "Fatal Cardiac
598 Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized
599 Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations." *PLOS*
600 *Genetics* 6(3):e1000874. doi:10.1371/journal.pgen.1000874.

- 601 Rodriguez, Alexander J., Claudio A. Mastronardi, and Gilberto J. Paz-Filho. 2015. "New
602 Advances in the Treatment of Generalized Lipodystrophy: Role of Metreleptin."
603 *Therapeutics and Clinical Risk Management* 11:1391–1400.
604 doi:10.2147/TCRM.S66521.
- 605 Salle-Teyssières, Laurence, Martine Auclair, Faraj Terro, Mona Nemani, Solaf M. Elsayed,
606 Ezzat Elsobky, Mark Lathrop, Marc Délépine, Olivier Lascols, Jacqueline Capeau,
607 Jocelyne Magré, and Corinne Vigouroux. 2016. "Maladaptative Autophagy Impairs
608 Adipose Function in Congenital Generalized Lipodystrophy Due to Cavin-1
609 Deficiency." *The Journal of Clinical Endocrinology & Metabolism*
610 101(7):2892–2904. doi:10.1210/jc.2016-1086.
- 611 Soares, Reivla Marques Vasconcelos, Monique Alvares da Silva, Julliane Tamara Araújo de
612 Melo Campos, and Josivan Gomes Lima. 2024. "Familial Partial Lipodystrophy
613 Resulting from Loss-of-Function PPAR γ Pathogenic Variants: Phenotypic, Clinical,
614 and Genetic Features." *Frontiers in Endocrinology* 15.
615 doi:10.3389/fendo.2024.1394102.
- 616 Sommer, Nadine, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J. Rochford,
617 and George D. Mcilroy. 2022. "Gene Therapy Restores Adipose Tissue and
618 Metabolic Health in a Pre-Clinical Mouse Model of Lipodystrophy." *Molecular*
619 *Therapy Methods & Clinical Development* 27:206–16.
620 doi:10.1016/j.omtm.2022.09.014.
- 621 Stea, Dante Maria, and Alessio D'Alessio. 2025. "Caveolae: Metabolic Platforms at the
622 Crossroads of Health and Disease." *International Journal of Molecular Sciences*
623 26(7):2918. doi:10.3390/ijms26072918.
- 624 Talman, Andrew H., Peter J. Psaltis, James D. Cameron, Ian T. Meredith, Sujith K.
625 Seneviratne, and Dennis T. L. Wong. 2014. "Epicardial Adipose Tissue: Far More
626 than a Fat Depot." *Cardiovascular Diagnosis and Therapy* 4(6):416–29.
627 doi:10.3978/j.issn.2223-3652.2014.11.05.
- 628 Tiwari, Mansi, Ahlima Roumane, Nadine Sommer, Weiping Han, Mirela Delibegović, Justin J.
629 Rochford, and George D. Mcilroy. 2024. "Preclinical Evaluation of Tissue-Selective
630 Gene Therapies for Congenital Generalised Lipodystrophy." *Gene Therapy*
631 31(9):445–54. doi:10.1038/s41434-024-00471-z.
- 632 Tsoukas, Michael A., Olivia M. Farr, and Christos S. Mantzoros. 2015. "Leptin in Congenital
633 and HIV-Associated Lipodystrophy." *Metabolism* 64(1):47–59.
634 doi:10.1016/j.metabol.2014.07.017.

635 Varlet, Alice-Anaïs, Emmanuèle Helfer, and Catherine Badens. 2020. "Molecular and
636 Mechanobiological Pathways Related to the Physiopathology of FPLD2." *Cells*
637 9(9):1947. doi:10.3390/cells9091947.

638 Ajluni, N., Dar, M., Xu, J., Neidert, A. H., & Oral, E. A. (2016). Efficacy and Safety of
639 Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded
640 Access Program. *Journal of Diabetes & Metabolism*, 7(3), 659.
641 <https://doi.org/10.4172/2155-6156.1000659>

642 Akinci, B., Gular, M. C., & Oral, E. A. (2024). Lipodystrophy Syndromes: Presentation and
643 Treatment. In *Endotext [Internet]*. MDText.com, Inc.
644 <https://www.ncbi.nlm.nih.gov/sites/books/NBK513130/>

645 Araújo-Vilar, D., & Santini, F. (2019). Diagnosis and treatment of lipodystrophy: A
646 step-by-step approach. *Journal of Endocrinological Investigation*, 42(1), 61–73.
647 <https://doi.org/10.1007/s40618-018-0887-z>

648 Broekema, M. F., Massink, M. P. G., De Ligt, J., Stigter, E. C. A., Monajemi, H., De Ridder, J.,
649 Burgering, B. M. T., van Haaften, G. W., & Kalkhoven, E. (2018). A Single Complex
650 Agpat2 Allele in a Patient With Partial Lipodystrophy. *Frontiers in Physiology*, 9.
651 <https://doi.org/10.3389/fphys.2018.01363>

652 Corvillo, F., & López-Trascasa, M. (2018). Acquired partial lipodystrophy and C3
653 glomerulopathy: Dysregulation of the complement system as a common
654 mechanism. *Nefrología (English Edition)*, 38(3), 258–266.
655 <https://doi.org/10.1016/j.nefro.2018.04.002>

656 Engin, A. B. (2017). What Is Lipotoxicity? In A. B. Engin & A. Engin (Eds.), *Obesity and*
657 *Lipotoxicity* (pp. 197–220). Springer International Publishing.
658 https://doi.org/10.1007/978-3-319-48382-5_8

659 Giralt, M., Domingo, P., Quesada-López, T., Cereijo, R., & Villarroya, F. (2025). Lipodystrophy
660 in HIV: Evolving Challenges and Unresolved Questions. *International Journal of*
661 *Molecular Sciences*, 26(14), 6546. <https://doi.org/10.3390/ijms26146546>

662 Gonzalo, S., Kreienkamp, R., & Askjaer, P. (2017). Hutchinson-Gilford Progeria Syndrome: A
663 premature aging disease caused by LMNA gene mutations. *Ageing Research*
664 *Reviews*, 33, 18–29. <https://doi.org/10.1016/j.arr.2016.06.007>

665 Grivas, D., González-Rajal, Á., Guerrero Rodríguez, C., Garcia, R., & de la Pompa, J. L. (2020).
666 Loss of Caveolin-1 and caveolae leads to increased cardiac cell stiffness and
667 functional decline of the adult zebrafish heart. *Scientific Reports*, 10(1), 12816.
668 <https://doi.org/10.1038/s41598-020-68802-9>

669 Hussain, I., & Garg, A. (2016). Lipodystrophy Syndromes. *Endocrinology and Metabolism*
670 *Clinics of North America*, 45(4), 783–797.
671 <https://doi.org/10.1016/j.ecl.2016.06.012>

672 Kikuchi, A., & Takamura, T. (2017). Where does liver fat go? A possible molecular link
673 between fatty liver and diabetes. *Journal of Diabetes Investigation*, 8(2), 152–154.
674 <https://doi.org/10.1111/jdi.12573>

675 Li, Y., Yang, X., Peng, L., Xia, Q., Zhang, Y., Huang, W., Liu, T., & Jia, D. (2022). Role of Seipin in
676 Human Diseases and Experimental Animal Models. *Biomolecules*, 12(6), 840.
677 <https://doi.org/10.3390/biom12060840>

678 Liu, Q, Bengmark, S., & Qu, S. (2010). The role of hepatic fat accumulation in pathogenesis
679 of non-alcoholic fatty liver disease (NAFLD). *Lipids in Health and Disease*, 9, 42.
680 <https://doi.org/10.1186/1476-511X-9-42>

681 Meehan, C. A., Cochran, E., Kassai, A., Brown, R. J., & Gorden, P. (2016). Metreleptin for
682 injection to treat the complications of leptin deficiency in patients with congenital
683 or acquired generalized lipodystrophy. *Expert Review of Clinical Pharmacology*,
684 9(1), 59–68. <https://doi.org/10.1586/17512433.2016.1096772>

685 Merz, K. E., & Thurmond, D. C. (2020). Role of Skeletal Muscle in Insulin Resistance and
686 Glucose Uptake. *Comprehensive Physiology*, 10(3), 785–809.
687 <https://doi.org/10.1002/cphy.c190029>

688 *Nephritic Factor—An overview | ScienceDirect Topics*. (n.d.). Retrieved May 3, 2026, from
689 <https://www.sciencedirect.com/topics/medicine-and-dentistry/nephritic-factor>

690 Patni, N., Chard, C., Araújo-Vilar, D., Phillips, H., Magee, D. A., & Akinci, B. (2024). Diagnosis,
691 treatment and management of lipodystrophy: The physician perspective on the
692 patient journey. *Orphanet Journal of Rare Diseases*, 19(1), 263.
693 <https://doi.org/10.1186/s13023-024-03245-3>

694 Santoro, A., McGraw, T. E., & Kahn, B. B. (2021). Insulin action in adipocytes, adipose
695 remodeling, and systemic effects. *Cell Metabolism*, 33(4), 748–757.
696 <https://doi.org/10.1016/j.cmet.2021.03.019>

697 *Search ClinicalTrials.gov for: Lipodystrophy | List Results | ClinicalTrials.gov*. (n.d.).
698 Retrieved April 15, 2026, from <https://clinicaltrials.gov/search>

699 Sies, H. (2020). Oxidative Stress: Concept and Some Practical Aspects. *Antioxidants*, 9(9),
700 852. <https://doi.org/10.3390/antiox9090852>

701

702 8. Acknowledgement

703 I would like to offer my sincere gratitude to my mentors, Dr. Hamidreza Shaye and Dr.
704 Lauren Tetz, for their guidance and valuable insights throughout the whole writing
705 process. This paper would not exist without their help and support. I also appreciate the
706 two anonymous reviewers for their thoughtful suggestions, which greatly improved the
707 clarity and quality of this review. I am grateful for my mom's support and for always
708 having faith in me.

709

710 9. Author Biography

711 Chiao Yun Cheng is a high school junior at Great Hearts Anthem Prep in Anthem,
712 Arizona. She is a young researcher with a deep interest in biochemistry, genetics, and
713 chemical engineering. She plans to pursue a degree in biochemistry or a related field, such
714 as chemical engineering, in college. Through this research project, Chiao Yun developed a
715 deeper passion for lab research and gained a deeper understanding of people with rare
716 diseases. In the future, she hopes to develop more treatments for individuals with rare
717 diseases and aims to solve existing problems in medical and scientific areas.

718 Beyond her studies and research, Chiao Yun is passionate about playing piano and
719 drawing. She uses them as a way to relax and generate ideas. She also enjoys traveling and
720 learning about different cultures, which helps broaden her perspective on the world.

721

722 10. Mentor Contribution Statement

723 Dr. Hamidreza Shaye provided guidance throughout the research and writing process
724 by offering conceptual advice, academic direction, and methodological choices. In addition,
725 he offered guidance on choosing research questions and identifying relevant and
726 appropriate sources for citation. He advised on using academic tools to produce images
727 and analyze information. He helped refine the paper's tone and scope by giving advisory
728 feedback.

729 Dr. Lauren Tetz served as an advisor to the research project. She gave suggestions on
730 how to structure the paper and strengthen the academic rigor. She also provided
731 resources that helped structure the paper's content.

732 Dr. Shaye and Dr. Tetz did not participate in the writing process of the manuscript or
733 the production of the images. The student determined the aim of this research and
734 conducted the literature review independently.